新・分子骨代謝学と骨粗鬆症

出版社： メディカルレビュー社
著者：
発行日： 2001-05-15
分野： 臨床医学：内科  >  内分泌/代謝
ISBN： 9784896003802
電子書籍版： 2001-05-15 （第1版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,950 円(税込)

購入する

目次

  • 表紙
  • 序文
  • CONTENTS
  • Author List-執筆者一覧
  • 序論 骨格系の分子制御機構の解明とその骨代謝学への応用
  • 1 骨・軟骨細胞の分化・機能の制御とその調節因子
  • 2 骨粗鬆症の病態の解明と診断法の開発
  • 3 骨粗鬆症の治療法の開発
  • 第1章 骨・軟骨細胞の形成・分化の分子機構
  • 1 骨・軟骨の微細構造
  • 1 軟骨組織
  • 2 骨組織
  • 2 軟骨細胞の分化制御と軟骨形成
  • 1 内軟骨性骨形成の機構
  • 2 軟骨分化を制御する成長分化因子
  • 3 軟骨分化を制御する基質蛋白質
  • 4 軟骨分化を制御する転写因子
  • 5 軟骨分化と軟骨形成研究のための細胞培養系
  • 3 造血幹細胞から破骨細胞への分化
  • 1 造血の系統発生
  • 2 造血の個体発生
  • 3 骨と骨髄の形成
  • 4 破骨細胞
  • 5 破骨細胞の分化制御
  • 6 破骨細胞分化と転写因子
  • 4 破骨細胞形成の制御機構
  • 1 破骨細胞の分化と機能を調節する骨芽細胞の役割
  • 2 マクロファージコロニー刺激因子(M-CSF)の破骨細胞分化における重要性
  • 3 破骨細胞の分化と機能を調節する腫瘍壊死因子(TNF)関連サイトカイン
  • 4 破骨細胞分化を制御するTリンパ球の役割
  • 5 TGF-βスーパーファミリーサイトカインとRANKL-RANK系とのクロストーク
  • 5 破骨細胞の機能とその調節
  • 1 破骨細胞の形態と酸・酵素分泌
  • 2 破骨細胞の活性化を調節するシグナル
  • 3 破骨細胞の生存期間の調節
  • 6 間葉系細胞からの骨芽細胞分化の転写制御
  • 1 runtファミリー遺伝子
  • 2 Cbfa1のゲノム構造と発現
  • 3 Cbfa1による骨芽細胞分化
  • 4 骨形成におけるCbfa1の位置づけ
  • 7 骨芽細胞の分化・機能調節因子とその作用
  • 1 骨芽細胞への分化を決定する転写・因子Cbfa1
  • 2 骨芽細胞の分化とBMP
  • 3 骨芽細胞の分化とヘッジホッグ
  • 4 IGF-I
  • 5 FGFs
  • 8 骨基質蛋白とその機能
  • 1 骨の非コラーゲン性蛋白
  • 2 オステオカルシン
  • 3 オステオネクチンのノックアウトマウス
  • 4 マトリックスグラ蛋白
  • 5 バイグリカン
  • 6 オステオポンチン
  • 9 骨芽細胞の成熟と骨基質の石灰化
  • 1 骨芽細胞の成熟
  • 2 骨基質の石灰化
  • 10 骨細胞(osteocyte)の形成と機能
  • 1 骨細胞の分化と形態的特徴
  • 2 骨細胞の機能
  • 3 骨における機械的刺激の伝達と骨細胞
  • 第2章 骨代謝調節因子の分子作用機構
  • 1 核内受容体を介する転写調節の分子機構
  • 1 核内受容体スーパーファミリー
  • 2 核内受容体の構造と機能
  • 3 核内受容体のコンセンサス標的エンハンサー
  • 4 核内受容体による転写促進の分子メカニズム
  • 5 リガンド結合による受容体の構造変化と転写共役因子群との相互作用
  • 6 核内受容体転写共役因子複合体の機能
  • 2 エストロゲン受容体を介する転写調節
  • 1 ERの構造と機能
  • 2 ER異常症と骨
  • 3 ERの骨における下流応答遺伝子
  • 3 ビタミンD受容体を介する転写調節
  • 1 VDRによる転写活性化と転写抑制
  • 2 転写共役因子
  • 3 ビタミンD誘導体
  • 4 VDRのin vivoでの機能
  • 4 25-水酸化ビタミンD3-1α水酸化酵素の転写調節
  • 1 1α-水酸化酵素遺伝子のクローニング
  • 2 1α-水酸化酵素遺伝子の発現調節
  • 5 副甲状腺ホルモン/副甲状腺ホルモン関連蛋白受容体の機能
  • 1 PTHrP遺伝子欠損マウスにおける軟骨の異常
  • 2 PTHrP遺伝子過剰発現マウスにおける軟骨・骨の異常について
  • 3 PTH/PTHrP受容体欠損マウスの異常, およびPTHrPとindian hedgehogのネガティブループ(negative loop)について
  • 4 PTH/PTHrP受容体のプロモーター領域とpseudohypoparathyroidism type Ib
  • 5 Jansen型およびBlomstrand型骨幹端軟骨異形成症とPTH/PTHrP受容体
  • 6 constitutive active PTH/PTHrP受容体を発現するトランスジェニックマウスについて
  • 7 PTH/PTHrP受容体欠損キメラマウスの作製と解析
  • 8 第2, 第3のPTHまたはPTHrPに対する受容体の発見
  • 9 PTHrPの核小体移行について
  • 6 カルシウム感知受容体の機能
  • 1 CaSRの構造
  • 2 CaSRの発現と機能
  • 3 CaSR異常とCa代謝異常症
  • 7 TGF-βスーパーファミリー受容体とその情報伝達機構
  • 1 TGF-βスーパーファミリーの受容体
  • 2 TGF-βスーパーファミリーのシグナル伝達におけるSmadの役割
  • 3 Smadの構造
  • 4 MAPKとのクロストーク
  • 5 転写因子
  • 6 SmadのDNA結合領域
  • 7 骨代謝におけるTGF-βの機能的役割
  • 8 骨芽細胞や軟骨細胞分化におけるBMPおよびSmadの機能的役割
  • 8 インスリン/IGF-I情報伝達系による骨代謝の制御
  • 1 脊柱靱帯骨化症とインスリン
  • 2 IRS-1ノックアウトマウスの骨組織
  • 9 四肢形態形成と骨成長因子
  • 1 四肢形態形成のメカニズム
  • 2 形態形成制御因子と軟骨形成
  • 10 骨吸収性サイトカインとその作用機構
  • 1 IL-1とTNFα
  • 2 PGEによる骨吸収
  • 3 骨髄Bリンパ球造血と骨吸収
  • 第3章 骨粗鬆症の病態と診断の分子医学
  • 1 エストロゲン欠乏による骨代謝変化
  • 1 エストロゲン欠乏による骨吸収亢進のメカニズム
  • 2 エストロゲンのカルシウム代謝に対する作用
  • 2 加齢による骨代謝変化
  • 1 加齢と骨粗鬆症
  • 2 老化に伴う骨・カルシウム代謝の変化
  • 3 高齢者の骨代謝における性ホルモンの役割
  • 4 老化モデルマウスにおける骨粗鬆症の病態
  • 3 副腎皮質ステロイドによる骨代謝変化
  • 1 Gの細胞内作用機構
  • 2 骨に対するGの作用機構
  • 3 G誘発性骨粗鬆症
  • 4 DHEAの骨への作用機構
  • 5 骨粗鬆症とDHEA(-S)
  • 4 慢性関節リウマチによる骨代謝変化
  • 1 ナース細胞
  • 2 RAにおける末梢血単球からの破骨細胞様細胞への分化
  • 3 RAナース細胞による軟骨破壊
  • 5 力学的負荷の軽減による骨代謝変化
  • 1 力学的負荷の軽減と骨動態
  • 2 力学的負荷を感知するメカニズム
  • 3 力学刺激のシグナル伝達機構
  • 4 力学的負荷軽減による骨髄細胞分化異常
  • 5 力学刺激に対する生体反応を修飾する因子
  • 6 骨微細構造と骨粗鬆症の画像診断
  • 1 マイクロCTとは
  • 2 マイクロCT装置とデータ収集・解析
  • 3 骨微細構造の定量化
  • 4 骨梁構造と骨力学特性の加齢変化
  • 5 骨強度に関係する骨梁構造パラメーター
  • 6 magnetic resonance imaging(MRI)
  • 7 シンクロトロン放射線を用いたマイクロCT
  • 7 骨形成マーカーによる骨形成過程の評価
  • 1 オステオカルシン
  • 2 骨型アルカリ性フォスファターゼ
  • 3 I型コラーゲンC末端ペプチド
  • 8 骨吸収マーカーによる骨吸収過程の評価
  • 1 骨吸収マーカーの測定法
  • 2 骨吸収マーカーと骨代謝
  • 9 遺伝子多型性と骨粗鬆症
  • 1 骨粗鬆症の病態と遺伝的素因解析の意義
  • 2 遺伝子多型性と疾患
  • 3 候補遺伝子の多型性と骨量との連関解析(association study)
  • 4 遺伝子多型性を用いた骨量に関する連鎖解析(linkage study)
  • 5 今後の展望：ポストシーケンスゲノム医学の進展のなかで
  • 第4章 骨粗鬆症治療薬の作用機序と効果
  • 1 エストロゲンの作用と閉経後骨粗鬆症の治療
  • 1 骨粗鬆症と性差
  • 2 閉経後の骨量低下の推移
  • 3 エストロゲンの作用機序
  • 4 エストロゲン剤の種類
  • 5 エストロゲン剤の使い方
  • 6 エストロゲン(HRT)の効果
  • 2 選択的エストロゲン受容体モジュレーター(SERM)の薬理作用と骨粗鬆症の適応
  • 1 SERMおよびエストロゲンの化学構造
  • 2 SERMの作用プロファイル
  • 3 SERMとエストロゲンの薬理作用比較
  • 4 SERMとビスフォスフォネートの薬理作用比較
  • 5 臨床開発中のSERM
  • 3 カルシトニンの作用と骨粗鬆症の治療
  • 1 カルシトニンおよび受容体
  • 2 カルシトニンの作用
  • 3 カルシトニンによる骨粗鬆症の治療
  • 4 ビスフォスフォネートの作用と骨粗鬆症の治療
  • 1 ビスフォスフォネートの薬理学的特性と種類
  • 2 ビスフォスフォネートの薬物動態
  • 3 ビスフォスフォネートの作用機序
  • 4 副作用
  • 5 ビスフォスフォネートの骨粗鬆症治療効果
  • 5 活性型ビタミンDおよびその誘導体の作用と骨粗鬆症の治療
  • 1 骨粗鬆症と骨軟化症
  • 2 高齢者にみられる潜在的ビタミンD作用の不足
  • 3 皮膚におけるビタミンD産生とビタミンD不足
  • 4 肝臓での25位の水酸化反応
  • 5 腎臓での1α水酸化反応
  • 6 腸管での1,25(OH)2Dの反応性低下
  • 7 骨粗鬆症に対するカルシウム補充の効果
  • 8 骨粗鬆症に対するカルシウムとビタミンD補充の効果
  • 9 活性型ビタミンD治療の優位性とその効果
  • 10 活性型ビタミンDの活性の分離と新しい誘導体への期待
  • 6 ビタミンKの作用と骨粗鬆症の治療
  • 1 ビタミンKとは？
  • 2 ビタミンKと骨研究の歴史
  • 3 栄養素としてのビタミンKと骨
  • 4 骨グラ蛋白と骨代謝
  • 5 ビタミンKによる骨代謝への影響(in vivo)
  • 6 ビタミンKと骨代謝への影響(in vitro)-骨形成促進・骨吸収抑制効果-
  • 7 ビタミンK依存性蛋白の新しい展開
  • 8 投与時の注意点
  • 7 副甲状腺ホルモンの作用と骨粗鬆症への応用
  • 1 Ca・骨代謝調節におけるPTHの作用
  • 2 PTHの骨形成促進作用とその機序
  • 3 骨粗鬆症治療薬としてのPTHの臨床応用への展開
  • 8 骨形成促進薬剤の開発アプローチ：コレステロール生合成阻害薬スタチンの骨形成促進作用とその作用メカニズム
  • 1 理想的な骨粗鬆症治療薬とは？
  • 2 基本的方針
  • 3 in vivoにおける骨形成促進作用の検討
  • INDEX
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序論 骨格系の分子制御機構の解明とその骨代謝学への応用

P.12 掲載の参考文献
1) Karp, S. J., Schipani, E., St-Jacques, B. et al.:Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and-independent pathways. Development 127:543-548, 2000
PubMed
2) Pathi, S., Rutenberg, J. B., Johnson, R. L. et al.:Interaction of Ihh and BMP/Noggin signaling during cartilage differentiation. Dev. Biol. 209:239-253,1999
PubMed
3) Zehentner, B. K., Dony, C., Burtsche, H.:The transcription factor Sox9 is involved in BMP-2 signaling. J. Bone Miner. Res. 14:1734-1741, 1999
 
4) Naski, M. C., Colvin, J. S., Coffin, J. d . et al:Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125:4977-4988, 1998
PubMed
5) Inada, M., Yasui, T., Nomura, S. et al.:Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev. Dyn. 214:279-290, 1999
PubMed
6) 金谷直子, 上田千里, 岩本容泰ほか:Cbfa 1 トランスジェニックマウスにおける軟骨細胞の成熟と内軟骨性骨化の促進. 日本骨代謝学会雑誌 18:6, 2000
 
7) Takeda, S., Priemel, M., Amling, M. et al.:Ectopic bone formation in transgenic mice expressing Cbfa1 in chondrocytes. J. Bone Miner. Res. (Abstract) 15:S145(#1026), 2000
 
8) Yoshizawa, T., Handa, Y., Uematsu, Y. et al.:Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16:391-396, 1997
PubMed
9) Koyama, E., Golden, E. B., Kirsch, T. et al.:Retinoid signaling is required for chondrocyte maturation and endochondral bone formation during limb skeletogenesis. Dev. Biol. 208:375-391, 1999
PubMed
10) Koyama, E., Iwamoto, M., Enomoto-Iwamoto, M. et al.:Regulation of indian hedgehog and Cbfa1 expression during chondrocyte maturation by retinoid signaling. J. Bone Miner. Res. (Abstract) 15:S145 (#1025), 2000
 
11) Komori, T., Yagi, H., Nomura, S. et al.:Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational-arrest of osteoblasts. Cell 89:755-764, 1997
 
12) Ducy, P., Zhang, R., Geoffroy, V. et al.:Osf2/Cbfa1:a transcriptional activator of osteoblast differentiation. Cell 89:747-754, 1997
PubMed
13) Otto, F., Thornell, A. P., Crompton, T. et al.:Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771, 1997
PubMed
14) Takeuchi, Y., Nakayama, K., Matsumoto, T.:Differentiation and cell surface expression of transforming growth factor-βreceptors are regulated by interaction with matrix collagen in murine osteoblastic cells. J. Biol. Chem. 271:3938-3944, 1996
 
15) Suzawa, M., Takeuchi, Y., Fukumoto, S. et al.:Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. Endocrinology 140:2125-2133, 1999
PubMed
16) Takeuchi, Y., Suzawa, M., Kikuchi, T. et al.:Differentiation and transforming growth factor-β receptor down-regulation by collagen-α2β1 integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells. J. Biol. Chem. 272:29309-29316, 1997
 
17) Xiao, G., Jiang, D., Thomas, P. et al.:MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem. 275:4453-4459, 2000
PubMed
18) 須澤美幸, 竹内靖博, 田村康博ほか:Ras/MAP キナーゼによる BMP/Smad1 を介する転写活性の促進作用. 日本骨代謝学会雑誌 16:24, 1998
Medical*Online
19) 中山耕之介, 田村康博, 須澤美幸ほか:チロシンキナーゼ受容体-Ras-ERK シグナルによる BMP依存性 Smad6 プロモータ活性の抑制. 日本骨代謝学会雑誌 18:30, 2000
 
20) 井上大輔, 松本俊夫:骨吸収系における最近の知見. 日本臨床 56:1412-1418, 1998
Medical*Online
21) Yasuda, H., Shima, N., Nakagawa, N. et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998
PubMed
22) Lacey, D. L., Timms, E., Tan, H. L. et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
PubMed
23) Hsu, H., Lacey, d. L, Dunstan, C. R. et al.:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96:3540-3545, 1999
PubMed
24) Nakagawa, N., Kinosaki, M., Yamaguchi, K. et al.:RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253:395-400, 1998
PubMed
25) Simonet, W. S., Lacey, D. L., Dunstan, C. R. et al.:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
PubMed
26) Yasuda, H., Shima, N., Nakagawa, N. et al.:Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):a machanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337, 1998
 
27) Kong, Y. Y., Yoshida, H., Sarosi, I. et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
PubMed
28) Li, j., Sarosi, I., Yan, X. Q. et al.:RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97:1566-1571, 2000
PubMed
29) Dougall, W. C., Glaccum, M., Charrier, K. et al.:RANK is essential for osteoclast and lymph node development. Genes. Dev. 13:2412-2424, 1999
PubMed
30) Kobayashi, K., Takahashi, N., Jimi, E. et al.:Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-286, 2000
 
31) Jimi, E., Nakamura, I., Duong, L. T. et al.:Interleukin 1 induces multinucleation and bone resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247:84-93, 1999
PubMed
32) Kong, Y. Y., Feige, U., Sarosi, I. et al.:Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309, 1999
PubMed
33) Onoe, Y., Miyaura, C., Ohta, H. et al.:Expression of estrogen receptor β in rat bone. Endocrinology 138:4509-4512, 1997
 
34) Smith, E. P., Boyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994
 
35) Morishima, A., Grumbach, M. M., Simpson, E. R. et al.:Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80:3689-3698, 1995
PubMed
36) Windahl, S. H., Vidal, O., Andersson, G. et al.:Increased cortical bone mineral content but unchanged trabacular bone mineral density in female ERβ (-/-) mice. J. Clin. Invest. 104:895-901, 1999
 
37) Vidal, O., Lindberg, M. K., Hollberg, K. et al.:Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl . Acad. Sci. USA 97:5474-5479, 2000
PubMed
38) Kuro-o, M., Matsumura, Y., Aizawa, H. et al.:Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51, 1997
PubMed
39) Kawaguchi, H., Manabe, N., Miyaura, C. et al.:Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J. Clin. Invest. 104:229-237, 1999
PubMed
40) Kodama, Y., Takeuchi, Y., Suzawa, M. et al.:Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6)-Relationship to osteopenia with enhanced adipogenesis-. J. Bone Miner. Res. 13:1370-1377, 1998
PubMed
41) Weinstein, R. S., Jilka, R. L., Parfitt, A. M. et al.:Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects of bone. J. Clin. Invest. 102:274-282, 1998
 
42) Hofbauer, L. C., Gori, F., Riggs, B. L. et al.:Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells:potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389, 1999
PubMed
43) Sakai, K., Mohtai, M., Shida, J. et al.:Fluid shear stress increases interleukin-11 expression in human osteoblast-like cells:its role in osteoclast induction. J. Bone Miner. Res. 14:2089-2098, 1999
PubMed
44) Jensen, O. B., Bjarnason, N. H., Rosequist, C. et al.:Serum CrossLaps for monitoring the response anti-resorptive therapy in the individual patient. J. Bone Miner. Res. (Abstract) 14:S162 (#1119), 1999
 
45) Chapurlat, R. S., Garnero, P., Breart, G. et al.:Afternoon sampled serum CrossLaps predicts hip fracture in elderly women:The EPIDOS Study. J. Bone Miner. Res. 14:S162 (#1118), 1999
 
46) Nishi, Y., Atley, L., Eyre, D. E. et al.:Determination of bone markers in pycnodysostosis:Effects of cathepsin K deficiency on bone matrix degradation. J. Bone Miner. Res. (Abstract) 14:1902-1908, 1999
 
47) Ettinger, B., Black, D. M., Mitlak, B. H. et al.:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-year randomized Clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645, 1999
PubMed
48) Cummings, S. R., Eckert, S., Krueger, K. A. et al.:The effect of raloxifene on risk of breast cancer in postmenopausal women:results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2819-2197, 1999
 
49) Walsh, B. W., Kuller, L. H., Wild, R. A. et al.:Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451, 1998
PubMed
50) Roe, E. B., Sancez, S. D., del Puerto, G. A. et al.:Parathyroid hormone 1-34 (hPTH1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis-results from a placebo-controlled randomized trial. J. Bone Miner. Res. (Abstract) 14:S137 (#1019), 1999
 

第1章 骨・軟骨細胞の形成・分化の分子機構

P.49 掲載の参考文献
1) Poole, R.:関節軟骨と骨関節炎(藤沢隆一 訳). 蛋白質核酸酵素 40:56-67, 1995
 
2) 小澤英浩:骨. 軟骨の構造. 最新内科学体系 73:3-12, 1995
 
3) Schmidt, C., Christ, B., Patel, K. et al.:Experimental induction of BMP-4 expression leads to apoptosis in the paraxial and lateral plate mesoderm. Dev. Biol. 202(2):253-263, 1998
PubMed
4) Macias, D., Ganan, Y., Sampath, T. K. et al.:Role of BMP-2 and OP-1 (BMP-7) in programmed cell death and skeletogenesis during chick limb development. Development 124(6):1109-1117, 199
 
5) Buckland, R. A., Collinson, J. M., Graham, E. et al.:Antagonistic effects of FGF 4 on BMP induction of apoptosis and chondrogenesis in the chick limb bud. Mech. Dev. 71(1-2):143-150, 1998
 
6) Zuniga, A., Haramis, A. P., McMahon, A. P. et al.:Signal relay by BMP antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds. Nature 401 (6753):598-602, 1997
 
7) Murtaugh, L. C., Chyung, J. H., Lassar, A. B.:Sonic hedgehog promotes somitic chondrogenesis by altering the cellular response to BMP signaling. Genes Dev. 13(2):225-237, 1999
PubMed
8) Mo, R., Freer, A. M., Zinyk, D. L. et al.:Specific and redundant functions of Gli2 and Gli3 zinc finger genes in skeletal patterning and Development. Development 124(1):113-123, 1997
PubMed
9) Rintala, M., Metsaranta, M., Saamanen, A. M. et al.:Abnormal craniofacial growth and early mandibular osteoarthritis in mice harbouring a mutant type II collagen transgene. J. Anat. 190:201-208, 1997
PubMed
10) Saamanen, A. M., Tammi, M., Jurvelin, J. et al.:Proteoglycan alterations following immobilization and remobilization in the articular cartilage of young canine knee (stifle) joint. J. Orthopaedic Res. 8(6):863-873, 199
 
11) Kato, Y., Nomura, Y., Daikuhara, Y. et al.:Cartilage-derived factor (CDF) I. Stimulation of proteoglycan synthesis in rat and rabbit costal chondrocytes in culture. Exp. Cell Res. 130 (1):73-81, 1980
PubMed
12) Kato, Y., Watanabe, R., Nomura, Y. et al.:Effect of bone-derived growth factor on DNA, RNA, and proteoglycan synthesis in cultures of rabbit costal chondrocytes. Metabol. Clin. Exp. 31 (8):812-815, 1982
 
13) Nakamura, H., Ozawa, H.:Immunohistochemical localization of heparan sulfate proteoglycan in rat tibiae. J. Bone Miner. Res. 9(8):1289-1299, 1994
PubMed
14) Hiraki, Y., Tanaka, H., Inoue, H. et al.:Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes. Biochem. Biophys. Res. Commun. 175:971-977, 1991
PubMed
15) Gerber, H. P., Vu, T. H., Ryan, A. M. et al.:VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5(6):623-628, 1999
PubMed
16) Vu, T. H., Shipley, J. M., Bergers, G. et al.:MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93(3):411-422, 1998
PubMed
17) Simonet, W. S., Lacey, D. L., Dunstan, C. R. et al.:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89(2):309-319, 1997
PubMed
18) Ikeda, T., Nomura, S., Yamaguchi A. et al.:In situ hybridization of bone matrix proteins in undercalcified adult rat bone sections. J. Histochem. Cytochem. 40:1079-1088, 1992
 
19) Wuthier, R. E.:The role of phospholipids in biological calcification:distribution of phospholipase activity in calcifying epiphyseal cartilage. Clin. Orthop. Res. 90:191-200, 1973
PubMed
20) Wuthier, R. E.:Proposed mechanism of matrix vesicle formation and vesicle-mediated mineralization. (Ascenzi A., Bonucci E., Bernard B. eds.:matrix vesicles) Wichting Editore srl., Milano, 1981, p.103
 
21) 須田立雄, 小澤英浩, 高橋栄明:骨の科学. 医歯薬出版, 1986
 
22) Fleish, H., Neuman, W. F.:Mechanisms of calcification:role of collagen, polyphosphates, and phosphate. Am. J. Physiol. 200:1296-1300, 1961
PubMed
23) Arana-Chavez, V. E., Soares, A. M. V., Katchburian, E.:Junctions between early developing osteoblasts of rat calvaria as revealed by freeze-fracture and ultrathin section electron microscopy. Arch. Histol. Cytol. 58(3):285-292, 1995
 
24) Tsukita, S., Oishi, K., Akiyama, T. et al.:Specific proto-oncogenic tyrosine kinases of src family are enriched in cell-to-cell adherens junctions where the level of tyrosine phosphorylation is elevated. J. Cell Biol. 113:867-879, 1991
PubMed
25) Lee, Y. S., Chuong, C. M.:Adhesion molecules in skeletogenesis:I. Transient expression of neural cell adhesion molecules (NCAM) in osteoblasts during endochondral and intramembranous ossification. J. Bone Miner. Res. 7:1435-1446, 1992
PubMed
26) Nakamura, H., Kenmotsu, S., Sakai, H. et al.:Localization of CD 44, the hyaluronate receptor, on the plasma membrane of osteocytes and osteoclasts in rat tibiae. Cell. Tissue Res. 280:225-233, 1995
 
27) Clover, J., Dodds, R. A., Gowen, M.:Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. J. Cell Sci. 103:267-271, 1992
PubMed
28) Grzesik, W. J., Robey, P. G.:Bone Matrix RGD Glycoproteins:Immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J. Bone Miner. Res. 9:487-496, 1994
PubMed
29) Katagiri, T., Yamaguchi, A., Komaki, M. et al.:Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127(6):1755-1766, 1994
PubMed
30) Wang, E. A., Israel, D. I., Kelly, S. et al.:Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 land 3T3 cells. Growth Factors 9(1):57-71, 1993
 
31) Winnier, G., Blessing, M., Labosky, P. A. et al.:Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 9(17):2105-2116, 1995
PubMed
32) Tanaka, M., Amizuka, N. Kim, K. J. et al.:Histochemical Examination of Ectopic Bone Formation Induced in Rat Bone Marrow. J. Bone Miner. Metab. 15:67-76, 1997
 
33) Amizuka, N., Yamada, M., Watanabe, J. et al.:Morphological examination of bone synthesis via direct administration of basic fibroblast growth factor into rat bone marrow. Micro. Res. Tech. 41:313-322, 1998
 
34) Nagai, H., Tsukuda, R., Mayahara, H.:Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 16:367-373, 1995
 
35) Peters, K., Ornitz, D., Werner, S. et al.:Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev. Biol. 155:423-430, 1993
PubMed
36) Peters, K. G., Werner, S., Chen, C. et al.:Two FGF receptor genes are differentially expressed in epitheila and mesenchymal tissues during limb formation and organogenesis in the mouse. Develoment 114:233-243, 1992
 
37) Miles, R. R., Turner, C. H., Santerre, R. et al.:Analysis of differential gene expression in rat tibia after an osteogenic stimulus in vivo:mechanical loading regulates osteopontin and myeloperoxidase. J. Cell. Biochem. 68(3):355-365, 1998
PubMed
38) Chow, J. W. M., Wilson, T. J., Chambers, T. J. et al.:Mechanical loading stimulates bone formation by reactivation of bone lining cells in 13-week-old rats. J. Bone Miner. Res. 13(11):1760-1767, 1998
 
39) Fitzsimmons, R. J., Ryaby, J. T., Magee, F. P. et al.:IGF-II receptor number is increased in TE-85 osteosarcoma cells by combined magnetic fields. J. Bone Miner. Res. 10(5):812-819, 1995
PubMed
40) Shinar, D. M., Endo, N., Halperin, D. et al.:Differential expression of insulin like growth factor-I (IGF-I) and IGF-II messenger ribonucleic acid in growing rat bone. Endocrinology 132(3):1158-1167, 1993
PubMed
41) Jackson, S. M., Demer. L. L.:Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett. 471(1):119-124, 2000
PubMed
42) Hara, F., Fukuda, K., Ueno, M. et al.:Pertussis toxin-sensitive G proteins as mediators of stretch induced decrease in nitric-oxide release of osteoblast-like cells. J. Orthop. Res. 17(4):593-597, 1999
 
43) Sato, M., Ochi, T., Nakase, T. et al.:Mechanical tension-stress induces expression of bone morphogenetic protein (BMP)-2 and BMP-4, but not BMP-6, BMP-7, and GDF-5 mRNA, during distraction osteogenesis. J. Bone Miner. Res. 14(7):1084-1095, 1999
 
44) Ikegame, M., Ishibashi, O., Yoshizawa, T. et al.:Tensile stress induces bone morphogenetic protein 4 (BMP-4) in preosteoblastic and fibroblastic cells, which later differentiate into osteoblasts leading to osteogenesis in the mouse calvariae in organ culture. J. Bone Miner. Res. (in press)
 
45) Horiuchi, K., Amizuka, N., Takeshita, S. et al.:Identification and characterization of a novel protein, Periostin (OSF-2) with restricted expression to periosteum and periodontal ligament and increased expression by transforming factor. J. Bone Miner. Res. 14:1239-1249, 1999
 
46) Mark, M. P., Butler, W. T. et al.:Developmental expression of 44-kDa phosphoprotein (osteopontin) and boneγ-carboxyglutamic acid (Gla)-containin protein (osteocalcin) in calcifying tissues of rat. Differentiation 37:123-136, 1988
 
47) Bosky, A. L, Maresca, M., Ullrich, W. et al.:Osteopontin-hydroxyapatite interactions in vitro:Inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 22:147-159, 1993
 
48) Nomura, S., Wills, A. J., Edwards, D. R. et al.:Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. J. Cell Biol. 106:441-450, 1988
PubMed
49) McKee, M. D., Nanci, A.:Post-embedding colloidal-gold immunocytochemistry of non-collagenous extracellualr matrix proteins in mineralized tissues. Microsc. Res. Tech. 31:44-62, 1995
 
50) McKee, M. D., Nanci, A.:Osteopontin at mineralized tissue interfaces in bone teeth and osteointegrated implants:Ultrastructural distribution and implications for mineralized tissue formation, turnover and repair. Microsc. Res. Tech. 33:141-164, 1996
 
51) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382(6590):448-452, 1996
PubMed
52) Luo, G., Ducy, P., McKee, M. D. et al.:Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386(6620):78-81, 1997
PubMed
53) Yoshitake, H., Rittling, S. R., Denhardt, D.T. et al.:Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc. Natl. Acad. Sci. USA 96(14):8156-8160, 1999
PubMed
54) Asou, Y., Amizuka, N., Yamashita, T. et al.:Osteopontin-deficient bone is defective in angiogenesis, osteoclast recruitment and ectopic resorption. J. Bone Miner. Res. 14:s133, 1999
 
55) McKee, M. D., Farach-Carson, M. C., Butler, W. T. et al.:Ultrastructural immunolocalization of non-collagenous (osteopontin and osteocalcin) and plasma (albumin and α2HS-glycoprotein) proteins in rat bone. J. Bone Miner. Res. 8:485-496, 1993
 
56) Hamilton, J. A., Lingelbach, S. R., Partridge, N. C. et al.:Stimulation of plasminogen activator in osteoblast-like cells by bone-resorbing hormones. Biochem. Biophys. Res. Commun. 122:230-236, 1984
PubMed
57) Jilka, R. L., Weinstein, R. S., Bellido, T. et al.:Osteoblast programmed cell death (apoptosis):modulation by growth factors and cytokines. J. Bone Miner. Res. 13(5):793-802, 1998
PubMed
58) Aarden, E. M., Wassenaar, A. M., Alblas, M. J. et al.:Immunocytochemical demonstration of extracellular matrix proteins in isolated osteocytes. Histochem. Cell Biol. 106(5):495-501, 1996
PubMed
59) Aarden, E. M., Burger, E. H., Nijweide, P. J.:Function of osteocytes in bone. J. Cell. Biochem. 55(3):287-299, 1994
 
60) Doty, S. B.:Morphological evidence of gap junctions between bone cells. Calcif. Tissue Int. 33:509-512, 1981
PubMed
61) Palumbo, C., Palazzini, S., Marotti, G.:Morphological study of intercellular junctions during osteocyte differentiation. Bone 11:401-406, 1990
PubMed
62) Belanger, L. F.:Osteocytic osteolysis. Calcif. Tissues Res. 4:1-12, 1969
PubMed
63) Pollak, M. R., Brown, E. M., Chou, Y. H. et al.:Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism Cell 75:1297-1303, 1993
PubMed
64) Desfleurs, E., Wittner, M., Simeone, S. et al.:Calcium-sensing receptor:regulation of electrolyte transport in the thick ascending limb of Henle's loop. Kidney & Blood Pressure Research 21(6):401-412, 1998
PubMed
65) 真野 博, 前島朋子, 久米川正好:骨細胞(osteocyte)を介するシグナリング, 骨形成 ・吸収のシグナリングと骨疾患. 実験医学 14(10):103-108, 1996
 
66) Chambers, T. J., Ali, N. N.:Inhibition of osteoclastic motility by prostaglandins I2, E1, E2 and 6-oxo-E1. J. Pathol. 139:383-389, 1983
PubMed
67) Rawlinson, S. C., Mosley, J. R., Suswillo, R. F. et al.:Calvarial and limb bone cells in organ and monolayer culture do not show the same early responses to dynamic mechanical strain. J. Bone Miner. Res. 10:1225-1232, 1995
PubMed
68) Rawlinson, S. C., Mohan, S., Baylink, D. J. et al.:Exogenous prostacyclin, but not prostaglandin E2, produces similar responses in both G6Pd activity and RNA production as mechanical loading, and increases IGF-II release, in adult cancellous bone in culture. Calcif. Tissue Int. 53:324-329, 1993
 
69) Lean, J. M., Mackay, A. G., Chow, J. W. et al.:Osteocytic expression of mRNA for c-fos and IGF-I:an immediate early gene response to an osteogenic stimulus. Am. J. Physiol. 270:E937-E945, 1996
 
70) Ypey, D. L., Weidema, A. F., Nijweide, P. J. et al.:Voltage, calcium, and stretch activated ionic channels and intracellular calcium in bone cells. J. Bone Miner. Res. 7 (Suppl.2):S377-S387, 1992
 
71) Resnick, N., Collins, T., Atkinson, W. et al.:Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc. Natl. Acad. Sci. USA 90:4591-4595, 1993
PubMed
72) Drake, F. H., Dodds, R. A., James, I. E. et al.:Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271(21):12511-12516, 1996
 
73) Minkin, C.:Bone acid phosphatase:tratrate resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 34:285-290, 1982
 
74) Salo, J., Lehenkari, P., Mulari, M. et al.:Removal of osteoclast bone resorption products by transcytosis. Science 276:270-273, 1997
PubMed
75) Nesbitt, S. A., Horton, M. A.:Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 276:266-269, 1997
PubMed
76) Nakamura, H., Ozawa, H.:Ultrastructural, enzyme-, lectin-and imunohistochemical studies of the erosion zone in rat tibiae. J. Bone Miner. Res. 11:1158-1164, 1996
 
77) Nakamura, H., Kenmotsu, S., Sakai, H. et al:Localization of CD44, the hyaluronate receptor, on the plasma membrane of osteocytes and osteoclasts in rat tibiae. Cell. Tissue Res. 280:225-233, 1995
PubMed
78) Nakamura, H., Moriyama, Y., Futai, M. et al.:Immunohistochemical localization of vacuolar H+-ATPase in osteoclasts of rat tibiae. Arch. Histol. Cytol. 57:535-539, 1994
PubMed
79) Baron, R., Neff, L, Brown, W. et al.:Cell-mediated extracellular acidification and bone resorption:evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J. Cell Biol. 101:2210-2222, 1985
 
80) Chambers, T. J., Revell, P. A., Fuller, K. et al.:Resorption of bone by isolated rabbit osteoclasts. J. Cell Sci. 66:383-399, 1984
PubMed
81) Akatsu, T., Takahashi, N., Debari, K. et al.:Prostaglandins promote osteoclast like cell formation by a mechanism involving cyclic adenosine 3',5'-monophosphate in mouse bone marrow cell cultures. J. Bone Miner. Res. 4(1):29-35, 1989
PubMed
82) Goto, T., Tsukuba, T., Kiyoshima, T. et al.:Immunohistochemical localization of cathepsins B, D and L in the rat osteoclast. Histochemistry 99(5):411-414, 1993
PubMed
83) Kakudo, S., Mano, H., Shiokawa, M. et al.:Concanavalin A directly stimulates bone-resorbing activity of osteoclasts and their gene expression of cathepsin K/OC-2. Biochem. Biophys. Res. Commum. 234 (3):600-604, 1997
 
84) Horton, M. A., Nesbit, M. A., Helfrich, M. H.:Interaction of osteopontin with osteoclast integrins. Ann. N. Y. Acad. Sci. 760:190-200, 1995
PubMed
85) Reponen, P., Sahlberg, C., Munaut, C. et al.:High expression of 92 kD type IV collagenase (gelatinasel B) in the osteoclast lineage during mouse development. J. Cell Biol. 124:1091-1103, 1994
PubMed
86) Okada, Y., Naka, K., Kawamura, K. et al.:Localization of matrix metalloproteinase 9 (92= kilodalton gelatinase/type IV collagenase=gelatinase B) in osteoclasts:Implications for bone resorption. Lab. Invest. 72:311-323, 1995
PubMed
87) Ejiri, S.:The preosteoclast and its cytodifferentiation into the osteoclast:ultrastructural and histochemical studies of rat fetal parietal bone. Arch. Histol. Jap. 46:533-577, 1983
PubMed
88) Burger, E. H., van der Meer, J. W., Nijweide, P. J. et al.:Osteoclast fromation from mononuclear phagocytes:role of bone-forming cells. J. Cell Biol. 99:1901-1906, 1984
 
89) Fuller, K., Gallagher, A. C., Chambers, T. J.:Osteoclast resorption stimulating activity is associated with the osteoblast cell surface and/or the extracellular matrix. Biochem. Biophys. Res. Commun. 181:67-73, 1991
PubMed
90) Yasuda, H., Shima, N., Nakagawa, N. et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95(7):3597-3602, 1998
PubMed
91) Kodama, H., Nose, M., Niida, S. et al.:Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med. 173:1291-1294, 1991
PubMed
92) Ikegame, M., Ejiri, S., Ozawa, H.:Histochemical and autoradiographic studies on Elcatonin in internalization and intracellular movement in osteoclasts. J. Bone Miner. Res. 9(1):25-37, 1994
PubMed
93) Warshawsky, H., Goltzman, D., Rouleau, M. F. et al.:Direct in vivo demonstration by radioautography of specific binding sites for calcitonin. J. Cell Biol. 85:682-694, 1980
PubMed
94) Hughes, D. E, Wright, K. R., Uy, H. L et al.:Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10 (10):1478-1487, 1995
PubMed
95) Hara-Irie, F, Amizuka, N, Ozawa, H.:Immunohistochemical and ultrastructural localization of CGRP-positive nerve fibers at the distal trabecules facing the growth plate of rat femurs. Bone 18:29-39, 1996
 
96) Tran, V. P., Vignery, A., Baron, R.:An electron-microscopic study of the bone-remodeling sequence in the rat. Cell Tissue Res. 225 (2):283-292, 1982
 
97) Wu, C.-H., Hara, K., Ozawa, H.:Enhanced osteoinduction by intramuscular grafting of BMP-β-TCP-compound pellets into murine models. Arch. Histol. Cytol. 55:97-112, 1992
 
98) Okuda, K., Nakajima, Y., Irie, K. et al.:Transforming growth factoer β-1 coated β-tricalcium phosphate pellets are osteoinductive in experimental bone defects of rat calvaria. Oral Dis. 1:92-97, 1995
 
P.65 掲載の参考文献
1) 須田立雄:硬組織の形成と吸収のしくみ. 口腔生化学, 第二版. (早川太郎, 須田立雄 編)医歯薬出版, 1994, p.89-111
 
2) Suzuki, F., Yoneda, T., Shimomura, Y.:Calcitonin and parathyroid hormone stimulation of acid mucopolysaccharide synthesis in cultured chondrocytes isolated from growth cartilage. FEBS Lett. 70:155-158, 1976
PubMed
3) Takigawa, M., Takano, T., Suzuki, F.:Effect of parathyroid hormone and cyclic AMP analogues on the activity of ornithine decarboxylase and expression of the differentiated phenotype of chondrocytes in culture. Cell. Physiol. 106:259-268, 1981
PubMed
4) Takigawa, M., Ishida, H., Takano, T. et al.:Polyamine and differentiation:Induction of ornithine decarboxylase by parathyroid hormone is a good marker of differentiated chondrocytes. Proc. Natl. Acad. Sci. USA 77:1481-1485, 1980
PubMed
5) 滝川正春, 鈴木不二男:軟骨細胞-細胞培養を中心に. 最新組織培養応用研究法, in vitro アッセイと有用物質生産. (山根績 編)ソフトサイエンス社, 1985, p.116-128
 
6) Kato, Y., Shimazu, A., Nakashima, K. et al.:Effect of parathyroid hormone and calcitonin on alkaline phosphatase activity and matrix calcificaton in rabbit growth-plate chondrocyte cultures. Endocrinol. 127:114-118, 1990
 
7) Enomoto, M., Kinoshita, A., Pan, H.-O. et al.:Demonstration of receptors for parathyroid hormone on cultured rabbit costal chondrocytes. Biochem. Biophys. Res. Commun. 162:1222-1229, 1989
PubMed
8) Koike, T., Iwamoto, M., Shimazu, A. et al.:Potent mitogenic effects of parathyroid hormone (PTH) on embryomic chick and rabbit chondrocytes. J. Clin. Invest. 85:626-631, 1990
 
9) Juppner, H., Abou-Samra, A.-B., Freeman, M. et al:A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024-1026, 1991
 
10) Abou-Samra, A.-B., Juppner, H., Force, T. et al.:Expression cloning of common receptor for parathyriod hormone and parathyroid hormone-related peptide from rat osteoblast-like cells:A single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc. Natl. Acad. Sci. USA 89:2732-2736, 1992
 
11) Urena, P., Kong, X.-F., Abou-Samra, A.-B. et al.:Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinol. 133:617-623, 1993
 
12) Lee, C., Gardella, T. J., Abou-Samra, A.-B. et al.:Role of the extracellular regions of the parathyriod hormone (PTH)/PTH-related peptide receptor in hormone binding. Endocrinol. 135:1488-1495, 1994
 
13) Schipani, E., Kruse, K., Juppner, H.:Aconstitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98-100, 1995
PubMed
14) Lanske, B., Karaplis, A., Luz, A. et al.:Characterization of mice heterozygous for the parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor gene knockout. Bone 16:86S, 1995
 
15) Takahashi, O. K., Okamoto, T., Krane, S. M. et al.:Stimulation by glycocorticoids of the differentiated phenotype of chondrocytes and the proliferation of rabbit costal chondrocytes in culture. Bone 16:87S, 1995
 
16) Takigawa, M., Enomoto, M., Shirai, E. et al.:differential effects of 1α, 25-dihydroxycholecalciferol and 24R, 25-dihydroxycholecalciferol on the proliferation and the differential phenotype of rabbit costal chondrocytes in culture. Endocrinol. 122:831-839, 1988
 
17) Yoshizawa, T., Handa, Y., Uematsu, Y. et al.:Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16:391-396, 1997
PubMed
18) 滝川正春:ヒト軟骨肉腫由来の軟骨培養細胞株(HCS-2/8). The Bone 12:37-43, 1990
 
19) Enomoto, M., Takigawa, M.:Regulation of tumor-derived and immortalized chondrocytes. Biological Regulation of the Chondrocyte. (Adolphe, M. ed. ) CRC press, Boca Raton, Florida, 1992, p.321-338
 
20) 高橋浩二郎, 滝川正春:軟骨と成長の制御. CLINICAL CALCIUM 5:29-32, 1995
 
21) Enomoto, M., Pan, H.-O., Suzuki, F. et al:Physiological role of vitamin A in growth cartilage cells:Low concentrations of retinoic acid strongly promote the proliferation of rabbit costal growth cartilage cell in culture. J. Biochem. 107:743-748, 1990
 
22) Iwamoto, M., Golden, E. B., Adams, S. L. et al.:Responsiveness to retinoic acid changes during chondrocyte maturation. Exp. Cell Res. 205:213-224, 1993
PubMed
23) 野地澄晴, 吉岡秀文, 谷口茂彦:発生分化とレチノイン酸レセプター. 実験医学 10:2368-2369, 1992
 
24) Saitou, M., Sugai, S., Tanaka, T. et al.:Inhibition of skin development by targeted expression of adominant-negative retinoic acid receptor. Nature 374:159-162, 1995
 
25) Trippel, S. T.:Role of IGF in the regulation of chondrocyte. Biological Regulation of the Chondrocyte. (Adolphe, M. ed.) CRC Press, Boca Raton, Florida, 1992, p.161-190
 
26) Klangsbrun, M., Langer, R., Levenson, R. et al.:The stimulation of DNA and cell division in chondrocytes and 3T3 cells by a growth factor isolated from cartilage. Exp. Cell Res. 105:99-108, 1977
 
27) Lobb, R., Sasse, J., Sullivan, R. et al.:Purification and characterization of heparine-binding endothelial cell growth factors. J. Biol. Chem. 261:1924-1928, 1986
PubMed
28) Kato, Y., Iwamoto, M.:Fibroblast growth factor is an inhibitor of chondrocyte terminal Differentiation. J. Biol. Chem. 265:5903-5909, 1990
PubMed
29) Iwamoto, M., Shimazu, A., Nakashima, K. et al.:Reduction of basic fibroblast growth factor receptor is coupled with terminal differentiation of chondrocytes. J. Biol. Chem. 266:461-467, 1991
PubMed
30) Erlebacher, A., Filvaroff, E. H., Gitelman, S. E. et al.:Toward a molecular understanding of skeletal development. Cell 80:371-378, 1995
 
31) Noda, M., Camilliere, J. J.:In vivo stimulation of bone formation by transforming growth factor-β. Endocrinol. 24:2991-2994, 1989
 
32) Gitelman, S. E., Kobrin, M. S. Ye, J.-Q. et al.:Recombinant Vgr-1/BMP-6-expressing tumors induce fibrosis and endochondral bone in vivo. J. Cell Biol. 126:1595-1609, 1994
PubMed
33) Chang, S. C., Hoang, B., Thomas, J. T. et al.:Cartilage-delived morphogenetic proteins (new members of the transforming growth factor-β superfamily predominantly expressed in long bones during human embryonic development) J. Biol. Chem. 269:28227-28234, 1994
 
34) Tsumaki, N., Tanaka, K., Arikawa-Hirasawa, E. et al.:Role of CDMP-1 in skeletal morphogenesis:promotion of mesenchymal cell recruitment and chondrocyte differentiation. J. Cell Biol. 144:161-173, 1999
PubMed
35) Nakanishi, T., Kimura, Y., Tamura, T. et al.:Cloning of a mRNA preferentially expressed in chondrocytes by differential display-PCR from a human chondrocytic cell line that is identical with connective tissue growth factor (CTGF) mRNA. Biochem. Biophys. Res. Commun. 234:206-210, 1997
PubMed
36) 中西徹, 滝川正春:結合組織成長因子CTGF/Hcs 24の生理機能-内軟骨性骨化における役割. 生化学 71:429-432, 1999
 
37) Nakanishi, T., Nishida, T., Shimo, T. et al.:Effects of CTGF/Hcs24, a product of a hypertrophic chondrocyte-specific gene, on the proliferation and differentiation of chondrocytes in culture. Endocrinol. 141:264-273, 2000
 
38) Shimo, T., Nakanishi, T., Nishida, T. et al.:Connective tissue growth factor induces the proliferation, migration and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J. Biochem. 126:137-145, 1999
PubMed
39) Gerber, H. P., Vu, T. H., Ryan, A. M. et al.:VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5:623-628, 1999
PubMed
40) Takigawa, M., Nishida, Y., Suzuki, F. et al.:Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2) . Biochem. Biophys. Res. Commun. 171:1264-1271, 1990
PubMed
41) Takigawa, M., Shirai, E., Enomoto, M. et al.:Cartilage-derived anti-tumor factor (CATF):Partial purification and correlation of inhibitory activity against tumor growth with anti-angiogenic activity. J. Bone Miner. Metabol. 6:83-92, 1988
 
42) Takigawa, M., Pan, H.-O., Enomoto, M. et al.:Aclonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res. 10:311-316, 1990
 
43) Ohba, Y., Goto, Y., Kimura, Y. et al.:Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochim. Biophys. Acta 1245:1-8, 1995
PubMed
44) Vortkamp, A., Lee, K., Lanske, B. et al.:Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613-622, 1996
PubMed
45) St Jacques, B., Hammerschmidt, M., McMahon, A. P.:Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13:2072-2086, 1999
PubMed
46) Karp, S. J., Schipani, E., St Jacques, B. et al.:Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and-independent pathways. Development 127:543-548, 2000
PubMed
47) Kimata, K., Barrach, H. J., Brown, K. S. et al.:Absence of proteoglycan core protein in cartilage from the cmd/cmd (cartilage matrix deficiency) mouse. J. Biol. Chem. 256:6961-6968, 1981
PubMed
48) Sandell, L. J., Morris, N., Robbins, J. R. et al.:Alternative speliced type II procollagen mRNAs define distrct populations of cells during vertebral development:Differential expression of the amino-propeptide. J. Cell Biol. 114:1307, 1991
 
49) Tuckwell, D. S., Ayad, S., Grant, M. E. et al.:Conformation dependence of integrin-type II collagen binding, Inability of collagen peptides to support α2β1 binding, and mediation of adhesion to denatured collagen by a novel α5β1-fibronectine bridge. J. Cell Sci. 107:993-1005, 1994
 
50) Chan, D., Cole, W. G., Chow, C. W. et al.:ACOL2A1 mutation in achondrogenesis type II results in the replacement of type II collagen by type I and III collagens in cartilage. J. Biol. Chem. 270:1714-1753, 1995
 
51) Rosati, R., Horan, G. S. B., Pinero, G. J. et al.:Normal long bone growth and development in type X collagen-null mice. Nat. Genet. 8:129-135, 1994
 
52) Li, Y., Lacerda, D. A., Warman, M. L. et al.:A fibrillar collagen gene, Col11a1, is essential for skeletal morphogenesis. Cell 80:423-430, 1995
PubMed
53) Vikkula, M., Mariman, E. C. M., Lui, V. C. H. et al.:Autosomal dominant and recessive osteochondrodysplasias associated with the COL11A2 locus. Cell 80:431-437, 1995
 
54) Lefebvre, V., de Crombrugghe, B.:Toward understanding SOX9 function in chondrocyte differentiation. Matrix Biol. 16:529-540, 1998
PubMed
55) Lefebvre, V., Li, P., de Crombrugghe, B.:A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. EMBO J. 17:5718-5733, 1998
PubMed
56) Asp, J., Thornemo, M., Inerot, S. et al.:The helix-loop-helix transcription factors Id1 and Id3 have a functional role in control of cell division in human normal and neoplastic chondrocytes. FEBS Lett. 438:85-90, 1998
PubMed
57) Nakazawa, M., Hasunuma, T., Ohshima, T. et al.:CBP:Atarget molecule of HTLV-1 Tax in synoviocyte activation. Biochem. Biophys. Res. Commun. 269:584-590, 2000
 
58) Enomoto, H., Enomoto-Iwamoto, M., Iwamoto, M. et al.:Cbfa 1 is a positive regulatory factor in chondrocyte maturation. J.Biol. Chem. 275:8685-8702, 2000
 
59) Takigawa, M., Tajima, K., Pan, H.-O. et al.:Establishment of a clonal human chondrosarcoma cell line with cartilage phenotypes. Cancer Res. 49:3996-4002, 1989
PubMed
60) 滝川正春:HCS-2/8, バイオテクノロジー素材としての培養細胞. 骨代謝(I). (久米川正好 編) 蛋白質核酸酵素 34:898-900, 1989
 
61) 滝川正春:軟骨培養細胞株の樹立. 組織培養 15:165-169, 1989
 
62) Zhu, J., Pan, H.-O., Suzuki, F. et al.:Proto-oncogene expression in a human chondrosarcoma cell line:HCS-2/8. Jpn. J. Cancer Res. 85:364-371, 1994
 
P.77 掲載の参考文献
1) Cooper, E. L., Klempau, A. E., Ramirez, J. A. et al.:Source of stem cells in evolution. In:development and differentiation of vertebrate lymphocytes. (Horton, J. D. ed. ) Elsevier/North-Holland, Amsterdam, 1980, p.3-14
 
2) Kurokawa, K.:The kidney and calcium homeostasis. Kidney Int. 45:97-105, 1994
 
3) Medvinsky, A., Dzierzak, E.:definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86:897-906, 1996
PubMed
4) Yoder, M. C., Hiatt, K., Mukherjee, P.:In vivo repopulating hematopoietic stem cells are present in the murine yolk sac at day 9.0 postcoitus. Proc. Natl. Acad. Sci. USA 94:6776-6780, 1997
 
5) Yoder, M. C., Hiatt, K., Dutt, P. et al.:Characterization of definitive lymphohematopoietic stem cells in the day 9 murine yolk sac. Immunity 7:335-344, 1997
PubMed
6) Godin, I., Dieterlen-Lievre, F., Cumano, A.:Emergence of multipotent hemopoietic cells in the yolk sac and paraaortic splanchnopleura in mouse embryos, beginning at 8.5 day postcoitus. Proc. Natl. Acad. Sci. USA 92:773-777, 1995
 
7) Cumano, A., Franise Dieterlen-Lievre, F., Godin, I.:Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. Cell 86:907-916, 1996
PubMed
8) Gerber, H.-P., Vu, T. H., Ryan, A. M. et al.:VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Med. 5:623-628, 1999
PubMed
9) Ash, P., Loutit, J. F., Townsend, K. M.:Osteoclasts derived from haematopoietic stem cells. Nature 283:669-670, 1980
PubMed
10) Scheven, B. A., Visser, J. W., Nijweide, P. J.:In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature 321:79-81, 1986
PubMed
11) Kurihara, N., Chenu, C., Miller, M. et al.:Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. Endocrinology 126:2733-2741, 1990
PubMed
12) Takahashi, N., Akatsu, T., Udagawa, N. et al.:Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600-2602, 1988
PubMed
13) Udagawa, N., Takahashi, N., Akatsu, T. et al.:The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 125:1805-1813, 1989
PubMed
14) Tanaka, S., Takahashi, N., Udagawa, N. et al.:Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91:257-263, 1993
PubMed
15) Yoshida, H., Hayashi, S., Kunisada, T. et al.:The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442-444, 1990
PubMed
16) Hofstetter, W., Wetterwald, A., Cecchini, M. C. et al.:detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts. Proc. Natl. Acad. Sci. USA 89:9637-9641, 1992
PubMed
17) Lacey, D. L, Timms, E., Tan, H. L. et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
PubMed
18) Yasuda, H., Shima, N., Nakagawa, N. et al.:Osteoclast differeritiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998
PubMed
19) Anderson, D. M., Maraskovsky, E., Billingsley, W. L. et al.:A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997
PubMed
20) Wong, B. R., Rho, J., Arron, J. et al.:TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190-25194, 1997
 
21) Yeh, W. C., Shahinian, A., Speiser, D. et al.:Early lethality, functional NF-B activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7:715-725, 1997
 
22) Galibert, L, Tometsko, M. E., Anderson, D. M. et al.:The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-B, a member of the TNFR superfamily. J. Biol. Chem. 273:34120-34127, 1998
 
23) Wong, B. R., Josien, R., Lee, S. Y. et al.:The TRAF family of signal transducers mediates NF-B activation by the TRANCE receptor. J. . Biol. Chem. 273:28355-28359, 1998
PubMed
24) Hsu, H., Lacey, D. L., Dunstan, C. R. et al.:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96:3540-3545, 1999
PubMed
25) Lomaga, M. A., Wen-Chen, W. Y., Sarosi, I. et al.:TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13:1015-1024, 1999
 
26) Iotsova, V., Caamano, J., Loy, J. et al.:Osteopetrosis in mice lacking NF-B1 and NF-B2. Nature Med. 3:1285-1289, 1997
 
27) Franzoso, G., Carlson, L., Xing, L. et al.:Requirement for NF-B in osteoclast and B-cell development. Genes Dev. 11:3482-3496, 1997
 
28) Kong, Y. Y., Yoshida, H., Sarosi, I. et al.:OPGL is a key regulator of osteoclastogenesis, lyrnphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
PubMed
29) Dougall, W. C., Glaccum, M., Charrier, K. et al.:RANK is essential for osteoclast and lymph node development. Genes Dev. 13:2412-2424, 1999
PubMed
30) Spangrude, G. J., Heimfeld, S., Weissman, I. L.:Purification and characterization of mouse hematopoietic stem cells. Science 241:58-62, 1988
PubMed
31) Okada, S., Nakauchi, H., Nagayoshi, K. et al.:In vivo and in vitro stem cell function of c-kit-and Sca-1-positive murine hematopoietic cells. Blood 80:3044-3050, 1992
PubMed
32) Morrison, S. J., Hemmati, H. D., Wandycz, A. M. et al.:The purification and characterization of fetal liver hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 92:10302-10306, 1995
PubMed
33) Sariban, E., Mitchell, T., Kufe, D.:Expression of the c-fms proto-oncogene during human monocytic differentiation. Nature 316:64-66, 1985
 
34) Arai, F., Miyamoto, T., Ohneda, O. et al.:Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor B (RANK) receptors. J. Exp. Med. 190:1741-1754, 1999
 
35) Begg, S. K., Bertoncello, I.:The hematopoietic deficiencies in osteopetrotic (op/op) mice are not permanent, but progressively correct with age. Exp. Hematol. 21:493-495, 1993a
PubMed
36) Begg, S. K., Radley, J. M., Pollard, J. W. et al.:Delayed hematopoietic development in osteopetrotic (op/op) mice. J. Exp. Med. 177:237-242, 1993b
 
37) Lagasse, E., Weissman, I. L.:Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 89:1021-1031, 1997
PubMed
38) Scott, E. W., Simon, M. C., Anastasi, J. et al.:Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265:1573-1577, 1994
PubMed
39) Grigoriadis, A. E., Wang, Z. Q., Cecchini, M. G. et al.:c-Fos:a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443-448, 1994
PubMed
40) Hodgkinson, C. A., Moore, K. J., Nakayama, A. et al.:Mutation at the mouse micropthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74:395-404, 1993
 
41) Baldwin, A. S. Jr.:The NF-xB and IxB proteins:New discoveries and insights. Annu. Rev. Immunol. 14:649-683, 1996
 
P.89 掲載の参考文献
1) Takahashi, N., Akatsu, T., Udagawa, N. et al.:Osteoblastic cells are involved in osteoclast differentiation. Endocrinology 123:2600-2602, 1988
PubMed
2) Udagawa, N., Takahashi, N., Akatsu, T. et al.:Origin of osteoclasts:mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA 87:7260-7264, 1990
 
3) Suda, T., Takahashi, N., Suda, T. et al.:Modulation of osteoclast differentiation. Endocr. Rev. 13:66-80, 1992
PubMed
4) Takeda, S., Yoshizawa, T., Nagai, Y. et al.:Stimulation of osteoclast formation by 1, 25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells:studies using VDR knockout mice. Endocrinology 140:1005-1008, 1999
PubMed
5) Liu, B. Y., Guo, J., Lanske, B. et al.:Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 139:1952-1964, 1998
PubMed
6) Sakuma, Y., Tanaka, K., Suda, M. et al.:Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast fomation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res. 15:218-227, 2000
 
7) Udagawa, N., Takahashi, N., Katagiri, T. et al.:Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast Progenitors. J. Exp. Med. 182:1461-1468, 1995
 
8) Jimi, E., Nakamura, I., Amano, H. et al.:Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137:2187-2190, 1996
 
9) Suda, T., Nakamura, I., Jimi, E. et al.:Regulation of osteoclast function. J. Bone Miner. Res. 12:869-879, 1997
PubMed
10) Suda, T., Takahashi, N., Udagawa, N. et al.:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357, 1999
PubMed
11) Yoshida, H., Hayashi, S., Kunisada, T. et al.:The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 31:442-444, 1990
 
12) Kodama, H., Yamasaki, A., Nose, M. et al.:Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J. Exp. Med. 173:269-272, 1991
PubMed
13) Felix, R., Cecchini, M. G., Fleisch, H.:Macrophage colony stimulating factor restores in in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 127:2592-2594, 1990
PubMed
14) Takahashi, N., Udagawa, N., Akatsu, T. et al.:Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. Endocrinology 128:1792-1796, 1991
PubMed
15) Tanaka, S., Takahashi, N., Udagawa, N. et al.:Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91:257-263, 1993
PubMed
16) Yasuda, H., Shima, N., Nakagawa, N. et al.:Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337, 1998
PubMed
17) Simonet, W. S., Lacey, d. L., Dunstan, C. R. et al.:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 18:309-319, 1997
 
18) Kwon, B. S, Wang, S., Udagawa, N. et al.:TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J. 12:845-854, 1998
PubMed
19) The American Society for Bone and Mineral Research President's Committee on Nomenclature.:Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J. Bone Miner. Res. 2000 (in press)
 
20) Yasuda, H., Shima, N, Nakagawa, N. et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998
PubMed
21) Anderson, D. M., Maraskovsky, E., Billingsley, W. L. et al.:Ahomologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997
PubMed
22) Wong, B. R., Rho, J., Arron, J. et al.:TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190-25194, 1997
 
23) Lacey, D. L., Timms, E., Tan, H. L. et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
PubMed
24) Matsuzaki, K., Udagawa, N., Takahashi, N. et al.:Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 246:199-204, 1998
PubMed
25) Quinn, J. M., Elliott, J., Gillespie, M. T. et al.:A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139:4424-4427, 1998
PubMed
26) Nakagawa, N., Kinosaki, M., Yamaguchi, K. et al.:RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253:395-400, 1998
PubMed
27) 高橋直之, 宇田川信之, 須田立雄:破骨細胞の分化と機能を調節する新規の TNF 様因子(破骨細胞分化因子)の役割. 生化学 71:241-253, 1999
 
28) 保田尚孝, 後藤雅昭:破骨細胞形成抑制因子 (Osteoclastogenesis inhibitory factor, OCIF) と破骨細胞分化因子 (Osteoclast differentiation factor, ODF):破骨細胞の分化 ・成熟を調節するメカニズム. 日本骨代謝学会雑誌 17:10-18, 1999
Medical*Online
29) Kobayashi, K., Takahashi, N., Jimi, E. et al.:Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-286, 2000
 
30) Azuma, Y., Kaji, K., Katogi, R. et al.:Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275:4858-4864, 2000
 
31) 小林幹一郎, 宇田川信之, 高橋直之:骨吸収を調節する TNF 関連サイトカインの作用とシグナル伝達. 実験医学 18:348-353, 2000
Medical*Online
32) Jimi, E., Nakamura, I., Duong, L. T. et al.:Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247:84-93, 1999
PubMed
33) Kong, Y. Y., Yoshida, H., Sarosi, I. et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
PubMed
34) Dougall, W. C., Glaccum, M., Charrier, K. et al.:RANK is essential for osteoclast and lymph node development. Genes. Dev. 13:2412-2424, 1999
PubMed
35) Li, J., Sarosi, I., Yan, X. Q. et al.:RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97:1566-1571, 2000
PubMed
36) Hughes, A. E., Ralston, S. H., Marken, J. et al.:Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 24:45-48, 2000
PubMed
37) Mizuno, A., Amizuka, N., Irie, K. et al.:Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247:610-615, 1998
PubMed
38) Bucay, N., Sarosi, I., Dunstan, C. R. et al.:Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-1268, 1998
PubMed
39) Udagawa, N., Takahashi, N., Yasuda, H. et al.:Osteoprotegerin (OPG) produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478-3484, 2000
PubMed
40) Takami, M., Woo, J. T., Nagai, K.:Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production. Cell Tissue Res. 298:327-334, 1999
PubMed
41) Jimi, E., Akiyama, S., Tsurukai, T. et al.:Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163:434-442, 1999
PubMed
42) Udagawa, N., Takahashi, N., Jimi, E.:Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor:receptor activator of NF-B ligand. Bone 25:517-523, 1999
PubMed
43) Lomaga, M. A., Yeh, W. C., Sarosi, I. et al.:TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13:1015-1024, 1999
PubMed
44) Naito, A., Azuma, S., Tanaka, S. et al.:Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 4:353-362, 1999
PubMed
45) Wong, B. R., Besser, D., Kim, N. et al.:TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Genes Cells 4:1041-1049, 1999
 
46) Kotake, S., Udagawa, N., Takahashi, N. et al.:IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345-1352, 1999
PubMed
47) Romas, E., Bakharevski, O., Hards, D. K. et al.:Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 43:821-826, 2000
PubMed
48) Horwood, N. J., Kartsogiannis, V., Quinn, J. M. et al.:Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265:144-150, 1999
PubMed
49) Kong, Y. Y., Feige, U., Sarosi, I. et al.:Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309, 1999
PubMed
50) 小竹茂, 宇田川信之, 須田立雄:関節病変における破骨細胞. リウマチ科 21:182-187, 1999
 
51) Koide, M., Murase, Y., Yamato, K. et al.:Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1α through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem. Biophys. Res. Commun. 259:97-102, 1999
 
52) Sells Galvin, R. J., Gatlin, C. L., Horn, J. W. et al.:TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem. Biophys. Res. Commun. 265:233-239, 1999
 
53) Fuller, K., Bayley, K. E., Chambers, T. J.:Activin A is an essential cofactor for osteoclast induction. Biochem. Biophys. Res. Commun. 268:2-7, 2000
PubMed
54) 伊藤雅波, 宇田川信之, 片桐岳信ほか:日本骨代謝学会雑誌18(抄):141, 2000
 
55) Hsu, H., Lacey, D. L., Dunstan, C. R. et al.:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96:3540-3545, 1999
PubMed
56) Iotsova, V., Caamano, J., Loy, J. et al.:Osteopetrosis in mice lacking NF-B1 and NF-B2 Nat. Med. 3:1285-1289, 199
 
57) Franzoso, G., Carlson, L., Xing, L. et al.:Required and nonessential functions of nuclear factor-B in bone cells. Genes Dev. 11:3482-3496, 1997
 
P.100 掲載の参考文献
1) Scimeca, J. C., Franchi, A., Trojani, C. et al.:The gene encoding the mouse homologue of the human osteoclast-specific 116-kda V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants Bone 26:207-213, 2000
 
2) Gowen, M., Lazner, F., dodds, R. et al.:Cathepsin K knockout mice develop osteopetrosis due to adeficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14:1654-1663, 1998
 
3) Saftig, P., Hunziker, E., Wehmeyer, O. et al.:Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 95:13453-13458, 1998
PubMed
4) Gelb, B.D., Shi, G. P., Chapman, H.A. et al.:Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238, 1996
PubMed
5) McHugh, K.P., Hodivala-Dilke, K., Zheng, M.H. et al.:Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105:433-440, 2000
PubMed
6) Soriano, P., Montgomery, C., Geske, R. et al.:Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702, 1991
 
7) Lowe, C., Yoneda, T., Boyce, B. F. et al.:Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Natl. Acad. Sci. USA 90:4485-4489;1993
 
8) Horne, W.C., Neff, L., Chatterjee, d. et al.:Osteoclasts express high levels of pp60c-src in association with intracellular membranes. J. Cell Biol. 119:1003-1013, 1992
PubMed
9) Tanaka, S., Takahashi, N., Udagawa, N. et al.:Osteoclasts express high levels of p60c-src, preferentially on ruffled border membranes. FEBS Lett. 313:85-89, 1992
PubMed
10) Stein, P.L., Vogel, H., Soriano, P.:Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev. 8:1999-2007, 1994
PubMed
11) Lowell, C.A., Niwa, M., Soriano, P. et al.:Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Blood 87:1780-1792, 1996
PubMed
12) Tanaka, S., Amling, M., Neff, L. et al.:c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383:528-531, 1996
 
13) Langdon, W. Y.:The cbl oncogene:a novel substrate of protein tyrosine kinases. . Aust. N. Z. J. Med. 25:859-864, 1995
PubMed
14) Murphy, M. A., Schnall, R. G., Venter, D. J. et al.:Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol. Cell. Biol. 18:4872-4882, 1998
 
15) Yokouchi, M., Kondo, T., Houghton, A. et al.:Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J. Biol. Chem. 274:31707-31712, 1999
 
16) Schwartzberg, P.L., Xing, L., Hoffmann, O. et al.:Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src mutant mice. Genes Dev. 11:2835-2844, 1997
PubMed
17) Schwartzberg, P.L:The many faces of Src:multiple functions of a prototypical tyrosine kinase. Oncogene 17:1463-1468, 1998
PubMed
18) Miyazaki, T., Takayanagi, H., Isshiki, M. et al.:In vitro and in vitro suppression of osteoclast function by adenovirus vector-induced csk gene. J. Bone Miner. Res. 15:41-51, 2000
 
19) Takayanagi, H., Juji, T., Miyazaki, T. et al.:Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J. Clin. Invest. 104:137-146, 1999
PubMed
20) Hughes, D.E., Dai, A., Tiffee, J.C. et al.:Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat.L Med. 2:1132-1136, 1996
 
21) Ullrich, A., Schlessinger, J.:Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990
PubMed
22) Miyazaki, T., Katagiri, H., Kanegae, Y. et al.:Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J. Cell. Biol. 148:333-342, 2000
PubMed
23) Jimi, E., Nakamura, I., Ikebe, T. et al.:Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 273:8799-8805, 1998
PubMed
24) Lomaga, M. A., Yeh, W. C., Sarosi, I. et al.:TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes. Dev. 13:1015-1024, 1999
PubMed
25) Wong, B.R., Besser, D., Kim, N. et al.:TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell. 4:1041-1049, 1999
 
26) Naito, A., Azuma, S., Tanaka, S. et al.:Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 4:353-362, 1999
PubMed
P.109 掲載の参考文献
1) Aubin, J. E., Turksen, K., Heersche, J. N. M.:Osteoblastic lineage, in Cellular and Molecular Biology of Bone. (Noda, M. ed. ) Academic Press, London, 1993, p.1-45
 
2) Komori, T., Yagi, H., Nomura, S. et al.:Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89:755-764, 1997
 
3) Otto, F., Thornell, A. P., Crompton, T. et al.:Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 89:765-771, 1997
PubMed
4) Komori, T., Kishimoto, T.:Cbfa1 in bone development. Curr. Opin. Genet. Dev. 8:494-499, 1998
PubMed
5) Weimin, B., Jian, M. D., Zhaoping, Z. et al.:Sox9 is required for cartilage formation. Nat. Genet. 22:85-89, 1999
 
6) Ogawa, E., Maruyama, M., Kagoshima, H. et al.:PEBP2/PEA2 represents a new family of transcription factor homologous to the products of the drosophila runt and the human AMLI gene. Proc. Natl. Acad. Sci. USA 90:6859-6863, 1993
 
7) Bae, S. C., Yamaguchi-Iwai, Y., Ogawa, E. et al.:Isolation of PEBP2αB cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene 8:809-814, 1993
 
8) Bae, S. C., Takahashi, E., Zhang, Y. W. et al.:Cloning, mapping and expression of PEBP2αC a third gene encoding the mammalian Runt domain. Gene 159:245-248, 1995
 
9) Ogawa, E., Inuzaka, M., Maruyama, M. et al.:Molecular cloning and characterization of PEBP2β, the heterodimeric partner of a novel dorosophila runt-related DNA binding protein PEBP2α. Virology 194:314-331, 1993
 
10) Wang, S., Wang, Q., Crute, B. E. et al:Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol. Cell. Biol. 13:3324-3339, 1993
 
11) Okuda, T., van Deursen, J., Hiebert, S. W. et al.:AML1, the target of multiple chromosomal translocation in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330, 1996
PubMed
12) Wang, Q., Stancy, T., Binder, M.:Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA 93:3444-3449, 1996
 
13) Sasaki, K, Yagi, H., Bronson, R. T. et al:Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor β. Proc. Natl. Acad. Sci. USA 93:12359-12363, 1996
 
14) Wang, Q., Stacy, T., Miller, J. d. et al.:The CBFβsubunit is essential for CBFα2 (AML1) function in vivo. Cell 87:697-708, 1996
 
15) Niki, M., Okada, H., Takano, H. et al.:Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcriptional factor, polyomavirus enhancer binding protein 2/core binding factor. Proc. Natl. Acad. Sci. USA 94:5697-5702, 1997
PubMed
16) Thirunavukkarasu, K., Mahajan, M., Mclarren, K. W. et al.:Two domains unique to osteoblastspecific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfβ. Mol. Cell. Biol. 18:4197-4208, 1998
 
17) Harada, H., Tagashira, S., Fujiwara, M. et al.:Cbfa1 isoforms exert functional differences in osteoblast differentiation. J. Biol. Chem. 274:6972-6978, 1999
PubMed
18) Fujiwara, M., Tagashira, S., Harada, H. et al.:Isolation and characterization of the distal promoter region of mouse Cbfa1. Biochim. Biophys. Acta. 1446:265-272, 1999
PubMed
19) Stewart, M., Terry, A., Hu, M. et al.:Proviral insertions induce the expression of bone-specific isoforms of PEBP2αA (CBFA1):evidence for a new myc collaborating oncogene. Proc. Natl. Acad. Sci. USA 94:8646-8651, 1997
 
20) Ducy, P., Zhang, R., Geoffroy, V. et al.:Osf2/Cbfa1:atranscriptional activator of osteoblast differentiation. Cell 89:747-754, 1997
 
21) Tsuji, K., Ito, Y., Noda, M. et al.:Expression of the PEBP2αA/AML3/CBFA1 gene is regulated by BMP4/7 heterodimer and its overexpression suppresses type I collagen and osteocalcin gene expression in osteoblastic and nonosteoblastic mesenchymal cells. Bone 22:87-92, 1998
 
22) Li, J., Tsuju, K., Komori, T. et al.:Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROSI7/2.8 cells. J. Biol. Chem. 273:31009-31015, 1998
 
23) Xiao, G., Jiang, D., Thomas, P. et al.:MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem. 275:4453-4459, 2000
PubMed
24) Selvamurugan, N., Pulimati, M. R., Tyson, D. R. et al.:Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factorα1.J. Biol. Chem. 275:5037-5042, 2000
 
25) Levanon, D., Goldstein R. E., Bernstein, Y. et al.:Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc. Natl. Acad. Sci. USA 95:11590-11595, 1998
PubMed
26) McLarren, K. W., Lo, R., Grbavec, D. et al.:The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfa1. J. Biol. Chem. 275:530-538, 2000
PubMed
27) Matsue, M., Kageyama, R., Denhardt, D. T. et al.:Helix-Loop-Helix-Type transcription factor (HES-1) is expressed in osteoblastic cells, suppressed by 1,25 (OH)2 vitamin D3, and modulates 1, 25 (OH)2 vitamin D3 enhancement of osteopontin gene expression. Bone 20:329-334, 1997
PubMed
28) Tintut, Y., Parhami, F., Le, V. et al.:Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. J. Biol. Chem. 274:28875-28879, 1999
 
29) Inada, M., Yasui, T., Nomura, S. et al.:Maturational disturbance of chondrocytes in Cbfa 1-deficient mice. Dev. Dyn. 214:279-290, 1999
 
30) Kim, I.S., Otto, F., Zabel, B. et al.:Regulation of chondrocyte differentiation by Cbfa1. Mech. Dev. 80:159-170, 1999
PubMed
31) Hoshi, K., Komori, T., Ozawa, H.:Morphological Characterization of Skeletal Cells in Cbfa1-Deficient Mice. . Bone 25:639-651, 1999
PubMed
32) Ducy, P., Starbuck, M., Priemel, M. et al.:A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 13:1025-1036, 1999
PubMed
33) Sato, M., Morii, E., Komori, T. et al.:Transcriptional regulation of osteopontin gene in vivo by PEBP2αA/CBFA1 and ETS1 in the skeletal tissues. Oncogene 17:1517-1525, 1998
 
34) Sasaki-lwaoka, H., Maruyama, K., Endoh, H. et al.:A trans-acting enhancer modulates estrogen-mediated transcription of reporter genes in osteoblasts. J. Bone Miner. Res. 14:248-255, 1999
 
35) Hanai, J., Chen, L. F., Kanno, T. et al.:Interaction and functional cooperation of PEBP2/CBF with Smads. J. Biol. Chem. 274:31577-31582, 1999
PubMed
36) Kobayashi, H., Gao, Y. H., Ueta, C. et al.:Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem. Biophys. Res. Commun. 273:630-636, 2000
PubMed
37) Jimenez, M. G., Balbin, M., Lopez, J. M. et al.:Collagenase-3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation. Mol. Cell. Biol. 19:4431-4442, 1999
 
38) Enomoto, H., Enomoto-Iwamoto, M., Iwamoto, M. et al.:Cbfa1 is a positive regulatory factor in chondrocyte maturation. J. Biol. Chem. 275:8695-8702, 2000
PubMed
39) Gao, Y. H., Shinki, T., Yuasa, T. et al.:Potential role of Cbfa1, an essential transcription factor for osteoblast differentiation, in osteogenesis:regulation of mRNA expression of osteoclast differentiation factor (ODF). Biochem. Biophys. Res. Commun. 252:687-702, 1998
 
P.119 掲載の参考文献
1) Komori, T., Yagi, H., Nomura, S. et al.:Target disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764, 1997
 
2) Ducy, P., Zhang, R., Geoffroy, V. et al.:Cbfa1/Osf2:Atranscriptional activator of osteoblast differentiation. Cell 89:747-754, 1997
 
3) Otto, F., Thornell, A. P., Crompton, T. et al.:Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771, 1997
PubMed
4) Yamaguchi, A., Komori, T., Suda, T.:Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs and Cbfa1. Endocr. Rev. 21:393-411, 2000
PubMed
5) Geoffroy, V., Ducy, P., Karsenty, G.:APEBP2α/AML-1-related factor increases osteocalcin promoter activity through its binding to an osteoblast-specific cis-acting element. J. Biol. Chem. 270:30973-30979, 1995
 
6) Ducy, P., Karsenty, G.:Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol. Cell Biol. 15:1858-1869, 1995
PubMed
7) Banerjee, C., Hiebert, S. W., Stein, J. L. et al.:An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteocalcin gene. Proc. Natl. Acad. Sci. USA 12:4968-4973, 1996
 
8) Hanai, J., Chen, L. F., Kanno, T.:Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline C α promoter. J. Biol. Chem. 274:31577-31582, 1999
 
9) Schinke, T., Karsenty, G.:Characterization of Osf1, an osteoblast-specific transcription factor binding to a critical cis-acting element in the mouse Osteocalcin promoters. J. Biol. Chem. 274:30182-30189, 1999
PubMed
10) Katagiri, T., Yamaguchi, A., Ikeda, T. et al.:The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem. Biophys. Res. Commun. 172:295-299, 1990
PubMed
11) Wang, E. A., Israel, D. I., Kelly, S. et al:Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors 9:57-71, 1993
PubMed
12) Asahina, I., Sampath, T. K., Hauschka, P. V.:Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Exp. Cell. Res. 222:38-47, 1996
 
13) Yamaguchi, A., Katagiri, T., Ikeda, T. et al.:Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J. Cell Biol. 113:681-687, 1991
PubMed
14) Thies, R. S., Bauduy, M., Ashton, B. A. et al.:Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 130:1318-1324, 1992
 
15) Yamaguchi, A., Ishizuya, T., Kintou, N. et al.:Effects of BMP-2, BMP-4 and BMP-6 on osteoblast differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem. Biophys. Res. Commun. 220:366-371, 1996
PubMed
16) Katagiri, T., Yamaguchi, A., Komaki, M. et al.:Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127:1755-1766, 1994
PubMed
17) Chen, D., Ji, X., Marris, M. A. et al.:Differential roles for bone morphogenetic protein (BMP) receptor type I B and I A in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J. Cell Biol. 142:295-305, 1998
 
18) Gimble, J. M., Morgan, C., Kelly, K. et al.:Morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells. J. Cell Biochem. 58:393-402, 1995
PubMed
19) Lecka-Czernik, B., Gubrij, I., Moerman, E. J.:Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J. Cell. Biochem. 74:357-371, 1999
 
20) Chiang, C., Litingtung, Y., Lee, E. et al.:Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383:407-413, 1996
PubMed
21) Vortkamp, A., Lee, K., Lanske, B. et al.:Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613-622, 1996
PubMed
22) Lanske, B., Karaplis, A. C., Lee, K. et al:PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273:663-666, 1996
PubMed
23) St-Jacques, B., Hammerschmidt, M., McMahon, A. P.:Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13:2072-2086, 1999
PubMed
24) Vortkamp, A., Pathi, S., Peretti, G. M. et al:Recapitulation of signals regulating embryonic bone formation during postnatal growth and in fracture repair. Mech. Dev. 71:65-76, 1998
PubMed
25) Ferguson, C., Alpern, E., Miclau, T. et al.:Does adult fracture repair recapitulate embryonic skeletal formation? Mech. Dev. 87:57-66, 1999
PubMed
26) Ito, H., Akiyama, H., Shigeno, C. et al.:Hedgehog signaling molecules in bone marrow cells at the initial stage of fracture repair. Biochem. Biophys. Res. Commun. 262:443-451, 1999
PubMed
27) Kinto, N., Iwamoto, M., Enomoto-Iwamoto, M. et al.:Fibroblasts expressing Sonic hedgehog induce osteoblast differentiation and ectopic bone formation. FEBS Lett. 404:319-323, 1997
 
28) Nakamura, T., Aikawa, T., Iwamono-Enomoto, M. et al.:Induction of osteogenic differentiation by hedgehog proteins. Biochem. Biophys. Res. Commun. 237:465-469, 1997
 
29) Bitgood, M. J., McMahon, A. P.:Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev. Biol. 172:126-138, 1995
PubMed
30) Murtaugh, L. C., Chyung, J. H., Lassar, A. B.:Sonic hedgehog promotes somitic chondrogenesis by altering the cellular response to BMP signaling. Genes Dev. 13:225-237, 1999
PubMed
31) Pathi, S., Rutenberg, J. B., Johnson, R. L. et al.:Interaction of Ihh and BMP/Noggin signaling during cartilage differentiation. Dev. Biol. 209:239-253, 1999
PubMed
32) Enomoto-Iwamoto, M., Nakamura, T., Aikawa, T. et al.:Hedgehog proteins stimulate chondrogenic cell differentiation and cartilage formation. J. Bone Miner. Res. 15:1659-1668, 2000
PubMed
33) McCarthy, T. L., Centrella, M., Canalis, E.:Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 124:301-309, 1989
 
34) Canalis, E., Rydziel, S., Delany, A. M. et al.:Insulin-like growth factors inhibit interstitial collagenase synthesis in bone cell cultures. Endocrinology 136:1348-1354, 1995
PubMed
35) Rydziel, S., Delany, A. M., Canalis, E.:Insulin-like growth factor I inhibits the transcription of collagenase 3 in osteoblast cultures. J. Cell. Biochem. 167:176-183, 1997
 
36) Birnbaum, R. S., Wiren, K. M.:Changes in insulin-like growth factor-binding protein expression and secretion during the proliferation, differentiation, and mineralization of primary cultures of rat osteoblasts. Endocrinology 135:223-230, 1994
PubMed
37) Hill, P. A., Tumber, A., Meikle, M. C.:Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology 138:3849-3858, 1997
PubMed
38) Shinar, D. M., Endo, N., Halperin, D. et al.:differential expression of insulin-like growth factor-I (IGF-I) and IGF-II messenger ribonucleic acid in growing rat bone. Endocrinology 132:1158-1167, 1993
PubMed
39) Turner, R. T., Backup, P., Sherman, P. J. et al.:Mechanism of action of estrogen on intramembranous bone formation:regulation of osteoblast differentiation and activity. Endocrinology 13:883-889, 1992
 
40) Lean, J. M., Jagger, C. J., Chambers, T. J. et al.:Increased insulin-like growth factor I mRNA expression in rat osteocytes in response to mechanical stimulation. Am. J. Physiol. 268 (2 Pt 1):E318-E327, 1995
 
41) Watson, P., Lazowski, D., Han, V. et al.:Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 16:357-365, 1995
PubMed
42) Ishizuya, T., Yokose, S., Hori, M. et al.:Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99:2961-2970, 1997
 
43) Zhao, G., Monier-Faugere, M. C., Langub, M. C. et al.:Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice:increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674-2682, 2000
PubMed
44) Globus, R. K., Patterson-Buckendahl, P., Gospodarowicz, D.:Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factor β. Endocrinology 123:98-105, 1988
 
45) Rodan, S. B., Wesolowski, G., Yoon, K. et al.:Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin, and type I collagen mRNA levels in ROS 17/2. 8 cells. J. Biol. Chem. 264:19934-19941, 1989
 
46) Canalis, E., Centrella, M., McCarthy, T.:Effects of basic fibroblast growth factor on bone formation in vitro. J. Clin. Invest. 81:1572-1577, 1988
 
47) Hurley, M. M., Abreu, C, Harrison, J. R. et al.:Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells. J. Biol. Chem. 268:5588-5593, 1993
 
48) Aspenberg, P., Lohmander, L. S.:Fibroblast growth factor stimulates bone formation. Bone induction studied in rats. Acta Orthop. Scand. 60:473-476, 1989
PubMed
49) Aspenberg, P., Thorngren, K. G., Lohmander, L. S.:dose-dependent stimulation of bone induction by basic fibroblast growth factor in rats. Acta Orthop. Scand. 62:481-484, 1991
PubMed
50) Mayahara, H., Ito, T., Nagai, H. et al.:In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 9:73-80, 1993
PubMed
51) Nagai, H., Tsukuda, R., Mayahara, H.:Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 16:367-373, 1995
 
52) Nakamura, T., Hanada, K., Tamura, M. et al.:Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 136:1276-1284, 1995
PubMed
53) Liang, H., Pun, S., Wronski, T. J.:Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology 140:5780-5788, 1999
PubMed
54) Kawaguchi, H., Kurokawa, T., Hanada, K. et al.:Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology 135:774-781, 1994
PubMed
55) Kuroda, S., Kasugai, S., Oida, S. et al.:Anabolic effect of aminoterminally truncated fibroblast growth factor 4 (FGF4) on bone. Bone 25:431-437, 1999
 
56) Nakamura, K., Kurokawa, T., Kawaguchi, H. et al.:Stimulation of endosteal bone formation by local intraosseous application of basic fibroblast growth factor in rats. Rev. Rhum. Engl. Ed. 64:101-105, 1997
PubMed
P.129 掲載の参考文献
1) Lian, J. B., Stein, G. S., Stewart, C. et al.:Osteocalcin:characterization and regulated expression of the rat gene. Connect. Tissue Res. 21 (1-4):61-68, 1989
PubMed
2) Binkley, N. C., Suttie, J. W.:Vitamin K nutrition and osteoporosis. J. Nutr. 125 (7):1812-1821, 1995
 
3) Price, P. A., Rice, J. S., Williamson, M. K.:Conserved phosphorylation of serines in the Ser-X-Glu /Ser (P) sequences of the vitamin K-dependent matrix Gla protein from shark, lamb, rat, cow, and human. Protein Sci. 3 (5):822-830, 1994
 
4) Hart, S. M., Eastell, R.:Biochemical markers of bone turnover. Curr. Opin. Nephrol. Hypertens. 8 (4):421-427, 1999
PubMed
5) Power, M. J., Fottrell, P. F.:Osteocalcin:diagnostic methods and Clinical applications. Crit. Rev. Clin. Lab. Sci. 28 (4):287-335, 1991
PubMed
6) Lian, J. B., Stein, G. S., Stein, J. L. et al.:Osteocalcin gene promoter:unlocking the secrets for regulation of osteoblast growth and differentiation. J. Cell. Biol. (Suppl1.) 30-31:62-72, 1998
 
7) Stein, G. S., Lian, J. B., Stein, J. L. et al.:Transcriptional control of osteoblast growth and differentiation. Physiol. Rev. 76 (2):593-629, 1996
PubMed
8) Ducy, P., Zhang, R., Geoffroy, V. et al.:Osf 2/Cbfa1:atranscriptional activator of osteoblast differentiation. cell 89 (5):747-754, 1997
 
9) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996
PubMed
10) Motamed, K.:SPARC (osteonectin/BM-40) . [Review][19 refs]Int. J. Biochem. Cell Biol. 31 (12):1363-1366, 1999
 
11) Yan, Q., Sage, E. H.:SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 47 (12):1495-1506, 1999
PubMed
12) Withold, W.:Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers. Eur. J. Clin. Chem. Clin. Biochem. 34 (10):785-799, 1996
PubMed
13) Kato, Y., Sakai, N., Baba, M. et al.:Stimulation of motility of human renal cell carcinoma by SPARC/Osteonectin/BM-40 associated with type IV collagen. Invasion Metastasis 18 (2):105-114, 1998-1999
 
14) Lecrone, V., Li, W., Devoll, R. E. et al:Calcium signals in prostate cancer cells:specific activation by bone-matrix proteins. Cell Calcium 27 (1):35-42, 2000
PubMed
15) Gilles, C., Bassuk, J. A., Pulyaeva, H. et al.:SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 58 (23):5529-5536, 1998
PubMed
16) lkemoto, M., Takita, M., Imamura, T. et al.:Increased sensitivity to the stimulant effects of morphine conferred by anti-adhesive glycoprotein SPARC in amygdala. Nat. Med. 6:910-915, 2000
 
17) Lane, T. F., Irueia-Arispe, M. L., Johnson, R. S. et al.:SPARC is a source of copper-binding peptides that stimulate angiogenesis. J. Cell Biol. 125 (4):929-943, 1994
 
18) Lane, T. F., Sage, E. H.:The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J:8 (2):163-173, 1994
PubMed
19) Fedarko, N. S., Robey, P. G., Vetter, U. K.:Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. J. Bone Miner. Res. 10 (7):1122-1129, 1995
PubMed
20) Muriel, M. P., Bonaventure, J., Stanescu, R. et al.:Morphological and biochemical studies of a mouse mutant (fro/fro) with bone fragility. Bone 12 (4):241-248, 1991
PubMed
21) Norose, K., Clark, J. I., Syed, N. A. et al.:SPARC deficiency leads to early-onset cataractogenesis. Invest. Opthalmol. Vis. Sci. 39 (13):2674-2680, 1998
 
22) Strandjord, T. P., Madtes, d. K., Weiss, d. J. et al.:Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am. J. Physiol. 277 (3 Pt 1):1628-1635, 1999
 
23) Bradshaw, A. D., Francki, A., Motamed, K. et al.:Primary mesenchymal cells isolated from SPARC
PubMed
24) Delany, A. M., Amling, M., Priemel, M. et al.:Osteopenia and decreased bone formation in osteonectin-deficient mice. J. Clin. Invest. 105:915-923, 2000
PubMed
25) Gorski, J. P.:Is all bone the same? Distinctive distributions and properties of non-collagenous matrix proteins in lamellar vs. woven bone imply the existence of different underlying osteogenic mechanisms. Crit. Rev. Oral Biol. Med. 9 (2):201-223, 1998
PubMed
26) Binkley, N. C., Suttie, J. W.:Vitamin K nutrition and osteoporosis. J. Nutr. 125 (7):1812-1821, 1995
 
27) Howe, A. M., Webster, W. S.:Vitamin K-its essential role in craniofacial development. A review of the literature regarding vitamin K and craniofacial development. Aust. Dent. J. 39 (2):88-92, 1994
PubMed
28) Schinke, T., McKee, M. D., Kiviranta, R. et al.:Molecular determinants of arterial calcification. Ann. Med. 30 (6):538-541, 1998
PubMed
29) Shanahan, C. M., Proudfoot, D., Farzaneh-Far, A. et al.:The role of Gla proteins in vascular calcification. Crit. Rev. Eukaryot. Gene Expr. 8 (3-4):357-375, 1998
 
30) Lawton, d. M., Andrew, J. G., Marsh, d. R. et al.:Expression of the gene encoding the matrix gla protein by mature osteoblasts in human fracture non-unions. Mol. Pa thol. 52 (2):92-96, 1999
 
31) Yagami, K., Suh, J. Y., Enomoto-Iwamoto, M. et al.:Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. J. Cell Biol. 147 (5):1097-1108, 1999
 
32) Luo, G., dugy, P., Mckee, M. d. et al.:Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78-81, 2000
 
33) Bonin, L. R., Madden, K., Shera, K. et al.:Generation and characterization of human smooth muscle celllines derived from atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 19 (3):575-587, 1999
 
34) Wallin, R., Cain, D., Sane, d. C.:Matrix Gla protein synthesis and γ-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells-a cell system which resembles the system in bone cells. Thromb. Haemost. 82 (6):1764-1767, 1999
 
35) Tsukamoto, K., Orimo, H., Hosoi, T. et al:Association of bone mineral density with polymorphism of the human matrix Gla protein locus in elderly women. J. Bone Miner. Metab. 18 (1):27-30, 2000
PubMed
36) Munroe, P. B., Olgunturk, R. O., Fryns, J. P. et al:Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat. Genet. 21 (1):142-144, 1999
PubMed
37) Yasui, T., Fujita, K., Sasaki, S. et al.:Expression of bone matrix proteins in urolithiasis model rats. Urol. Res. 27 (4):255-261, 1999
PubMed
38) Hocking, A. M., Shinomura, T., McQuillan, d. J.:Leucine-rich repeat glycoproteins of the extracellular martrix. Matrix Biol. 17 (1):1-19, 1998
 
39) Hall, R. C., Embery G.:The use of immunohistochemistry in understanding the structure and function of the extracellular matrix of dental tissues. Adv. Dental Res. 11 (4):478-486, 1997
PubMed
40) Kresse, H., Hausser, H., Schonherr, E. et al.:Biosynthesis and interactions of small chondroitin/ dermatan sulphate proteoglycans. Eur. J. Clin. Chem. Clin. Biochem. 32 (4):259-264, 1994
PubMed
41) Matsushima, N., Ohyanagi, T., Tanaka, T. et al.:Super-motifs and evolution of tandem leucinerich repeats within the small proteoglycans-biglycan, decorin, lumican, fibromodulin, PRELP, keratocan, osteoadherin, epiphycan, and osteoglycin. Proteins 38 (2):210-225, 2000
PubMed
42) Krishnan, P., Hocking, A. M., Scholtz, J. M. et al.:distinct secondary structures of the leucine-rich repeat proteoglycans decorin and biglycan. Glycosylation-dependent conformational stability. J. Biol. Chem. 274 (16):10945-10950, 1999
PubMed
43) Tianshun, Xu., Paolo, B., Larry, W. et al:Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 20:78-82, 1998
 
44) Inoue, A., Hayakawa, T., Otsuka, E. et al:Correlation between induction of expression of biglycan and mineralization by C-type natriuretic peptide in osteoblastic cells. J. Biochem. 125 (1):103-108, 1999
 
45) Edwin, A. C., Todd, R. G., Eric, S. et al.:Genomic analysis of metastasis reveals an essential role for Rho C. Nature 406:532-535, 2000
 
46) McCormick, C., duncan, G., Tufaro, F.:New perspectives on the molecular basis of hereditary bone tumours. Mol. Med. Today 5 (11):481-486, 1999
PubMed
47) Bowe, M. A., Mendis, d. B., Fallon, J. R.:The small leucine-rich repeat proteoglycan biglycan binds to α-dystroglycan and is upregulated in dystrophic muscle. J. Cell Biol. 148(4):801-810, 2000
 
48) Stokes, M. B., Holler, S., Cui, Y. et al.:Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int. 57 (2):487-498, 2000
PubMed
49) Kavanagh, E., Ashhurst, d. E.:development and aging of the articular cartilage of the rabbit knee joint:distribution of biglycan, decorin, and matrilin-1. J. Histochem. Cytochem. 47 (12):1603-1616, 1999
PubMed
50) Eddy, A. A.:Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J. Am. Soc. Nephrol. 5 (6):1273-1287, 1994
PubMed
51) Patarca, R., Saavedra, R. A., Cantor, H.:Molecular and cellular basis of genetic resistance to bacterial infection:the role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol. 13 (3-4):225-246, 1993
 
52) Chambers, A. F., Tuck, A. B.:Ras-responsive genes and tumor metastasis. Crit. Rev. Oncogene. 4 (2):95-114, 1993
PubMed
53) Baik, M. G., Lee, M. J., Choi, Y. J.:Gene expression during involution of mammary gland. Int. J. Mol. Med. 2 (1):39-44, 1998
PubMed
54) Denhardt, d. T., Noda, M.:Osteopontin expression and function:role in bone remodeling. J. Cell. Biochem. (Suppl. ) 30-31:92-102, 1998
 
55) Rittling, S. R., Denhardt, d. T.:Osteopontin function in pathology:lessons from osteopontindeficient mice. Exp. Nephrol. 7 (2):103-113, 1999
PubMed
56) McKee, M. D., Nanci, A.:Osteopontin:an interfacial extracellular matrix protein in mineralized tissues. Connect. Tissue Res. 35 (1-4):197-205, 1996
 
57) Nanci, A.:Content and distribution of noncollagenous matrix proteins in bone and cementum:relationship to speed of formation and collagen packing density. J. Struct. Biol. 126 (3):256-269, 1999
PubMed
58) Noda, M., Yoon, K., Prince, C. W. et al.:Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type β transforming growth factor. J. Biol. Chem. 263:13916-13921, 1988
 
59) Noda, M., Rodan, G. A.:Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J. Cell Biol. 108 (2):713-718, 1989
PubMed
60) Heymann, D., Guicheux, J., Gouin, F. et al.:Cytokines, growth factors and osteoclasts. Cytokine 10 (3):155-168, 1998
PubMed
61) Rittling, S. R., Matsumoto, H. N., McKee, M. d. et al.:Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J. Bone Miner. Res. 13 (7):1101-1111, 1998
PubMed
62) Liaw, L, Birk, d. E., Ballas, C. B. et al:Altered wound healing in mice lacking a functional osteopontin gene (spp1) . J. Clin. Invest. 101 (7):1468-1478, 1998
PubMed
63) Crawford, H. C., Matrisian, L. M., Liaw, L.:distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 58 (22):5206-5215, 1998
PubMed
64) Yoshitake, H., Susan, R., Rittling, D. T. et al.:Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc. Natl. Acad. Sci. USA 96:8156-8160, 1999
 
65) Asou, Y., Rittling, S. R., Yoshitake, H. et al.:Osteopontin facilitates angiogenesis, accumulation of osteoclasts and resorption in ectopic bone. Endocrinology 142:(in press), 2001
 
66) Ihara, H., Denhardt, d. T., Furuya, K. et al.:Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J. Biol. Chem. 276:(in press), 2001
PubMed
67) Benson, M. D., Bargeon, J. L, Xiao, G. et al:Identification of a homeodomain binding element in the bone sialoprotein gene promoter that is required for its osteoblast-selective expression. J. Biol. Chem. 275 (18):13907-13917, 2000
PubMed
68) Bellahcene, A., Bonjean, K., Fohr, B. et al.:Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ. Res. 86 (8):885-891, 2000
PubMed
P.142 掲載の参考文献
1) Stein, G. S., Lian, J. B.:Molecular mechanisms mediating proliferation/differentiation inter-relationships during progressive development of the osteoblast phenotype. Endocr. Rev. 14:424-442, 1993
 
2) ducy, P., Karsenty, G.:Genetic control of cell differentiation in the skeleton. Curr. Opin. Cell Biol. 10:614-619, 1998
PubMed
3) Ibaraki, K., Termine, J. D., Whitson, W. et al.:Bone matrix mRNA expression in differentiating fetal bovine osteoblasts. J. Bone Miner. Res. 7:743-754, 1992
 
4) Harris, S., Bonewald, L. F., Harris, M. A. et al.:Effects of transforming growth factor β on bone nodule formation and expression of bone morphogenetic protein 2, Osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J. Bone Miner. Res. 9:855-863, 1994
 
5) Wrana, J. L:Regulation of Smad activity. Cell 100:189-192, 2000
PubMed
6) ducy, P., Zhang, R., Geoffroy, V. et al:Osf2/Cbfa1:Atranscriptional activator of osteoblast differentiation. Cell 89:747-754, 1997
 
7) Young, M. F., Kerr, J. M., Ibaraki, K. et al:Structure, expression and regulation of the major noncollagenous matrix proteins of bone. Clin. Orthop. 281:275-294, 1992
PubMed
8) Raines, E. W., Lane, T. F., Iruela-Arispe, M. L. et al:The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PdGF)-AB and-BB and inhibits the binding of PdGF to its receptors. Proc. Natl Acad. Sci. USA 89:1281-1285, 1992
PubMed
9) Takeuchi, Y., Kodama, Y., Matsumoto, T.:Bone matrix decorin binds transforming growth factor-β and enhances its bioactivity. J. Biol. Chem. 269:32634-32638, 1994
 
10) 久保木芳徳:骨と軟骨の有機成分-コラーゲン. BONE SCIENCE骨形成と骨吸収及びそれらの調節因子. (須田立雄 編)廣川書店, 1995, p. 59-75
 
11) Rossert, J., Eberspaecher, H., de Crombrugghe, B.:Separate cis-acting dNA elements of the mouse pro-α1 (I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. J. Cell Biol. 129:1421-1432, 1995
 
12) Pavlin, D., Lichtler, A. C., Bedalov, A. et al.:differential utilization of regulatory domains within the α1 (d collagen promoter in osseous and fibroblastic cells. J. Cell Biol. 116:227-236, 1992
 
13) Rossert, J. A., Chen, S. S., Eberspaecher, H. et al.:Identification of a minimal sequence of the mouse pro-α1 (d collagen promoter that confers high-level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblasts. Proc. Natl. Acad. Sci. USA 93:1027-1031, 1996
 
14) Jimenez, S. A., Varga, J., Olsen, A. et al.:Functional analysis of human α1(I) procollagen gene promoter:differential activity in collagen-producing and-nonproducing cells and response to transforming growth factor b1. J. Biol. Chem. 269:12684-12691, 1994
 
15) Nakamura, T., Hanada, K., Tamura, M. et al.:Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 136:1276-1284, 1995
PubMed
16) Cosman, F., Lindsay, R.:Is parathyroid hormone a therapeutic option for osteoporosis? A review of the Clinical evidence. Calcif. Tissue Int. 62:475-480, 1998
PubMed
17) Komori, T., Yagi, S., Nomura, S. et al.:Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764, 1997
 
18) Ducy, P., Starbuck, M., Priemel, M. et al.:A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes. Dev. 13:1025-1036, 1999
PubMed
19) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996
PubMed
20) Delany, A. M., Amling, M., Priemel, M. et al.:Osteopenia and decreased bone formation in osteonectin-deficient mice. J. Clin.Invest. 105:915-923, 2000
PubMed
21) Yoshitake, H., Rittling, S. R., Denhardt, D. T. et al.:Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc. Natl. . Acad. Sci. USA 96:8156-8160, 1999
PubMed
22) Xu, T., Bianco, P., Fisher, L. W. et al.:Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 20:78-82, 1998
 
23) Zhao, W., Byrne, M. H., Boyce, B. F. et al.:Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J. Clin. Invest. 103:517-524, 1999
PubMed
24) Franceschi, R., Iyer, B. S., Cui, Y.:Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3-E1 cells. J. Bone Miner. Res. 9:843-854, 1994
 
25) Schiro, J. A., Chan, B. M. C., Roswit, W. T. et al:Integrinα2β1 (VLA-2) mediates reorganization and contraction of collagen matrices by human cells. Cell 67:403-410, 1991
 
26) Takeuchi, Y., Nakayama, K, Matsumoto, T.:differentiation and cell surface expression of transforming growth factor-β receptors are regulated by interaction with matrix collagen in murine osteoblastic cells. J. Biol. Chem. 271:3938-3944, 1996
 
27) Riikonen, T., Koivisto, L., Vihinen, P. et al.:Transforming growth factor-β regulates collagen gel contraction by increasing α2 β1 integrin expression in osteogenic cells. J. Biol. Chem. 270:376-382, 1995
 
28) Jikko, A., Harris, S. E., Chen, d. et al.:Collagen. integrin receptors regulate early osteoblast differentiation induced by BMP-2. J. Bone Miner. JRes. 14:1075-1083, 1999
 
29) Xiao, G., Wang, D., Benson, M. d. et al.:Role of the α2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor. J. Biol. Chem. 273:32988-32994, 1998
 
30) Clark, E. A., Brugger, J. S.:Integrins and signal transduction pathways:the road taken. Science 268:233-239, 1995
 
31) Takeuchi, Y., Suzawa, M., Kikuchi, T. et al.:differentiation and transforming growth factor-β receptor down-regulation by collagen-α2βi integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells. J. Biol. Chem. 272:29309-29316, 1997
 
32) Xiao, G., Jiang, D., Thomas, P. et al.:MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem. 275:4453-4459, 2000
PubMed
33) Kretzschmar, M., Doody, J., Massague, J.:Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature 389:618-622, 1997
 
34) Suzawa, M., Takeuchi, Y., Fukumoto, S. et al:Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. Endocrinology 140:2125-2133, 1999
PubMed
35) Wu, L. N. Y., Sauer, G. R., Wuthier, R. E.:Induction of mineral deposition by primary cultures of chicken growth plate chondrocytes in ascorbate-containing media:evidence of an association between matrix vesicles and collagen. J. Biol. Chem. 264:10917-10921, 1989
 
36) Matsumoto, T., Kawanobe, Y., Morita, K. et al:Effect of 1,25-dihydroxyvitamin D3 on phospholipid metabolism in a clonal osteoblast-like rat osteogenic sarcoma cell line. J. Biol. Chem. 260:13704-13709, 1985
 
37) Scott, J. E.:Proteoglycan-fibrillar collagen interactions. Biochem. J. 252:313-323, 1988
PubMed
38) Hoshi, K., Kemmotsu, S., Takeuchi, Y. et al.:The primary calcification in bones follows removal of decorin and fusion of collagen fibrils. J. Bone Miner. Res. 14:273-280, 1999
PubMed
39) Takeuchi, Y., Matsumoto, T., Ogata, E. et al.:1,25-dihydroxyvitamin D, inhibits synthesis and enhances degradation of proteoglycans in osteoblastic cells. J. Biol. Chem. 264:18407-18413, 1989
 
40) 佐々木 哲:石灰化の機構. BONE SCIENCE骨形成と骨吸収及びそれらの調節因子. (須田立雄 編)廣川書店, 1995, p.149-159
 
41) Waymire, K. G., Mahuren, J. D., Jaje, J. M. et al.:Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nat. Genet. 11:45-51, 1995
PubMed
42) Heath, J. K., Suva, L. J., Yoon, K. et al:Retinoic acid stimulates transcriptional activity from the alkaline phosphatase promoter in the immortalized rat calvarial cell line, RCT-1. Mol. Endocrinol. 6:636-646, 1992
PubMed
P.154 掲載の参考文献
1) Parfitt, A. M.:The cellular basis of bone turnover and bone loss:arebuttal of the osteocytic resorption-bone flow theory. Clin. Orthop. 127:236-247, 1977
PubMed
2) Doty, S. B.:Morphological evidence of gap junctions between bone cells. Calcif. Tissue Int. 33:509-512, 1981
PubMed
3) Ilvesaro, J., Vaananen, K., Tuukkanen, J.:Bone-resorbing osteoclasts contain gap-junctional connexin-43 [In Process Citation]. J. Bone Miner. Res. 15:919-926, 2000
 
4) Palazzini, S., Palumbo, C., Ferretti, M. et al.:Stromal cell structure and relationships in perimedullary spaces of chick embryo shaft bones. Anat. Embryol. (Berl.) 197:349-357, 1998
PubMed
5) Eriksen, E. F., Mosekilde, L, Melsen, F.:Kinetics of trabecular bone resorption and formation in hypothyroidism:evidence for a positive balance per remodeling cycle. Bone 7:101-108, 1986
PubMed
6) Palumbo, C., Palazzini, S., Marotti, G.:Morphological study of intercellular junctions during osteocyte differentiation. Bone 11:401-406, 1990
PubMed
7) Marotti, G.:The structure of bone tissues and the cellular control of their deposition. Ital. J. Anat. Embryol. 101:25-79, 1996
PubMed
8) Nefussi, J. R., Sautier, J. M., Forest, N.:Cell culture model and concept of bone surface. C. R. Seances Soc. Biol. Fil. 187:620-632, 1993
PubMed
9) Mikuni-Takagaki, Y., Suzuki, Y., Kawase, T. et al.:distinct responses of different populations of bone cells to mechanical stress. Endocrinology 137:2028-2035, 1996
PubMed
10) Martin, R. B.:Does osteocyte formation cause the nonlinear refilling of osteons? Bone 26:71-78, 2000
PubMed
11) Dunstan, C. R., Somers, N. M., Evans, R. A.:Osteocyte death and hip fracture. Calcif. Tissue Int. 53 (Suppl.1):S113-S116, 1993
 
12) Frost, H. M.:In vivo osteocyte death. J. Bone Joint Surg. 42A:138-143, 1960 13) Vaughan, J. M.:The effects of radiation on bone. The Biochemisry and Physiology of Bone. (Bourne, G. H. ed. ) New York, Academic Press, 1956, p. 729-766
 
14) Ham, A. W., Harris, W. R.:Repair and transplantation of bone. The Biochemisry and Physiology of Bone. (Bourne, G. H. ed. ) New York, Academic Press, 1956, p. 475-506
 
15) Wong, S. Y., Evans, R. A., Needs, C. et al.:The pathogenesis of osteoarthritis of the hip. Evidence for primary osteocyte death. Clin. Orthop 214:305-312, 1987
PubMed
16) Tomkinson, A., Reeve, J., Shaw, R. W. et al.:The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 82:3128-3135, 1997
 
17) Tomkinson, A., Gevers, E. F, Wit, J. M. et al.:The role of estrogen in the control of rat osteocyte apotosis. J.Bone Miner. Res. 13:1243-1250, 1998
 
18) Stevens, H. Y., Reeve, J., Noble, B. S.:Bcl-2, tissue transglutaminase and p53 protein expression in the apoptotic cascade in ribs of premature infants. J. Anat. 196 (Pt 2):181-191, 2000
 
19) Weinstein, R. S., Jilka, R. L., Parfitt, A. M. et al.:Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102:274-282, 1998
 
20) Jilka, R. L., Weinstein, R. S., Bellido, T. et al.:Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone[see comments]. J. Clin. Invest. 104:439-446, 1999
 
21) Plotkin, L. I., Weinstein, R. S., Parfitt, A. M. et al.:Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104:1363-1374, 1999
PubMed
22) Marotti, G., Farneti, D., Remaggi, F. et al:Morphometric investigation on osteocytes in human auditory ossicles. Anat. Anz. 180:449-453, 1998
 
23) Migliaccio, A., Piccolo, D., Castoria, G. et al.:Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17:2008-2018, 1998
PubMed
24) Wolff, J. L.:1986 The Law of Bone Remodeling (das Gesetz der Transformation der Knochen, 1892) . (Translated by Maquet, P., Furlong, R. ) . Springer-Verlag, Berlin
 
25) Pead, M. J., Suswillo, R. S., Skerry, T. M. et al.:Increased 3H-uridine levels in osteocytes following asingle short period of dynamic loading in vivo. Calcif. Tissue Int. 43:92-96, 1988
 
26) Skerry, T. M., Bitensky, L, Chayen, J. et al.:Early strain-related changes in enzyme activity in osetocytes following bone loading in vivo. J. Bone Miner. Res. 4:783-788, 1989
PubMed
27) Rawlinson, S. C., El-Haj, A. J., Minter, S. L. et al.:Loading-related increases in prostaglandin production in cores of adult canine cancellous bone in vitro:arole for prostacyclin in adaptive bone remodeling? J. Bone Miner. Res. 6:1345-1351, 1991
 
28) Cowin, S. C., Moss-Salentijn, L, Moss, M. L:Candidates for the mechanosensory system in bone. J. Biomed. Eng. 113:191-197, 1991
 
29) Van der Plas, A., Nijweide, P. J.:Isolation and purification of osteocytes. J. Bone Miner. .Res. 7:389-396, 1992
 
30) Mikuni-Takagaki, Y., Kakai, Y., Satoyoshi, M. et al.:Matrix mineralization and the differentiation of osteocyte-like cells in culture. J. Bone Miner. Res. 10:231-242, 1995
PubMed
31) Klein-Nulend, J., Semeins, C. M., Ajubi, N. E. et al.:Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts-correlation with prostaglandin upregulation. Biochem. Biophys. Res. Commun. 217:640-648, 1995
 
32) Lean, J. M., Mackay, A. G., Chow, J. W. et al.:Osteocytic expression of mRNA for c-fos and IGF-I:an immediate early gene response to an osteogenic stimulus. Am. J. Physiol. 270:E937-E945, 1996
 
33) Kawata, A., Mikuni-Takagaki, Y.:Mechanotransduction in stretched osteocytes-temporal expres sion of immediate early and other genes. Biochem. Biophys. Res. Commun. 246:404-408, 1998
 
34) Maejima-Ikeda, A., Aoki, M., Tsuritani, K. et al.:Chick osteocyte derived protein inhibits osteoclastic bone resorption. Biochem. J. 322:245-250, 1997
PubMed
35) Rubin, C., Sun, Y. Q., Hadjiargyrou, M. et al.:Increased expression of matrix metalloproteinaselin osteocytes precedes bone resorption as stimulated by disuse:evidence for autoregulation of the cell:s mechanical environment? J. Orthop. Res. 17:354-361, 1999
PubMed
36) Resnick, N., Collins, T., Atkinson, W. et al.:Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc. Natl. Acad. Sci. USA 90:4591-4595, 1993
PubMed
37) Khachigian, L. M., Resnick, N., Gimbrone, M. A. Jr. et al.:Nuclear factor-xB interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J. Clin. Invest. 96:1169-1175, 1995
 
38) Chien, S., Li, S., Shyy, Y. J.:Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension 31:162-169, 1998
PubMed
39) 安藤譲二 編:シェアストレスと内皮細胞. メディカルレビュー社
 
40) Reich, K. M., Frangos, J. A.:Effect of flow on prostaglandin E2 and inositol triphosphate levels in osteoblasts. Am. J. Physiol. 261:c428-c432, 1991
 
41) Klein-Nulend, J., Burger, E. H., Semeins, C. M. et al:Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J. Bone Miner. Res. 12:45-51, 1997
 
42) Zaman, G., Pitsillides, A. A., Rawlinson, S. C. et al.:Mechanical strain stimulates nitric oxide production by rapid activation of endothelial nitric oxide synthase in osteocytes. J. Bone Miner. Res. 14:1123-1131, 1999
PubMed
43) McAllister, T. N., Frangos, J. A.:Steady and transient fluid shear stress stimulate NO release in osteoblasts through distinct biochemical pathways. J. Bone Miner. Res. 14:930-936, 1999
PubMed
44) McAllister, T. N., du, T., Frangos, J. A.:Fluid shear stress stimulates prostaglandin and nitric oxide release in bone marrow-derived preosteoclast-like cells. Biochem. Biophys. Res. Commun. 270:643-648, 2000
PubMed
45) Shen, J., Luscinskas, F. W., Gimbrone, M. A. Jr. et al.:Fluid flow modulates vascular endothelial cytosolic calcium responses to adenine nucleotides. Microcirculation 1:67-78, 1994
PubMed
46) Naemsch, L. N., Weidema, A. F., Sims, S. M. et al.:P2X (4) purinoceptors mediate an ATP-activated, non-selective cation current in rabbit osteoclasts. J. Cell. Sci. 112:4425-4435, 1999
PubMed
47) Yao, X., Kwan, H. Y., Chan, F. L. et al:Aprotein kinase G-sensitive channel mediates flow-induced Ca (2+) entry into vascular endothelial cells. FASEB J. 14:932-938, 2000
 
48) Hirooka, K., Kourennyi, d. E., Barnes, S.:Calcium channel activation facilitated by nitric oxide in retinal ganglion cells. J. Neurophysiol. 83:198-206, 2000
PubMed
49) Westbroek, I., Ajubi, N. E, Alblas, M. J. et al:differential stimulation of prostaglandin G/H synthase-2 in osteocytes and other osteogenic cells by pulsating fluid flow. Biochem. Biophys. Res. Commun. 268:414-419, 2000
PubMed
50) Sakai, K., Mohtai, M., Iwamoto, Y.:Fluid shear stress increases transforming growth factor β1 expression in human osteoblast-like cells:modulation by cation channel blockades. Calcif Tissue Int. 63:515-520, 1998
 
51) Owan, I., Burr, d. B., Turner, C. H. et al:Mechanotransduction in bone:osteoblasts are more responsive to fluid forces than mechanical strain. Am. J. Physiol. 273:C810-C815, 1997
PubMed
52) Chow, J. W., Fox, S., Jagger, C. J. et al.:Role for parathyroid hormone in mechanical responsiveness of rat bone. Am. J. Physiol. 274:E146-E154, 1998
PubMed
53) Sekiya, H., Mikuni-Takagaki, Y., Kondoh, T. et al.:Synergistic effect of PTH on the mechanical responses of human alveolar osteocytes. Biochem. Biophys. Res. Commun. 264:719-723, 1999
PubMed
54) Miyauchi, A., Notoya, K., Mikuni-Takagaki, Y. et al.:Parathyroid hormone-activated volume-sensitive calcium influx pathways in mechanically loaded osteocytes. J. Biol. Chem. 275:3335-3342, 2000
PubMed
55) Chow, J. W., Chambers, T. J.:Indomethacin has distinct early and late actions on bone formation induced by mechanical stimulation. Am. J. Physiol. 267:E287-E292, 1994
 
56) 曽我部正博, 千 文可, 威 智ほか:伸展活性化Ca2+透過チャネル. カルシウムイオンとシグナル伝達. 蛋白質核酸酵素43:1628-1635, 1998
 
57) Corey, d. P., Garcia-Anoveros, J.:Mechanosensation and the DEG/ENaC ion channels. Science 273:323-324, 1996
PubMed
58) Trussell, L.:Mutant ion channel in cochlear hair cells causes deafness. Proc. Natl. Acad. Sci. USA97:3786-3788, 2000
 
59) Okabe, K., Okamoto, F., Kajiya, H. et al.:Multiple Ionic Channels Play the Role of Mechano-Receptor in Stretched Rat Osteocytes. J. Bone Miner. Res. 14:S480, 1999
 
60) Mikuni-Takagaki, Y., Kawata, A., Kawase, T. et al.:Mechanosensitive Ion Channels Specific to Osteocytes. J. Bone. Miner. Res. 14:S206, 1999
 
61) Laketic-Ljubojevic, I., Suva, L. J., Maathuis, F. J. et al.:Related Articles Functional characterization of N-methyl-D-aspartic acid-gated channels in bone cells. Bone 25:631-637, 1999
 
62) Maingret, F., Fosset, M., Lesage, F. et al.:TRAAK is a mammalian neuronal mechano-gated K+ channel. J. Biol. Chem. 274:1381-1387, 1999
 
63) Duan, D., Winter, C., Cowley, S. et al.:Molecular identification of a volume-regulated chloride channel. Nature 390:417-421, 1997
PubMed
64) Suzuki, M., Sato, J., Kutsuwada, K. et al.:Cloning of a stretch-inhibitable nonselective cation channel. J. Biol. Chem. 274:6330-6335, 1999
 
65) Sukharev, S. I., Blount, P., Martinac, B. et al.:A large-conductance mechanosensitive channel in E. coli encoded by MscL alone. Nature 368:265-268, 1994
 
66) Kanzaki, M., Nagasawa, M., Kojima, I. et al.:Related Articles Molecular identification of a eukaryotic, stretch-activated nonselective cation channel. Science 285:882-886, 1999
 
67) Mikuni-Takagaki, Y.:Mechanical responses and signal transduction pathways in stretched osteocytes. J. Bone Miner. Metab. 17:57-60, 1999
PubMed
68) Langton, P. d.:Calcium channel currents recorded from isolated myocytes of rat basilar artery are stretch sensitive. J. Physiol. (Lond. ) 471:1-11, 1993
PubMed
69) Duncan, R. L., Kizer, N., Barry, E. L. et al.:Antisense oligodeoxynucleotide inhibition of a swelling-activated cation channel in osteoblast-like osteosarcoma cells. Proc. Natl. Acad. Sci. USA 93:1864-1869, 1996
PubMed

第2章 骨代謝調節因子の分子作用機構

P.170 掲載の参考文献
1) Mangelsdorf, J., Thummel, C., Beato, M. et al.:The nuclear receptor superfamily the second decade. Cell 83:835-839, 1995
 
2) Beato, M., Herrlich, P., Schutz, G.:Steroid hormone receptors. Many actors in search of a plot. Cell 83:851-857, 1995
PubMed
3) Tontonoz, P., Nagy, L., Alvarez, J. et al.:PPARγpromotes monocyte/macrophage differentiation and uptake of oxidized. LDL. Cell 93:241-252, 1998
 
4) Makishima, M., Okamoto, A., Repa, J. et al:Identification of a Nuclear Receptor for Bile Acids. Science 284:1362-1365, 1999
PubMed
5) Beato, M., Heerrlich, P., Chambon, P.:Steroid hormone receptors. many actors in search of plot. Cell 83:851-857, 1995
 
6) Tasset, D., Tora, L., Fromental, C. et al.:distinct classes of transcriptional activating domains function by different mechanisms. Cell 62:1177-1187, 1990
PubMed
7) Kato, S., Endo, H., Masuhiro, Y. et al.:Activation of the estrogen receptor through phosphorilation by mitogen-activated protein kinase. Science 270:1491-1494, 1995
 
8) Umesono, K., Murakami, K., Thompson, C. et al.:direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65:1255-1266, 1991
PubMed
9) Bjorklund, S., Almouzni, G., Davidson, I. et al.:Global transcription regulators of eukaryotes. Cell 96:759-767, 1999
PubMed
10) Freedman, P.:Increasing the complexity of coactivation in nuclear receptor signaling. Cell 97:5-8, 1999
 
11) Wurtz, M., Bourguet, W., Renaud, P. et al:Acanonical structure for the ligand-binding domain of nuclear receptors. Nature Structural Biology 3:87-94, 1996
 
12) Shiau, A., Barstad, D., Loria, P. et al:The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937, 1998
PubMed
13) Kobayashi, Y., Kitamoto, T., Masuhiro, Y. et al.:p300 mediates functional synergims between AF-1 and AF-2 of estrogen receptor α and β by interacting directly with the N-terminal A/B domains. J. Boil. Chem. 275:15645-15651, 2000
 
14) Tora, L., White, J., Brou, C. et al.:The human estrogen receptor has two independent non-acidic transcriptional activation functions. Cell 59:477-487, 1989
 
15) Cavailles, V., Dauvois, S., Danielian, P. S. et al.:Interaction of proteins with transcriptionally active estrogen receptors. Proc. Natl. Acad. 91:10009-10013, 1994
PubMed
16) Halachmi, S., Marden, E., Martin, G. et al.:Estrogen receptor-associated proteins:possible mediators of hormone-induced transcription. Science 264:1455-1458, 1994
PubMed
17) Onate, A., Tsai, Y., Tsai, J. et al.:Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 27e:1354-1357, 1995
 
18) Heery, d. M., Kalkhoven, E., Hoare, S. et al:Asignature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736, 1997
PubMed
19) Rachez, C., Lemon, D., Suldan, Z. et al.:Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398:824-828, 1999
 
20) Takeyama, K., Masuhiro, Y., Fuse, H. et al.:Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol. Cell. Biol. 19:1049-1055, 1999
 
21) Kamei, Y., Xu, L., Heinzel, T. et al.:A CBP integrator complex mediates transcriptional activation and AP-l inhibition by nuclear receptors. Cell 85:403-414, 1996
 
22) Kalkhoven, E., Valentine, J. E, Heery, d. M. et al.:Isoforms of steroid receptor co-activator l differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 17:232-243, 1998
 
23) Lanz, B., McKenna, J., Onate, A. et al:As teroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-l complex. Cell 97:17-27, 1999
 
24) Gu, W., Malik, S., Ito, M. et al.:Anovel human SRB/MEd-containing cofactor complex, SMCC, involved in transcription regulation. Mol. Cell 3:97-108, 1999
 
25) Spencer, T. E., Jenster, G., Burcin, M. M. et al.:Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194-198, 1997
PubMed
26) Chen, H., Lin, R. J., Xie, W. et al.:Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675-686, 1999
 
27) Nagy, L., Kao, Y., Chakravarti, d. et al.:Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380, 1997
 
28) Wu, Z., Puigserver, P., Andersson, U. et al.:Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1. Cell 98:115-124, 1999
PubMed
29) Endoh, H., Maruyama, K., Masuhiro, Y. et al.:Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function l of human estrogen receptor α. Mol. Cell. Biol. 19:5363-5372, 1999
 
P.182 掲載の参考文献
1) Evans, R. M.:The steroid and thyroid hormone receptor superfamily. Science 240:889-895, 1988
PubMed
2) Kuiper, G. G., Enmark, E., Pelto-Huikko, M. et al:Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci USA 93:5925-5930, 1996
PubMed
3) Ogawa, S., Inoue, S., Watanabe, T. et al.:The complete primary structure of human estrogen receptor β (hERβ) and its heterodimerization with ERαin vivo and in vitro. Biochem. Biophys. Res. Commun. 243:122-126, 1998
 
4) Hiroi, H., Inoue, S., Watanabe, T. et al.:Differential immunolocalization of estrogen receptor α and β in rat ovary and uterus. J. Mol. Endocrinol. 22 (1):37-44, 1999
 
5) Watanabe, T., Inoue, S., Ogawa, S. et al.:Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype:functional difference between estrogen receptors α and β. Biochem. Biophys. Res. Commun. 236:140-145, 1997
 
6) Onoe, Y., Miyaura, C., Ohta, H. et al:Expression of estrogen receptor β in rat bone. Endocrinology I38:4509-4512, 1997
 
7) Arts, J., Kuiper, G. G., Janssen, J. M. et al:differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138:5067-5070, 1997
 
8) Kameda, T., Mano, H., Yuasa, T. et al.:Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. . Exp. Med. 186:489-495, 1997
PubMed
9) Windahl, S. H., Norgard, M., Kuiper, G. G. et al.:Cellular distribution of estrogen receptor β in neonatal rat bone. Bone 26 (2):117-121, 2000
 
10) Vidal, O., Kindblom, L. G., Ohlsson, C.:Expression and localization of estrogen receptor-β in murine and human bone. J. Bone Miner. Res. 14 (6):923-929, 1999
 
11) Paech, K., Webb, P., Kuiper, G. G. et al.:differential ligand activation of estrogen receptors ERα and ERβ at API sites. Science 277 (5331):1508-1510, 1997
 
12) Brzozowski, A. M., Pike, A. C., Dauter, Z. et al.:Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (6652):753-758, 1997
PubMed
13) Smith, E. P., Boyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994
 
14) Sudhir, K., Chou, T. M., Chatterjee, K. et al.:Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96:3774-3777, 1997
 
15) Lubahn, d. B., Moyer, J. S., Golding, T. S. et al.:Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl. Acad. Sci. USA 90:11162-11166, 1993
 
16) Krege, J. H., Hodgin, J. B., Couse, J. F. et al.:Generation and reproductive phenotypes of mice lacking estrogen receptorβ. Proc. Natl. Acad. Sci. USA 95 (26):15677-15682, 1998
 
17) Windahl, S. H., Vidal, O., Andersson, G. et al.:Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERβ (-/-) mice. J. Clin. .Invest. 104 (7):895-901, 1999
 
18) Karas, R. H., Hodgin, J. B., Kwoun, M. et al.:Estrogen inhibits the vascular injury response in estrogen receptorβ-deficient female mice. Proc. Natl. Acad. Sci. USA 96 (26):15133-15136, 1999
 
19) Simpson, E. R.:Genetic mutations resulting in estrogen insufficiency in the male. Mol. Cell. Endocrinol. 145:55-59, 1998
PubMed
20) Fisher, C. R., Graves, K. H., Parlow, A. F. et al.:Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp 19 gene. Proc. Natl. Acad. Sci. USA 95:6965-6970, 1998
PubMed
21) Couse, J. F., Korach, K. S.:Estrogen receptor null mice:what have we learned and where will they lead us? Endocr. Rev. 20 (3):358-417, 1999
PubMed
22) Couse, J. F., Hewitt, S. C., Bunch, D. O. et al.:Postnatal sex reversal of the ovaries in mice lacking estrogen receptors α and β. Science 286 (5448):2328-2331, 1999
 
23) Ogawa, S., Inoue, S., Orimo, A. et al.:Cross-inhibition of both estrogen receptor α and β pathways by each dominant negative mutant. FEBS Lett. 423:129-132, 1998
 
24) Ogawa, S., Fujita, M., Ishii, Y. et al.:Impaired estrogen sensitivity in bone by inhibiting both estrogen receptor α and β pathways. J. Biol. Chem. 275 (28):21372-21379, 2000
 
25) Inoue, S., Kondo, S., Hashimoto, M. et al.:Isolation of estrogen receptor-binding sites in human genomic DNA. Nucleic. . Acids. Res. 19 (15):4091-4096, 1991
 
26) Inoue, S., Kondo, S., Muramatsu, M.:Identification of target genes for a transcription factor by genomic binding site (GBS) cloning (1998) Transcription Factors-A Practical Approach, 2nd Edition (Latchman, d. S. ed. ) IRL press, 1998, p. 165-178
 
27) Inoue, S., Orimo, A., Hosoi, T. et al.:Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc. Natl. Acad. Sci. USA 90:11117-11121, 1993
PubMed
28) Orimo, A., Inoue, S., Ikeda, K. et al.:Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localization with estrogen receptor mRNA in target organs. J. Biol. Chem. 270:24406-24413, 1995
PubMed
29) Ikeda, K., Orimo, A., Higashi, Y. et al.:Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett. 472 (1):9-13, 2000
PubMed
30) Orimo, A., Inoue, S., Minowa, O. et al.:Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor α. Proc. Natl. Acad. Sci. USA 96 (21):12027-12032, 1999
 
31) Inoue, S., Urano, S., Ogawa, S. et al.:Molecular cloning of rat efp:expression and regulation in primary osteoblasts. Biochem. Biophys. Res. Commun. 261:412-418, 1999
 
32) Muramatsu, M., Inoue, S.:Estrogen receptors:How do they control reproductive and nonreproductive functions. Biochem. Biophys. Res. Commun. 270 (1):1-10, 2000
PubMed
P.195 掲載の参考文献
1) Baker, A. R., Mcdonnell, D. P., Hughes, M. et al.:Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci. USA 85:3294-3298, 1988
PubMed
2) Kamei, Y., Kawada, T., Fukuwatari, T. et al.:Cloning and sequencing of the gene encoding the mouse vitamin D receptor. Gene 152:281-282, 1995
PubMed
3) Burmester, J. K., Maeda, N., deLuca, H. F.:Isolation and expression of rat 1,25-dihydroxyvitamin D3 receptor cDNA. Proc. Natl. Acad. Sci. USA 85:1005-1009, 1988
PubMed
4) Neibergs, H. L, Bosworth, B. T., Reinhardt, T. A.:Nucleotide sequence of the bovine vitamin D3 receptor. J. Dairy Sci. 79:1313-1315, 1996
PubMed
5) Lu, Z., Hanson, K., deLuca, H. F.:Cloning and origin of the two forms of chicken vitamin D receptor. Arch. Biochem. Biophys. 339:99-106, 1997
PubMed
6) Elaroussi, M. A., Prahl, J. M., deLuca, H. F.:The avian vitamin D receptors:primary structures and their origins. Proc. Natl. Acad. Sci. USA 91:11596-11600, 1994
PubMed
7) Hughes, S., Zelus, D., Mouchiroud, d.:Warm-blooded isochore structure in Nile crocodile and turtle. Mol Biol. Evol. 16:1521-1527, 1999
PubMed
8) Li, Y. C., Bergwitz, C., Juppner, H. et al.:Cloning and characterization of the vitamin D receptor from Xenopus laevis. Endocrinology 138:2347-2353, 1997
PubMed
9) Suzuki, T., Suzuki, N., Srivastava, A. S. et al.:Identification of cDNAs encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Biochem. Biophys. Res. Commun. 270:40-45, 2000
 
10) Fisk, G. J., Thummel, C. S.:Isolation, regulation, and DNA-binding properties of three Drosophila nuclear hormone receptor superfamily members. Proc. Natl. Acad. Sci. USA 92:10604-10608, 1995
PubMed
11) Waterston, R., Martin, C., Craxton, M. et al.:A survey of expressed genes in Caenorhabditis elegans. Nat. Genet. 1:114-123, 1992
 
12) Michigami, T., Suga, A., Yamazaki, M. et al:Identification of amino acid sequence in the hinge region of human vitamin D receptor that transfers a cytosolic protein to the nucleus. J. Biol. Chem. 274:33531-33538, 1999
 
13) Kliewer, S. A., Umesono, K., Mangelsdorf, d. J. et al.:Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355:446-449, 1992
PubMed
14) Kurokawa, R., Yu, V. C., Naar, A. et al.:differential orientations of the dNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. Genes. dev. 7:1423-1435, 1993
PubMed
15) Solomon, C., White, J. H., Kremer, R.:Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor α. J. Clin. Invest. 103:1729-1735, 1999
 
16) Hsieh, J. C., Whitfield, G. K., Oza, A. K. et al.:Characterization of unique DNA-binding and transcriptional-activation functions in the carboxyl-terminal extension of the zinc finger region in the human vitamin D receptor. Biochemistry 38:16347-16358, 1999
PubMed
17) Nakajima, S., Hsieh, J. C, Macdonald, P. N. et al.:The C-terminal region of the vitamin D receptor is essential to form a complex with a receptor auxiliary factor required for high affinity binding to the vitamin D-responsive element. Mol. Endocrinol. 8:159-172, 1994
 
18) Whitfield, G. K., Hsieh, J. C., Nakajima, S. et al.:A highly conserved region in the hormonebinding domain of the human vitamin D receptor contains residues vital for heterodimerization with retinoid X receptor and for transcriptional activation [published erratum appears in Mol. Endocrinol. 1995 Nov;9 (11):1509]. Mol. Endocrinol. 9:1166-1179, 1995
 
19) Ebihara, K., Masuhiro, Y., Kitamoto, T. et al.:Intron retention generates a novel isoform of the murine vitamin D receptor that acts in a dominant negative way on the vitamin D signaling pathway. Mol. Cell. Biol. 16:3393-3400, 1996
 
20) Umesono, K., Murakami, K. K, Thompson, C. C. et al:direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors α 1165:1255-1266, 1991
 
21) Schrader, M., Nayeri, S., Kahlen, J. P. et al.:Natural vitamin D3 response elements formed by inverted palindromes:polarity-directed ligand sensitivity of vitamin D3 receptor-retinoid X receptor heterodimer-mediated transactivation. Moll. Cell. Biol. 15:1154-1161, 1995
 
22) Mackey, S. L., Heymont, J. L, Kronellberg, H. M. et al.:vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid X receptor. Mol. Endocrinol. 10:298-305, 1996
 
23) Liu, S. M., Koszewski, N., Lupez, M. et al.:Characterization of a response element in the 5'-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D3 and binds the vitamin D3 receptor. Mol. Endocrinol. 10:206-215, 1996
PubMed
24) Kurokawa, R., diRenzo, J., Boehm, M. et al:Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature 371:528-531, 1994
PubMed
25) Nishishita, T., Okazaki, T., Ishikawa, T. et al:A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with Ku antigen to mediate negative gene regulation by vitamin D. J. Biol. Chem. 273:10901-10907, 1998
PubMed
26) Towers, T. L, Freedman, L. P.:Granulocyte-macrophage colony-stimulating factor gene transcription is directly repressed by the vitamin D3 receptor. Implications for allosteric influences on nuclear receptor structure and function by a DNA element. J. Biol. Chem. 273:10338-10348, 1998
PubMed
27) Towers, T. L., Staeva, T. P., Freedman, L. P.:A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene:vitamin D receptor competes for DNA binding with NFATI and stabilizes c-Jun. Mol. Cell. Biol. 19:4191-4199, 1999
 
28) Alroy, I., Towers, T. L, Freedman, L. P.:Transcriptional repression of the interleukin-2 gene by vitamin D3:direct inhibition of NFATp/AP-l complex formation by a nuclear hormone receptor. Mol. Cell. Biol. 15:5789-5799, 1995
 
29) Takeuchi, A., Reddy, G. S., Kobayashi, T. et al.:Nuclear factor of activated T cells (NFAT) as a molecular target for 1α, 25-dihydroxyvitamin D3-mediated effects. J. Immunol. 160:209-218, 1998
 
30) Chrivia, J. C., Kwok, R. P., Lamb, N. et al.:Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365:855-859, 1993
 
31) Yang, X. J., Ogryzko, V. V., Nishikawa, J. et al.:A p300/CBP-associated factor that competes with the adenoviral oncoprotein EIA. Nature 382:319-324, 1996
 
32) Torchia, J., Rose, d. W., Inostroza, J. et al.:The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677-684, 1997
PubMed
33) Kurokawa, R., Kalafus, D., Ogliastro, M. H. et al.:Differential use of CREB binding protein-coactivator complexes. Science 279:700-703, 1998
PubMed
34) Kamei, Y., Xu, L., Heinzel, T. et al.:A CBP integrator complex mediates transcriptional activation and AP-l inhibition by nuclear receptors. Cell 85:403-414, 1996
 
35) diamond, M. I., Miner, J. N., Yoshinaga, S. K. et al.:Transcription factor interactions:selectors of positive or negative regulation from a single DNA element. Science 249:1266-1272, 1990
PubMed
36) Nagy, L., Kao, H. Y., Chakravarti, d. et al.:Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380, 1997
PubMed
37) Heinzel, T., Lavinsky, R. M., Mullen, T. M. et al.:Acomplex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48, 1997
 
38) Ogryzko, V. V., Schiltz, R. L, Russanova, V. et al.:The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959, 1996
PubMed
39) Minucci, S., Horn, Y., Bhattacharyya, N. et al.:A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl. Acad. Sci. USA 94:11295-11300, 1997
 
40) Glass, C. K., Rosenfeld, M. G.:The coregulator exchange in transcriptional functions of nuclear receptors. Genes. . Dev. 14:121-141, 2000
PubMed
41) Baudino, T. A., Kraichely, d. M., Jefcoat, S. C. Jr. et al.:Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J. Biol. Chem. 273:16434-16441, 1998
PubMed
42) Leo, C., Li, H., Chen, J. d.:Differential mechanisms of nuclear receptor regulation by receptor-associated coactivator 3. J. Biol. Chem. 275:5976-5982, 2000
 
43) Rachez, C., Lemon, B. D., Suldan, Z. et al.:Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398:824-828, 1999
PubMed
44) Rachez, C., Suldan, Z., Ward, J. et al.:A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes. Dev. 12:1787-1800, 1998
 
45) Ito, M., Yuan, C. X., Malik, S. et al.:Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol. Cell 3:361-370, 1999
PubMed
46) Naar, A. M., Beaurang, P. A., Zhou, S. et al.:Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature 398:828-832, 1999
PubMed
47) Cooney, A. J., Leng, X., Tsai, S. Y. et al:Multiple mechanisms of chicken ovalbumin upstream promoter transcription factor-dependent repression of transactivation by the vitamin D, thyroid hormone, and retinoic acid receptors. J. Biol. Chem. 268:4152-4160, 1993
PubMed
48) Lee, Y.-F., Young, W.-J., Lin, W.-J. et al.:Differential regulation of direct repeat 3 vitamin D3 and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor. J. Biol. Chem. 274:16198-16205, 1999
PubMed
49) Nakajima, S., Yamagata, M., Sakai, N. et al.:Effect of cyclic adenosine 3', 5:-monophosphate and protein kinase A on ligand-dependent transactivation via the vitamin D receptor. Mol. Cell. Endocrinol. 159:45-51, 2000
PubMed
50) Yanagisawa, J., Yanagi, Y., Masuhiro, Y. et al.:Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283:1317-1321, 1999
 
51) Okano, T., Tsugawa, N., Masuda, S. et al.:Regulatory activities of 2β-(3-hydroxypropoxy)-1α, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem. Biophys. Res. Commun. 163:1444-1449, 1989
 
52) Ono, Y., Kawase, A., Watanabe, H. et al.:Syntheses and preventive effects of analogues related to 1α, 25-dihydroxy-2β-(3-hydroxypropoxy) vitamin D3, (ED-71) on bone mineral loss in ovariectomized rats. Bioorg. Med. Chem. 6:2517-2523, 1998
 
53) Song, L. N., Cheng, T.:Effects of 1,25-dihydroxyvitamin D3 analogue l, 24 (OH) 2-22-ene-24-cyclopropyl D3 on proliferation and differentiation of a human megakaryoblastic Leukemia cell line. Biochem. Pharmacol. 43:2292-2295, 1992
 
54) Colston, K. W., Chander, S. K., Mackay, A. G. et al.:Effects of synthetic vitamin D analogues on breast cancer cells proliferation in vivo and in vitro. Biochem. Pharmacol. 44:693-702, 1992
PubMed
55) Hickish, T., Cunningham, D., Colston, K. et al.:The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br. J. Cancer 68:668-672, 1993
PubMed
56) Binderup, L., Latini, S., Binderup, E. et al:20-epi-vitamin D3 analogues:a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol. 42:1569-1575, 1991
PubMed
57) Blutt, S. E., Mcdonnell, T. J., Polek, T. C. et al.:Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10-17, 2000
PubMed
58) Kiriyama, T., Okamoto, S., Ejima, E. et al.:Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. Endocrinology 128:81-86, 1991
PubMed
59) Asou, H., Koike, M., Elstner, E. et al.:19-nor vitamin-d analogs:a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92:2441-2449, 1998
 
60) Inoue, D., Matsumoto, T., Ogata, E. et al:22-Oxacalcitriol, a noncalcemia analogue of calcitriol, suppresses both cell proliferation and parathytoid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells. J. Biol. Chem. 268:16730-16736, 1993
 
61) Kanatani, M., Sugimoto, T., Kaji, H. et al:Effects of 22-oxacalcitriol on bone metabolism in vitro:comparison with calcitriol-effects of 22-oxacalcitriol on osteoclast-like cell formation and boneresorbing activity. Eur. J. Endocrinol. 133:618-625, 1995
 
62) Takeyama, K., Masuhiro, Y., Fuse, H. et al.:Selective interaction of vitamin D receptor with transcriptional coactivator by a vitamin D analog. Mol. Cell. Biol. 19:1049-1055, 1999
 
63) Yang, W., Freedman, L. P.:20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor. J. Biol. Chem. 274:16838-16845, 1999
 
64) Rochel, N., Wurtz, J. M., Mitschler, A. et al.:The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell. 5:173-179, 2000
PubMed
65) Ozono, K., Saito, M., Miura, d. et al.:Analysis of the molecular mechanism for the antagonistic action of a novel 1α, 25-dihydroxyvitamin D(3) analogue toward vitamin D receptor function. J. Biol. Chem. 274:32376-32381, 1999
 
66) Miura, D., Manabe, K., Ozono, K. et al.:Antagonistic action of novel 1α, 25-dihydroxyvitamin D3-26, 23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1α, 25-dihydroxyvitamin D3. J. Biol. Chem. 274:16392-16399, 1999
 
67) Yoshizawa, T., Handa, Y., Uematsu, Y. et al.:Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16:391-396, 1997
PubMed
68) Takeyama, K., Kitanaka, S., Sato, T. et al.:25-Hydroxyvitamin D3 1α-hydroxylase and vitamin D synthesis. Science 277:1827-1830, 1997
 
P.212 掲載の参考文献
1) Anderson, A., Davis, d. L., Dahlback, H. et al.:Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem. 264:8222-8229, 1989
 
2) Masumoto, O., Ohyama, Y., Okuda, K.:Purification and characterization of vitamin D 25-hydroxylase from rat liver mitochondria. J. Biol. Chem. 263:14256-14260, 1988
PubMed
3) Usui, E., Noshiro, M., Okuda, K.:Molecular cloning of cDNA for vitamin D3 25-hydroxylase from rat liver mitochondria. FEBS. Lett. 262:135-138, 1990
PubMed
4) Ohyama, Y., Hayashi, S., Okuda, K.:Purification of 25-hydroxyvitamin D3 24-hydroxylase from rat kidney mitochondria. FEBS. Lett. 255 (2):405-408, 1989
PubMed
5) Ohyama, Y., Noshiro, M., Okuda, K.:Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase. FEBS. Lett. 278:195-198, 1991
PubMed
6) Shinki, T., Shimada, H., Wakino, S. et al:Cloning and expression of rat 25-hydroxyvitamin D3-1α-hydroxylase cDNA. Proc. Natl. Acad. Sci. USA 94:12920-12925, 1997
 
7) Fu, G. K., Lin, D., Zhang, M. Y. H. et al:Cloning of human 25-hydroxyvitamin D3-1α-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol. Endocrinol. 11 (13):1961-1970, 1997
 
8) St-Arnaud, R., Messerian, S., Moir, J. M. et al.:The 25-hydroxyvitamin D3-1α-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J. Bone. Miner. Res. 12 (10):1552-1559, 1997
 
9) Takeyama, K., Kitanaka, S., Sato, T. et al:25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D synthesis. Science・277 (5333):1827-1830, 1997
 
10) Monkawa, T., Yoshida, T., Wakino, S. et al.:Molecular cloning of cDNA and genomic DNA for human 25-hydroxyvitamin D3-1α-hydroxylase. Biochem. Biophys. Res. Commun. 239:527-533, 1997
 
11) Yoshida, T., Yoshida, N., Nakamura, A. et al.:Cloning of porcine 25-hydroxyvitamin D3-1α-hydroxylase and its regulation by cAMP in LLC-PKI cells. J. Am. Soc. Nephrol. 10:963-970, 1999
 
12) DeLuca, H. F.:The vitamin D story:a collaborative effort of basic science and Clinical medicine. FASSEB J. 2:224-236, 1988
 
13) Suda, T., Shinki, T., Kurokawa, K.:The mechanisms of regulation of vitamin D metabolism in the kidney. Curr. Opin. Nephrol. Hypertens. 3:59-64, 1994
PubMed
14) Boyle, L T., Gray, R. W., DeLuca, H. F.:Regulation by calcium of in vivo synthesis of 1,25-dihydroxycholecalciferol and 21, 25-dihydroxycholecalciferol. Proc. Natl. Acad. Sci. USA 68:2131-2134, 1971
 
15) Garabedian, M., Holick, M. F., DeLuca, H. F. et al.:Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc. Natl. Acad. Sci. USA 69:1673-1676, 1972
PubMed
16) Horiuchi, N., Suda, T., Sasaki, S. et al.:Absence of regulatory effects of 1α, 25-dihydroxyvitamin D3 on 25-hydroxyvitamin D3 metabolism in rats constantly infused with parathyroid hormone. Biochem. Biophys. Res. Commun. 73 (4):869-875, 1976
 
17) Horiuchi, N., Suda, T., Takahashi, H. et al.:In vivo evidence for the intermediary role of 3', 5:-cyclic AMP in parathyroid hormone-induced stimulation of 1α, 25-dihydroxyvitamin D3 synthesis in rats. Endocrinology 101:969-974, 1977
 
18) Tanaka, Y., Chen, T. C., Deluca, H. F.:dependence of 25-hydroxycholecalciferol-l-hydroxylase regulation on RNA and protein synthesis. Arch. Biochem. . Biophys. 152 (1):291-298, 1972
 
19) Shinki, T., Ueno, Y., deLuca, H. F. et al.:Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1α-hydroxylase gene in normocalcemic rats. Proc. Natl. Acad. Sci. USA 96:8253-8258, 1999
 
20) Brenza, H. L., Kimmel-Jehan, C., Jehan, F. et al:Parathyroid hormone activation of the 25-hydroxyvitamin D3-1α-hydroxylase gene promotor. Proc. Natl. Acad. Sci. USA 95:1387-1391, 1998
 
21) Kong, X. F, Zhu, X. H., Pei, Y. L. et al.:Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1α-hydroxylase gene. Proc. Natl. Acad. Sci. USA 96:6988-6993, 1999
 
22) Murayama, A., Takeyama, K., Kitanaka, S. et al.:The promoter of the human 25-hydroxyvitamin D3-1α-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1α, 25(OH)2 D3. Biochem. Biophys. Res. Commun. 249 (1):11-16, 1998
 
23) Murayama, A., Takeyama, K, Kitanaka, S. et al.:Positive and negative regulations of the renal 25-hydroxyvitamin D3-1α-hydroxylase gene by parathyroid hormone, calcitonin, and 1α, 25(OH)2 D3 in intact animals. Endocrinology 140 (5):2224-2231, 1999
 
24) Galante, L., Colston, K. W., MacAuley, S. J. et al.:Effect of calcitonin on vitamin D metabolism. Nature 238:271-273, 1972
PubMed
25) Lorenc, R., Tanaka, Y., DeLuca, H. F. et al.:Lack of effect of calcitonin on the regulation of vitamin D metabolism in the rat. Endocrinology 10:468-472, 1977
 
26) Kawashima, H., Torikai, S., Kurokawa, K.:Localization of 25-hydroxyvitamin D3-1α-hydroxylase and 24-hydroxylase along the rat nephron. Proc. Natl. Acad. Sci. USA 78:1199-1203, 1981
 
27) Morel, F.:Sites of hormone action in the mammalian nephron. Am. J. Physiol. 240:F159-F164, 1981
PubMed
28) Kawashima, H., Torikai, S., Kurokawa, K. et al.:Calcitonin selectively stimulates 25-hydroxyvitamin D3-1α-hydroxylase in proxmal straight tubule of rat kidney. Nature 291:327-329, 1981
 
29) Yoshida, N., Yoshida, T., Nakamura, A. et al.:Calcitonin induces 25-hydroxyvitamin D31α-hydroxylase mRNA expression via protein kinase C pathway in LLC-PKI cells. J. Am. Soc. Nephrol. 10:2474-2479, 1999
 
30) Iida, K., Shinki, T., Yamaguchi, A. et al.:A possible role of vitamin D receptors in regulating vitamin D activation in the kidney. Proc. Natl. Acad. Sci. USA 92:6112-6116, 1995
 
31) Bland, R., Walker, E. A., Hughes, S. V. et al.:Constitutive expression of 25-hydroxyvitamin D3-1α-hydroxylase in a transformed human proximal tubule cell line:evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology 140 (5):2027-2034, 1999
 
32) Akeno, N., Matsunuma, A., Maeda, T. et al.:Regulation of vitamin D-1α-hydroxylase and-24-hydroxylase expression by dexamethasone in mouse kidney. J. Endocrinology 164:339-348, 2000
 
P.227 掲載の参考文献
1) Juppner, H., Abou-Samra, A. B., Freeman, M. W. et al.:AG protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024-1026, 1991
 
2) Usdin, T. B., Cruber, C., Bonner, T. I.:Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J. Biol. Chem. 270:15455-15458, 1995
 
3) Rubin, D., Juppner, H.:Zebrafish express the common parathyroid hormone/parathyroid hormone-related peptide receptor (PTH1R) and a novel receptor (PTH3R) that is preferentially activated by mammalian and fugufish parathyroid hormone-related peptide. J. Biol. Chem. 274:28185-28190, 1999
 
4) Senior, P. V., Heath, D. A., Beck, F.:Expression of parathyroid hormone-related protein mRNA in the rat before birth:demonstration by hybridization histochemistry. J. Mol. Endocrinol. 6:281, 1990
 
5) Kramer, S., Reynolds, F. H. Jr., Castillo, M. et al:Immunological identification and distribution of parathyroid hormone-like protein polypeptides in normal and malignant tissues. Endocrinology 128:1927, 1991
PubMed
6) Karaplis, A. C., Luz, A., Glowacki, J. et al.:Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes. dev. 8:277-289, 1994
PubMed
7) Amizuka, N., Henderson, J. E., Warshawsky, H. et al:Parathyroid hormone-related peptide (PTHrP)-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J. Cell Biol. 126:1611-1623, 1994
PubMed
8) Amizuka, N., Henderson, J. E., Hoshi, K. et al.:Programmed cell death of chondrocytes and aberrant chondrogenesis in mice homozygous for parathyroid hormone-related peptide (PTHrP) gene deletion. Endocrinology 137:5055-5067, 1996
PubMed
9) Amizuka, N., Karaplis, A. C., Henderson, J. E. et al.:Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal post-natal bone development. Develop. Biol. 175:166-176, 1996
 
10) Weir, E., Philbrick, W., Neff, L. et al.:Targeted over-expression of parathyroid hormone-related peptide in chondrocytes causes skeletal dysplasia and delayed osteogenesis. Proc. Natl. Acad. Sci. USA 93:10240, 1996
 
11) Lanske, B., Karaplis, A. C., Luz, A. et al.:Characterization of mice homozygous for the PTH/ PTHrP receptor gene null mutation. Science 273:663-666, 1996
 
12) Vortkamp, A., Lee, K., Lanske, B. et al.:Regulation of rate of cartilage differentiation by indian hedgehog and PTH-related peptide. Science 273:613, 1996
 
13) McCuaig, K. A., Clarke, J. C., White, J. H.:Molecular cloning of the gene encoding the mouse parathyroid hormone/parathyroid hormone-related peptide receptor. Proc. Natl. Acad. Sci. USA 91:5051-5055, 1994
PubMed
14) McCuaig, K. A., Lee, H., Clarke, J. C. et al.:Parathyroid hormone/parathyroid hormone related peptide receptor gene transcripts are expressed from tissue-specific and ubiquitous promoters. Nucleic. Acids. Res. 23:1948-1955, 1995
PubMed
15) Amizuka, N., Lee, H. S., Kwan, M. Y. et al.:Cell-specific expression of the parathyroid hormone (PTH) /PTH-related peptide receptor gene in rat kidney from kidney-specific and ubiquitous promoters. Endocrinology 138:469-481, 1997
 
16) Maren, D., Palmer, G., Bonjour, J. P. et al.:Sequence and activity of parathyroid hormone/ parathyroid hormone-related protein receptor promoter region in human osteoblast-like cells. Gene 218:49-56, 1998
 
17) Amizuka, N., Kwan, M., Goltzman, d. et al.:vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage. J. Clin. Invest. 103:373-381, 1999
PubMed
18) Fukumoto, S., Suzawa, M., Kikuchi, T. et al.:Cloning and characterization of kidney-specific promoter of human PTH/PTHrP receptor gene:Absence of mutation in patients with pseudohypoparathyroidism type I b. Mol. Cell Biol. 141:41-47, 1998
 
19) Jansen, M.:Uber atypische Chondrodystrophie (Achondroplasia) und uber eine noch nicht beschriebene angeborene Wachstumsstarung des Knochensystems:Metaphysare dysostosis. Z. Orthop. Chir. 61:253-286, 1934
 
20) Schipani, E., Klaus, K., Juppner, H.:A constitutive active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodisplasia. Science 268:98-100, 1995
 
21) Schipani, E., Langman, C. B., Parfitt, A. M. et al.:Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N. Engl. J. Med. 335:708, 1996
 
22) Schipani, E., Langman, C., Hunzelman, J. et al.:A novel parathyroid hormone (PTH) /PTHrelated peptide receptor mutation in Jansen's metaphyseal chondrodysplasia. J. Clin. Endocrinol. Metab. 84:3052-3057, 1999
 
23) Jobert, A. S., Zhang, P., Couvineau, A. et al.:Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J. Clin.Invest. 102:34, 1998
PubMed
24) Blomstrand, S., Claesson, I., Save-Soderbergh, J.:A case of lethal congenital dwarfism with accelerated skeletal maturation. Pediatric Radiology 15:141, 1985
 
25) den Hollander, N. S., van der Harten, H. J., Vermeij-Keers, C. et al.:First-trimester diagnosis of Blomstrand lethal osteochondrodysplasia. Am. J. Med. Genet. 73:345, 1997
PubMed
26) Karaplis A, He, M. B., Nguyen, A. et al.:Blomstrand chondrodisplasia caused by a missense mutation in the human parathyroid hormone receptor-1. Endocrinology 139:5255, 1999
 
27) Zhang, P., Jobert, A. S., Couvineau, A. et al:A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J. Clin. Endocrinol. Metab. 83:3365-3368, 1998
PubMed
28) Schipani, E., Lanske, B., Hunzelman, J. et al:Targeted expression of constitutive active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescures mice that lack parathyroid hormone-related peptide. Proc. Natl. Acad. Sci. USA 94:13689, 1997
 
29) Chung, U., Lanske, B., Lee, K. et al.:The parathyroid homone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Proc. Natl. Acad. Sci. USA 95:13030, 1998
 
30) Gardella, T. J., Luck, M. D., Jensen, G. S. et al.:Converting parathyroid hormone-related peptide (PTHrP) into potent PTH-2 receptor agonist. J. Biol. Chem. 271:19888-19893, 1996
PubMed
31) Usdin, T. B., Bonner, T. I., Harta, G. et al.:distribution of parathyroid hormone-2 receptor messenger ribonucleic acid in rat. Endocrinology 137:4285-4297, 1996
PubMed
32) Henderson, J. E., Amizuka, N., Warshawsky, H. et al.:Nucleolar targeting of PTHrP enhances survival of chondrocytes under conditions that promote cell death by apoptosis. Mol. Cell. Biol. 15:4064-4075, 1995
PubMed
33) Lam, M. H., Olsen, S. L, Rankin, W. A. et al.:PTHrP and cell division:expression and localization of PTHrP in a kertinocyte cell line (HaCaT) during the cell cyle. J. Cell. Physiol. 173:433-446, 1997
 
34) Lam, M. H., House, C. M., Tiganis, T. et al.:Phosphorylation at the cyclin-dependent kinases site (Thr85) of parathyroid hormone-related protein negatively regulates its nuclear localization. J. Biol. Chem. 274:18559-18566, 1999
PubMed
35) Lam, M. H., Briggs, L. J., Hu, W. et al.:Importin beta recognizes parathyroid hormone-related protein with high affinity and mediates its nuclear import in the absence of importin alpha. J. Biol. Chem. 274:7391-7398, 1999
PubMed
36) Amizuka, N., Fukushi-Irie, M., Sasaki, T. et al.:In efficient Function of the Signal Sequence of PTHrP for Targeting into the Secretory Pathway. Biochem. Biophys. Res. Commun. 273:621-629, 2000
 
37) Aarts, M. M., Levy, D., He, B. et al:Parathyroid hormone related protein (PTHrP) interacts with RNA. J. Biol. Chem. 274:4832-4838, 1999
PubMed
38) Aarts, M. M., Rix, A., Guo, J. et al.:The nucleolar targeting signal (NTS) of parathyroid hormone-related protein mediates endocytosis and nucleolar translocation. J. Bone Miner. Res. 14:1493-1503, 1999
PubMed
39) Watson, P. H., Fraher, L. J., Hendy, G. N. et al:Nuclear localization of the type 1 PTH/PTHrP receptor in rat tissue. J. Bone Miner. Res. 15:1033-1044, 2000
 
P.238 掲載の参考文献
1) Brown, E. M., Gamba, G., Riccardi, d. et al.:Cloning and characterization of an extracellular Ca (2+)-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
PubMed
2) Riccardi, D., Park, J., Lee, W. S. et al.:Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc. Natl. Acad. Sci. USA 92:131-135, 1995
 
3) Ruat, M., Molliver, M. E., Snowman, A. M. et al:Calcium sensing receptor:molecular cloning in rat and localization to nerve terminals. Proc. Natl. Acad. Sci. USA 92:3161-3165, 1995
PubMed
4) Garrett, J. E., Capuano, I. V., Hammerland, L. G. et al.:Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J. Biol. Chem. 270:12919-12925, 1995
PubMed
5) Oda, Y., Tu, C. L., Chang, W. et al:The calcium sensing receptor and its alternatively spliced form in murine epidermal differentiation. J. Biol. Chem. 275:1183-1190, 2000
PubMed
6) Pi, M., Garner, S. C., Flannery, P. et al:Sensing of extracellular cations in CasR-deficient osteoblasts-Evidence for a novel cation-sensing mechanism. J. Biol. Chem. 275:3256-3263, 2000
PubMed
7) Butters, R. Jr., Chattopadhyay, N., Nielsen, P. et al.:Cloning and characterization of a calcium-sensing receptor from the hypercalcemic New Zealand white rabbit reveals unaltered responsiveness to extracellular calcium. J. Bone. Miner. Res. 12:568-579, 1997
PubMed
8) Diaz, R., Hurwitz, S., Chattopadhyay, N. et al.:Cloning, expression, and tissue localization of the calcium-sensing receptor in chicken (Gallus domesticus) . Am . J. Physiol. 273:R1008-R1016, 1997
PubMed
9) Pace, A. J., Gama, L., Breitwieser, G. E.:Dimerization of the calcium-sensing receptor occurs within the extracellular domain and is eliminated by Cys-->Ser mutations at Cys 101 and Cys236. J. . Biol. Chem. 274:11629-11634, 1999
PubMed
10) Conigrave, A. D., Quinn, S. J., Brown, E. M.:L-Amino acid sensing by the extracellular Ca2+-sensing receptor. Proc. Natl. Acad. Sci. USA 97:4814-4819, 2000
PubMed
11) Bai, M., Trivedi, S., Lane, C. R. et al.:Protein kinase C phosphorylation of threonine at position 888 in Ca2+o-sensing receptor (CaR) inhibits coupling to Ca2+store release. J. Biol. Chem. 273:21267-21275, 1998
PubMed
12) Garrett, J. E., Tamir, H., Kifor, O. et al.:Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 136:5202-5211, 1995
PubMed
13) Ray, J. M., Squires, P. E., Curtis, S. B. et al.:Expression of the calcium-sensing receptor on human antral gastrin cells in culture. J. Clin. Invest. 99:2328-2333, 1997
PubMed
14) Chattopadhyay, N, Cheng, I., Rogers, K. et al.:Identification and localization of extracellular Ca (2+)-sensing receptor in rat intestine. Am. J. Physiol. 274:G122-G130, 1998
PubMed
15) McNeil, S. E., Hobson, S. A., Nipper, V. et al.:Functional calcium-sensing receptors in rat fibroblasts are required for activation of SRC kinase and mitogen-activated protein kinase in response to extracellular calcium. J. Biol. Chem. 273:1114-1120, 1998
PubMed
16) McNeil, L., Hobson, S., Nipper, V. et al.:Functional calcium-sensing receptor expression in ovarian surface epithelial cells. Am. J. Obstet. Gynecol. 178:305-313, 1998
PubMed
17) Cheng, I., Klingensmith, M. E., Chattopadhyay, N. et al.:Identification and localization of the extracellular calcium-sensing receptor in human breast. J. Clin. Endocrinol. Metab. 83:703-707, 1998
 
18) Yamaguchi, T., Olozak, I., Chattopadhyay, N. et al.:Expression of extracellular calcium (Ca2+o)-sensing receptor in human peripheral blood monocytes. Biochem. Biophys. Res. Commun. 246:501-506, 1998
PubMed
19) Chattopadhyay, N., Ye, C., Singh, D. P. et al.:Expression of extracellular calcium-sensing receptor by human lens epithelial cells. Biochem. Biophys. Res. Commun. 233:801-805, 1997
PubMed
20) Tu, C. L., Oda, Y., Bikle, D. D.:Effects of a calcium receptor activator on the cellular response to calcium in human keratinocytes. J. Invest. Dermatol. 113:340-345, 1999
PubMed
21) Chang, W., Tu, C., Chen, T. H. et al.:Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology 140:5883-5893, 1999
 
22) Rasschaert, J., Malaisse, W. J.:Expression of the calcium-sensing receptor in pancreatic islet B-cells. Biochem. Biophys. Res. Commun. 264:615-618, 1999
PubMed
23) Romoli, R., Lania, A., Mantovani, G. et al:Expression of calcium-sensing receptor and characterization of intracellular signaling in human pituitary adenomas. J. Clin. Endocrinol. Metab. 84:2848-2853, 1999
PubMed
24) Bradbury, R. A., Sunn, K. L, Crossley, M. et al.:Expression of the parathyroid Ca (2+)-sensing receptor in cytotrophoblasts from human term placenta. J. Endocrinol 156:425-430, 1998
PubMed
25) Kameda, T., Mano, H., Yamada, Y. et al.:Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem. Biophys. Res. Commun. 245:419-422, 1998
PubMed
26) House, M. G., Kohlmeier, L, Chattopadhyay, N. et al.:Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J. Bone Miner. Res. 12:1959-1970, 1997
PubMed
27) Kanatani, M., Sugimoto, T., Kanzawa, M. et al.:High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calcium-sensing receptor existing in osteoclast precursor cells. Biochem. Biophys. Res. Commun. 261:144-148, 1999
PubMed
28) Yamaguchi, T., Kifor, O., Chattopadhyay, N. et al.:Expression of extracellular calcium (Ca2+o)-sensing receptor in the clonal osteoblast-like cell lines, UMR-106 and SAOS-2. Biochem. Biophys. Res. Commun. 243:753-757, 1998
PubMed
29) Yamaguchi, T., Chattopadhyay, N., Kifor, O. et al.:Mouse osteoblastic cell line (MC3T3-E1) expresses extracellular calcium (Ca2+o)-sensing receptor and its agonists stimulate chemotaxis and proliferation of MC3T3-E1 cells. J. Bone Miner. Res. 13:1530-1538, 1998
 
30) Quarles, L. D., Hartle, J. E., Siddhanti, S. R. et al.:Adistinct cation-sensing mechanism in MC3T3-E1 osteoblasts functionally related to the calcium receptor. J. Bone Miner. Res. 12:393-402, 1997
 
31) Lundgren, S., Carling, T., Hjalm, G. et al.:Tissue distribution of human gp330/megalin, a putative Ca (2+)-sensing protein. J. Histochem. Cytochem. 45:383-392, 1997
 
32) Zaidi, M., Shankar, V. S., Tunwell, R. et al.:Aryanodine receptor-like molecule expressed in the osteoclast plasma membrane functions in extracellular Ca2+sensing. J. Clin. Invest. 96:1582-1590, 1995
 
33) Brown, E. M., Pollak, M., Hebert, S. C.:The extracellular calcium-sensing receptor:its role in health and disease. Annu. Rev. Med. 49:15-29, 1998
PubMed
34) Ye, C., Kanazirska, M., Quinn, S. et al.:Modulation by polycationic Ca (2+)-sensing receptor agonists of nonselective cation channels in rat hippocampal neurons. Biochem. Biophys. Res. Commun. 224:271-280, 1996
PubMed
35) Brown, E. M.:Extracellular Ca2+sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol. Rev. 71:371-411, 1991
PubMed
36) Marx, S. J., Spiegel, A. M., Brown, E. M. et al.:Divalent cation metabolism. Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. . Am. J. Med. 65:235-242, 1978
PubMed
37) Aida, K., Koishi, S., Inoue, M. et al:Familial hypocalciuric hypercalcemia associated with mutation in the human Ca (2+)-sensing receptor gene. J. Clin. Endocrinol. Metab. 80:2594-2598, 1995
 
38) Bai, M., Quinn, S., Trivedi, S. et al.:Expression and characterization of inactivating and activating mutations in the human Ca2+o-sensing receptor. J. Biol. Chem. 271:19537-19545, 1996
PubMed
39) Bai, M., Janicic, N., Trivedi, S. et al.:Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. J. Clin. Invest. 99:1917-1925, 1997
PubMed
40) Bai, M., Pearce, S. H., Kifor, O. et al.:In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene:normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familia (benign hypercalcemia. J. Clin. Invest. 99:88-96, 1997
 
41) Chikatsu, N., Fukumoto, S., Suzawa, M. et al.:An adult patient with severe hypercalcemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor. Clin. Endocrinol. (Oxf. ) 50:537-543, 1999
PubMed
42) Chou, Y. H., Pollak, M. R., Brandi, M. L. et al.:Mutations in the human Ca (2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am. J. Hum. Genet. 56:1075-1079, 1995
PubMed
43) Heath, H. 3D., Odelberg, S., Jackson, C. E. et al.:Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains. J. Clin. Endocrinol. Metab. 81:1312-1317, 1996
 
44) Janicic, N., Pausova, Z., Cole, d. E. et al.:Insertion of an Alu sequence in the Ca (2+)-sensing receptor gene in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Am. J. Hum. Genet. 56:880-886, 1995
PubMed
45) Pearce, S. H., Trump, D., Wooding, C. et al.:Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J. Clin. Invest. 96:2683-2692, 1995
PubMed
46) Pearce, S. H., Brown, E. M.:Calcium-sensing receptor mutations:insights into a structurally and functionally novel receptor. J. Clin. Endocrinol. Metab. 81:1309-1311, 1996
PubMed
47) Pearce, S. H., Wooding, C., Davies, M. et al.:Calcium-sensing receptor mutations in familial hypocalciuric hypercalcaemia with recurrent pancreatitis. Clin. Endocrinol (Oxf) 45:675-680, 1996
PubMed
48) Pollak, M. R., Brown, E. M., Chou, Y. II. et al.:Mutations in the human Ca (2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297-1303, 1993
 
49) Lloyd, S. E., Pannett, A. A., Dixon, P. H. et al.:Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. Am. J. Hum. Genet. 64:189-195, 1999
PubMed
50) Trump, D., Whyte, M. P., Wooding, C. et al.:Linkage studies in a kindred from Oklahoma, with familial benign (hypocalciuric) hypercalcaemia (FBH) and developmental elevations in serum parathyroid hormone levels, indicate a third locus for FBH. Hum. Genet. 96:183-187, 1995
 
51) Marx, S. J., Attie, M. F., Spiegel, A. M. et al:An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. N. Engl. J. Med. 306:257-264, 1982
PubMed
52) Kobayashi, M., Tanaka, H., Tsuzuki, K. et al.:Two novel missense mutations in calcium-sensing receptor gene associated with neonatal severe hyperparathyroidism. J. Clin. Endocrinol. Metab. 82:2716-2719, 1997
PubMed
53) Ho, C., Conner, d. A., Pollak, M. R. et al.:A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat. Genet. 11:389-394, 1995
PubMed
54) Bai, M., Trivedi, S., Kifor, O. et al.:Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function. Proc. Natl. Acad. Sci. USA 96:2834-2839, 1999
PubMed
55) Carling, T., Szabo, E., Ridefelt, P. et al.:Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J. Clin. Endocrinol. Metab. 85:2042-2047, 2000
PubMed
56) Hosokawa, Y., Pollak, M. R., Brown, E. M. et al.:Mutational analysis of the extracellular Ca (2+-sensing receptor gene in human parathyroid tumors. J. Clin. Endocrinol. Metab. 80:3107-3110, 1995
PubMed
57) Gogusev, J., Duchambon, P., Hory, B. et al.:Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 51:328-336, 1997
PubMed
58) Kifor, O., Moore, F., Wang, P. et al.:Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81:1598-1606, 1996
PubMed
59) Chikatsu, N., Fukumoto, S., Takeuchi, Y. et al.:Cloning and characterization of two promoters for human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas. J. Biol. Chem. 275:7553-7557, 2000
PubMed
60) Pollak, M. R., Brown, E. M., Estep, H. L. et al.:Autosomal dominant hypocalcaemia caused by a Ca (2+)-sensing receptor gene mutation. Nat. Genet. 8:303-307, 1994
 
61) Pearce, S. H., Williamson, C., Kifor, O. et al.:A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335:1115-1122, 1996
PubMed
62) Lovlie, R., Eiken, H. G., Sorheim, J. I. et al:The Ca (2+)-sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism. Hum. Genet. 98:129-133, 1996
PubMed
63) Okazaki, R., Chikatsu, N., Nakatsu, M. et al.:A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. J. Clin. Endocrinol. Metab. 84:363-366, 1999
PubMed
64) Watanabe, T., Bai, M., Lane, C. R. et al.:Familial hypoparathyroidism:identification of a novel gain of function mutation in transmembrane domain 5 of the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 83:2497-2502, 1998
PubMed
65) De Luca, F., Ray, K., Mancilla, E. E. et al.:Sporadic hypoparathyroidism caused by de novo gain-of-function mutations of the Ca (2+)-sensing receptor. J. Clin. Endocrinol. Metab. 82:2710-2715, 1997
PubMed
66) Li, Y., Song, Y. H., Rais, N. et al.:Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J. Clin. Invest. 97:910-914, 1996
 
67) Klein, G. L, Nicolai, M., Langman, C. B. et al.:Dysregulation of calcium homeostasis after severe burn injury in children:possible role of magnesium depletion. J. Pediatr. 131:246-251, 1997
PubMed
68) Nielsen, P. K., Rasmussen, A. K., Butters, R. et al.:Inhibition of PTH secretion by interleukin-l β in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. Biochem. Biophys. Res. Commun. 238:880-885, 1997
 
69) Murphey, E. D., Chattopadhay, N., Traber, D. L. et al.:Increased parathyroid calcium-sensing receptor mRNA following burn injury in sheep. Bone 23:S458, 1998
 
P.252 掲載の参考文献
1) Massague, J.:TGF-β signal transduction. Annu. Rev. Biochem. 67:753-791, 1998
 
2) Rosenzweig, B. L., Imamura, T., Okadome, T. et al:Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. USA 92:7632, 1995
PubMed
3) Heldin, C. H., Miyazono, K., ten dijke, P.:TGF-β signalling from cell membrane to nucleus through SMAd proteins. Nature 390:465-471, 1997
 
4) ten dijke, P., Yamashita, H., Sampath, T. K. et al.:Identification of type I receptors for osteogenic protein-l and bone morphogenetic protein-4. J. Biol. Chem. 269:16985-16988, 1994
 
5) ten dijke, P., Yamashita, H., Ichijo, H. et al:Characterization of type I receptors for transforming growth factor-β and activin. Science 264:101-104, 1994
 
6) Ebisawa, T., Tada, K., Kitajima, L et al.:Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J. Cell. Sci. 112:3519, 1999
 
7) Hahn, S. A., Schutte, M., Hoque, A. T. et al.:DPC4, a candidate tumor suppressor gene at human chromosome 18q21. 1. Science 271:350-353, 1996
PubMed
8) Savage, C., Das, P., Finelli, A. L. et al.:Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components. Proc. Natl. Acad. Sci. USA 93:790-794, 1996
 
9) Raftery, L. A., Twombly, V., Wharton, K. et al.:Genetic screens to identify elements of the decapentaplegic signaling pathway in Drosophila. Genetics 139:241-254, 1995
PubMed
10) Sekelsky, J. J., Newfeld, S. J., Raftery, L. A. et al.:Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 139:1347-1358, 1995
PubMed
11) Zhou, S., Buckhaults, P., Zawel, L. et al.:Targeted deletion of Smad4 shows it is required for transforming growth factor β and activin in colorectal cancer cells. Proc. Natl. Acad. Sci. USA 95:2412-2416, 1998
 
12) Kawabata, M., Inoue, H., Hanyu, A. et al.:Smad proteins exist as monomers in vivo and undergo homo-and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J. 17:4056-4065, 1998
PubMed
13) Imamura, T., Takase, M., Nishihara, A. et al.:Smad6 inhibits signalling by the TGF-β superfamily. Nature 389:622-626, 1997
 
14) Nakao, A., Afrakhte, M., Moren, A. et al.:Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 389:631-635, 1997
 
15) Takase, M., Imamura, T., Sampath, T. K. et al.:Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem. Biophys. Res. Commun. 244:26-29, 1998
PubMed
16) Ulloa, L, Doody, J., Massague, J.:Inhibition of transforming growth factor-β/SMAd signalling by the interferon-γ/STAT pathway. Nature 397:710-713, 1999
 
17) Afrakhte, M., Moren, A., Jossan, S. et al:Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members. Biochem. Biophys. .Res. Commun. 249:505-511, 1998
 
18) Bitzer, M., von Gersdorff, G., Liang, d. et al:A mechanism of suppression of TGF-β/SMAd signaling by NF-κB/RelA. Genes. Dev. 14:187-197, 2000
 
19) Shi, Y., Hata, A., Lo, R. S. et al.:A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 388:87-93, 1997
PubMed
20) Lo, R. S., Chen, Y. G., Shi, Y. et al.:The L3 loop:a structual motif determining specific interactions between SMAd proteins and TGF-β receptors. EMBO J. 17:996-1005, 1998
 
21) Chen, Y. G., Massague, J.:Smad1 recognition and activation by the ALKI group of transforming growth factor-β family receptors. J. Biol. Chem. 274:3672-3677, 1999
 
22) Lagna, G., Hemmati-Brivanlou, A.:A molecular basis for Smad specificity. Dev. Dyn. 214:269-277, 1999
 
23) Shi, Y., Wang, Y. F., Jayaraman, L. et al.:Crystal structure of a Smad MH1 domain bound to DNA binding in TGF-β signaling. Cell 94:585-594, 1998
 
24) Yagi, K., Goto, D., Hamamoto, T. et al.:Alternatively spliced variant of Smad2 lacking exon3. Comparison with wild-type Smad2 and Smad3. J. Biol. Chem. 274:703-709, 1999
 
25) Kretzschmar, M., Doody, J., Massague, J.:Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature 389:618-622, 1997
 
26) Kretzschmar, M., Doody, J., Timokhina, I. et al.:A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes. Dev. 13:804-816, 1999
 
27) de Caestecker, M. P., Parks, W. T., Frank, C. J. et al.:Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes. Dev. 12:1587-1592, 1998
PubMed
28) Brown, J. D., DiChiara, M. R., Anderson, K. R. et al.:MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J. Biol. Chem. 274:8797-8805, 1999
PubMed
29) Zhang, Y., Feng, X. H., derynck, R.:Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature 394:909-913, 1998
 
30) Liberati, N. T., Datto, M. B., Frederick, J. P. et al.:Smads bind directly to the Jun family of AP-1 transcription factors. Proc. Natl. Acad. Sci. USA 96:4844-4849, 1999
 
31) Sano, Y., Harada, J., Tashiro, S. et al.:ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling. J. Biol. Chem. 274:8949-8957, 1999
 
32) Chen, X., Weisberg, E., Fridmacher, V. et al.:Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 389:85-89, 1997
PubMed
33) Komori, T., Yagi, H., Nomura, S. et al.:Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764, 1997
 
34) Hanai, J., Chen, L. F., Kanno, T. et al.:Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline C α promoter. J. Biol. Chem. 274:31577-31582, 1999
 
35) Zawel, L., Le dai, J., Buckhaults, P. et al.:Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell. 1:611-617, 1998
 
36) Dennler, S., Itoh, S., Vivien, d. et al.:Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-typel gene. EMBO J. 17:3091-3100, 1998
 
37) Jonk, L. J., Itoh, S., Heldin, C. H. et al.:Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer. J. Biol. Chem. 273:21145-21152, 1998
 
38) Pardali, E., Xie, X. Q., Tsapogas, P. et al.:Smad and AML proteins synergistically confer transforming growth factor β1 responsiveness to human germ-line IgA genes. J. Biol. Chem. 275:3552-3560, 2000
 
39) Kim, J., Johnson, K., Chen, H. J. et al.:Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic. Nature 388:304, 1997
PubMed
40) Kusanagi, K., Inoue, H., Ishidou, Y. et al.:Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol. Biol. Cell. 11:555-565, 2000
PubMed
41) Ishida, W., Hamamoto, T., Kusanagi, K. et al:Smad6 is a Smad1/5-induced smad inhibitor Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J. Biol. Chem. 275:6075-6079, 2000
PubMed
42) Parfitt, A. M.:Osteonal and hemi-osteonal remodeling:the spatial and temporal framework for signal traffic in adult human bone. J. Cell. Biochem. 55:273-286, 1994
 
43) Pelton, R. W., Saxena, B., Jones, M. et al.:Immunohistochemical localization of TGFβ1, TGFβ2, and TGFβ3 in the mouse embryo:expression patterns suggest multiple roles during embryonic development. J. Cell. Biol. 115:1091-1105, 1991
 
44) Oursler, M. J.:Osteoclast synthesis and secretion and activation of latent transforming growth factor β. J. Bone Miner. Res. 9:443-452, 1994
 
45) Erlebacher, A., Derynck, R.:Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell. Biol. 132:195-210, 1996
 
46) Erlebacher, A., Filvaroff, E. H., Ye, J. Q. et al.:Osteoblastic responses to TGF-β during bone remodeling. Mol. Biol. Cell. 9:1903-1918, 1998
 
47) Filvaroff, E., Erlebacher, A., Ye, J. et al.:Inhibition of TGF-β receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126:4267-4279, 1999
 
48) Katagiri, T., Yamaguchi, A., Komaki, M. et al.:Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell. Biol. 127:1755-1766, 1994
PubMed
49) Wieser, R., Wrana, J. L., Massague, J.:GS domain mutations that constitutively activate T β R-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 14:2199-2208, 1995
 
50) Fujii, M., Takeda, K., Imamura, T. et al:Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol. Biol Cell. 10:3801-3813, 1999
PubMed
51) Atfi, A., Djelloul, S., Chastre, E. et al.:Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor β-mediated signaling. J. Biol. Chem. 272:1429-1432, 1997
 
52) Liberati, N. T., Datto, M. B., Frederick, J. P. et al:Smads bind directly to the Jun family of AP-1 transcription factors. Proc. Natl. Acad. Sci. USA 96:4844-4849, 1999
 
53) Hocevar, B. A., Brown, T. L, Howe, P. H. et al.:TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 18:1345-1356, 1999
 
54) Nakamura, K., Shirai, T., Morishita, S. et al:p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. Exp. Cell. Res. 250:351-363, 1999
PubMed
P.260 掲載の参考文献
1) Thomas, D. M., Hards, D. K., Rogers, S. D. et al.:Insulin and bone, Clinical and scientific view. Endocrinol. Metab. Clin. North Am. 4:5-17, 1997
 
2) Thomas, D. M., Hards, D. K., Rogers, S. D. et al.:Insulin receptor expression in bone. J. Bone Miner. Res. 11:1312-1320, 1996
 
3) Canalis, E.:Insulin like growth factors and the local regulation of bone formation. Bone 14:273-276, 1993
PubMed
4) Rosen, C. J., Donahue, L. R.:Insulin-like growth factors and bone, the osteoporosis connection revisited. Proc. Soc.Exp. Biol. Med. 219:1-7, 1998
PubMed
5) Hough, S., Avioli, L. V., Teitelbaum, S. L. et al.:Correction of abnormal bone and mineral metabolism in chronic streptozotocin-induced diabetes mellitus in the rat by insulin therapy. Endocrinology 108:2228-2234, 1981
PubMed
6) Buysschaert, M., Cauwe, F., Jamart, J. et al.:Proximal femur density in type I and type II diabetic patients. DiabetMetab. Rev. 18:32-37, 1992
 
7) Piepkorn, B., Kann, P., Forst, T. et al.:Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. 29:584-591, 1997
PubMed
8) Krakauer, J. C., McKenna, M. J., Rao. d, S. et al.:Bone mineral density in diabetes. Diabetes Care 20:1339-1340, 1997
PubMed
9) Haffner, S. M., Bauer, R. L.:The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. Metabolism 42:735-738, 1993
PubMed
10) Kao, C. H., Tsou, C. T., Chen, C. C. et al:Bone mineral density in patients with noninsulin-dependent diabetes mellitus by dual photon absorptiometry. Nucl. Med. Commun. 14:373-377, 1993
PubMed
11) Van Daele, P. L, Stolk, R. P., Burger. H. et al:Bone density in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 122:409-414, 1995
PubMed
12) Rosen, C. J., Dimai, H. P., Vereault, d. et al.:Circulating and skeletal insulin-like growth factor-I (IGF-d concentrations in two inbred strains of mice with different bone mineral densities. Bone 21:217-223, 1997
 
13) Canalis, E.:Insulin-like growth factors and osteoporosis. Bone 21:215-216, 1997
PubMed
14) Reed, B. Y., Zerwekh, J. E., Sakhaee, K. et al.:Serum IGF-I is low and correlated with osteoblastic surface in idiopathic osteoporosis. J. Bone Miner. Res. 10:1218-1224, 1995
 
15) Laron, Z., Klinger, B., Silbergeld, A.:Patients with Laron syndrome have osteopenia/osteoporosis. J. Bone Miner. Res. 14:156-161, 1999
 
16) Mamada, T., Nakamura, K., Hoshino, Y. et al.:Bone mineral density in patients with ossification of the posterior longitudinal ligament. Minimal decrease of bone mineral density with aging. Spine 22:2388-2392, 1997
PubMed
17) Kawaguchi, H., Kurokawa, T., Kodama, Y. et al.:Metabolic background of ossification of the posterior longitudinal ligament. In OPLL:Ossification of the Posterior Longitudinal Ligament. (Yonenobu, K., Sakou, T., Ono, K. eds. ) Springer-Verlag, Tokyo, 1997, p. 73-77
 
18) Shingyouchi, Y., Nagahama, A., Niida, M.:Ligamentous ossification of the cervical spine in the late middle-aged Japanese men. Its relation to body mass index and glucose metabolism. Spine 21:2474-2478, 1996
PubMed
19) Takeuchi, Y., Matsumoto, T., Takuwa, Y. et al.:High incidence of obesity and elevated serum immunoreactive insulin level in patients with paravertebral ligamentous ossification;a relationship to the development of ectopic ossification. J. Bone Miner. Metab. 7:17-21, 1989
 
20) Tamemoto, H., Kadowaki, T., Tobe, K. et al.:Insulin resistance and growth retardation in mice lacking insulin receptor substrate-l. Nature 372:182-186, 1994
 
21) Ogata, N., Chikazu, D., Kubota, N. et al.:Insulin receptor substratein osteoblast is indispensable for maintaining bone turnover. J. Clin. Invest. 105:935-943, 2000
 
P.272 掲載の参考文献
1) 上野直人, 野地澄晴:ダイナミックな器官形成, ニワトリの翼. 新形づくりの分子メカニズム. 東京, 羊土社, 1999, p.96-134
 
2) 竹内 純, 小柴和子, 小椋利彦:前後肢の違いを決めるTbx遺伝子とidentityの獲得. 実験医学18(9):1183-1193, 2000
 
3) Rodriguez, E. C., Tsukui, T., Yonei, S. et al.:The T-box genes Tbx4 and Tbx5 regulate limb outgrowth and identity [see comments]. Nature 398:814-818, 1999
 
4) Takeuchi, J. K., Koshiba, T. K., Matsumoto, K. et al.:Tbx5 and Tbx4 genes determine the wing /leg identity of limb buds[see comments]. Nature 398:810-814, 1999
 
5) Ohuchi, II., Nakagawa, T., Yamamoto, A. et al.:The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor. Development 124:2235-2244, 1997
 
6) Xu, X., Weinstein, M., Li, C. et al.:Fibroblast growth factor receptor 2(FGFR2)-mediated reciprocal regulation loop between FGF8 and FGFIO is essential for limb induction. Development 125:753-765, 1998
PubMed
7) Laufer, E., Nelson, C. E., Johnson, R. L. et al.:Sonic hedgehog and Fgf-4 act through a signaling cascade and feedback loop to integrate growth and patterning of the developing limb bud. Cell 79:993-1003, 1994
PubMed
8) Niswander, L, Jeffrey, S., Martin, G. R. et al:A positive feedback loop coordinates growth and patterning in the vertebrate limb. Nature 371:609-612, 1994
 
9) Tabin, C.:The initiation of the limb bud:growth factors, Hox genes and retinoids. Cell 80:671-674, 1995
PubMed
10) Riddle, R., Johnson, R. L., Laufer, E. et al:Sonic hedgehog mediates the polarizing activity of the ZPA. Cell 75:1401-1416, 1993
PubMed
11) Echelard, Y., Epstein, D. J., St, J. B. et al.:Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell 75:1417-1430, 1993
 
12) Johnson, R. L, Laufer, E., Riddle, R. d. et al.:Ectopic expression of Sonic hedgehog alters dorsalventral patterning of somites. Cell 79:1165-1173, 1994
PubMed
13) Francis, P. H., Richardson, M. K., Brickell, P. M. et al.:Bone morphogenetic proteins and a signalling pathway that controls patterning in the developing chick limb. Development 120:209-218, 1994
 
14) Bitgood, M. J., McMahon, A. P.:Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev. Biol. 172:126-238, 1995
PubMed
15) Kawakami, Y., Ishikawa, T., Shimabara, M. et al.:BMP signaling during bone pattern determination in the developing limb. Development 122:3557-3566, 1996
PubMed
16) Parr, B. A., McMahon, A. P.:Dorsalizing signal Wnt-7a required for normal polarity of D-V and A-P axes of mouse limb. Nature 374:350-353, 1995
 
17) Riddle, R. D., Ensini, M., Nelson, C. et al.:Induction of the LIM homeobox gene Lmx1 by WNT7a establishes dorsoventral pattern in the vertebrate limb. Cell 83:631-640, 1995
PubMed
18) Rodriguez, E. C., Schwabe, J. W., De, L. P. J. et al.:Radical fringe positions the apical ectodermal ridge at the dorsoventral boundary of the vertebrate limb[see comments][published erratum appears in Nature 1997 Aug 28;388 (6645):906]. . Nature 386:360-366, 1997
 
19) Logan, C., Hornbruch, A.,:Campbell, I. et al.:The role of Engrailed in establishing the dorsoventral axis of the chick limb. Development 124:2317-2324, 1997
PubMed
20) Nusse, R., Varrdus, H. E.:Wnt genes. Cell 69:1073-1087, 1992
 
21) Cadigan, K. M., Nusse, R.:Wnt signaling:a common theme in animal development. Genes. Dev. 11:3286-3305, 1997
PubMed
22) Niswander, L., Martin, G. R.:FGF-4 and BMP-2 have opposite effects on limb growth. Nature 361:68-71, 1993
PubMed
23) Niswander, L., Tickle, C., Vogel, A. et al.:Function of FGF-4 in limb development. Mol. Reprod. Dev. 39:83-88, 1994
PubMed
24) Marigo, V., Roberts, D. J., Lee, S. M. et al.:Cloning, expression, and chromosomal location of SHH and IHH:two human homologues of the Drosophila segment polarity gene hedgehog. Genomics 28:44-51, 1995
PubMed
25) Ciang, C., Litingtung, Y., Lee, E. et al.:Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383:407-413, 1996
 
26) St-Jacques, B., Hammerschmidt, M., McMahon, A. P.:Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes. Dev. 13:2072-2086, 1999
PubMed
27) Murtaugh, C. L., Chyung, J. H., Lassar, A. B.:Sonic hedgehog promotes somitic chondrogenesis by altering the cellular response to BMP signaling. Genes. Dev. 13:225-237, 1999
 
28) lwasaki, M., Le, A. X., Helms, J. A.:Expression of indian hedgehog, bone morphogenetic protein 6 and gli during skeletal morphogenesis. Mech. Dev. 69:197-202, 1997
 
29) Kinto, N., Iwamoto, M., Enomoto-Iwamoto, M. et al.:Fibroblasts expressing sonic hedgehog induce osteoblast differentiation and ectopic bone formation. FEBS Lett. 404:319-323, 1997
 
30) lwamoto, M., Enomoto-Iwamoto, M., Kurisu, K.:Actions of hedgehog proteins on skeletal cells. Crit. Rev. Oral. Biol.Med. 10:477-486, 1999
 
31) Enomoto-Iwamoto, M., Nakamura, T., Aikawa, T. et al.:Hedgehog proteins stimulate chondrogenic cell differentiation and cartilage formation. J. Bone Miner. Res. 2000 (in press)
 
32) Vortkamp, A., Lee, K., Lanske, B. et al.:Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613-622, 1996
PubMed
33) Scott, N. S., Choung, C.-M.:dual action of sonic hedgehog on chondrocyte hypertrophy:retrovirus mediated ectopic sonic hedgehog expression in limb bud micromass culture induces novel cartilage nodules that are positive for alkaline phosphatase and type X collagen. J. Cell Sci. 110:2691-2701, 1997
 
34) Watanabe, A., Ide, H.:Basic FGF maintains some characteristics of the progress zone of chick limb bud in cell culture. Dev. Biol. 159:223-231, 1993
PubMed
35) Rousseau, F., Bonaventure, J., Legeai, M. L. et al.:Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371:252-254, 1994
 
36) Wang, Y., Spatz, M. K., Kannan, K. et al.:A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc. Natl. Acad. Sci. USA 96:4455-4460, 1999
 
37) Deng, C., Wynshaw, B. A., Zhou, F. et al.:Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921, 1996
 
38) Minowada, G., Jarvis, L. A., Chi, C. L. et al.:Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development 126:4465-4475, 1999
PubMed
39) Kato, Y., Iwamoto, M., Koike, T.:Fibroblast growth factor stimulates colony formation of differentiated chondrocytes in soft agar. J. Cell Physiol. 133:491-498, 1987
 
40) Sahni, M., Ambrosetti, D. C., Mansukhani, A. et al.:FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-l pathway. Genes. Dev. 13:1361-1366, 1999
 
41) Enomoto-Iwamoto, M., Iwamoto, M., Kazuhisa, N. et al.:Involvement of α5β1 integrin in matrix interactions and proliferation of chondrocytes. J. Bone Miner. Res. 12:1124-1132, 1997
 
42) Zou, H., Niswander, L.:Requirement for BMP signaling in interdigital apoptosis and scale formation. Science 272:738-741, 1996
PubMed
43) Yokouchi, Y., Sakiyama, J., Kameda, T. et al.:BMP-2/-4 mediate programmed cell death in chicken limb buds. Development 122:3725-3734, 1996
PubMed
44) Yi, S. E., daluiski, A., Pederson, R. et al.:The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 127:621-630, 2000
PubMed
45) Enomoto-Iwamoto, M., Iwamoto, M., Mukudai, Y. et al.:Bone morphogenetic protein signaling is required for maintenance of differentiated phenotype, control of proliferation, and hypertrophy in chondrocytes. J. Cell Biol. 140:409-418, 1998
PubMed
46) Zou, H., Wieser, R., Massague, J. et al:Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes. Dev. 11:2191-2203, 1997
PubMed
47) Thomas, J. T., Kilpatrick, M. W., Lin, K. et al.:Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1. Nat. Genet. 17:58-64, 1997
PubMed
48) Tsumaki, N., Tanaka, K., Arikawa-Hirasawa, E. et al.:Role of CDMP-1 in skeletal morphogenesis:promotion of mesenchymal cell recruitment and chondrocyte differentiation. J. Cell Biol. 144:161-173, 1999
PubMed
49) Parr, B. A., McMahon, A. P.:Dorsalizing signal Wnt-7a required for normal polarity of D-V and A-P axes of mouse limb. Nature 374:350-353, 1995
 
50) Kawakami, Y., Wada, N., Nishimatsu, S. I. et al.:Involvement of Wnt-5a in chondrogenic pattern formation in the chick Iimb bud. Dev. Growth Differ. 41:29-40, 1999
 
51) Rudnicki, J. A., Brown, A. M.:Inhibition of chondrogenesis by Wnt gene expression in vivo and in vitro. Dev. Biol. 185:104-118, 1997
PubMed
52) Wang, S., Krinks, M., Lin, K. et al:Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell 88:757-766, 1997
PubMed
53) Leyns, L, Bouwmeester, T., Kim, S. H. et al.:Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 88:747-756, 1997
PubMed
54) Hoang, B. H., Thomas, J. T., Abdul, K. F. et al.:Expression pattern of two Frizzled-related genes, Frzb-1 and Sfrp-1, during mouse embryogenesis suggests a role for modulating action of Wnt family members. Dev. Dyn. 212:364-372, 1998
 
55) Ladher, R. K., Church, V. L, Allen, S. et al:Cloning and expression of the Wnt antagonists Sfrp-2 and Frzb during chick development. Dev. Biol. 218:183-198, 2000
PubMed
56) Duprez, D., Leyns, L, Bonnin, M. A. et al:Expression of Frzb-1 during chick development. Mech. Dev. 89:179-183, 1999
PubMed
57) Wada, N., Kawakami, Y., Ladher, R. et al.:Involvement of Frzb-1 in mesenchymal condensation and cartilage differentiation in the chick limb bud. Int. J. Dev. Biol. 43:495-500, 1999
PubMed
58) Wang, S., Krinks, M., Moos, M. J.:Frzb-1, an antagonist of Wnt-1 and Wnt-8, does not block signaling by Wnts-3A,-5A, or-ll. Biochem. Biophys. Res. Commun. 236:502-504, 1997
 
59) Eastman, Q., Grosschedl, R.:Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Cell. Biol. 11:233-240, 1999
PubMed
60) Ishitani, T., Ninomiya, T. J., Nagai, S. et al.:The TAKl-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 399:798-802, 1999
 
61) Nishita, M., Hashimoto, M. K., Ogata, S. et al.:Interaction between Wnt and TGF-β signallihg pathways during formation of Spemann's organizer. Nature 403:781-785, 2000
 
P.286 掲載の参考文献
1) Suda, T., Takahashi, N., Udagawa, N. et al.:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357, 1999
PubMed
2) Kong, Y. Y., Yoshida, H., Sarosi, I. et al:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
PubMed
3) Simonet, W. S., Lacey, d. L., Dunstan, C. R. et al:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
PubMed
4) Tsuda, E., Goto, M., Mochizuki, S. et al:Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234:137-142, 1997
PubMed
5) Jimi, E., Nakamura, I., Ikebe, T. et al.:Activation of NF-κB is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 273:8799-8805, 1998
 
6) 稲田全規 ・宮浦千里:炎症性骨吸収とマトリックスメタロプロテアーゼ. CLINICAL CALCIUM 8:300-305, 1998
 
7) Kusano, K., Miyaura, C., Inada, M. et al:Regulation of matrix metalloproteinases (MMP-2, 3, 9, and 13) by interleukin-1 and interleukin-6 in mouse calvaria:Association of MMP induction with bone resorption. Endocrinology 139:1338-1345, 1998
PubMed
8) Chen, Q.-R., Miyaura, C., Higashi, S. et al:Activation of cytosolic phospholipase A2 by platelet-derived growth factor is essential for cyclooxygenase-2-dependent prostaglandin E2 synthesis in mouse osteoblasts cultured with interleukin-1. J. Biol. Chem. 272:5952-5958, 1997
PubMed
9) Tai, H., Miyaura, C., Pilbeam, C. C. et al:Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology 138:2372-2379, 1997
PubMed
10) Onoe, Y., Miyaura, C., Kaminakayashiki, T. et al.:IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J. Immunol. 156:758-764, 1996
PubMed
11) 宮浦千里:ホルモンおよびサイトカインによる骨吸収の調節. 生化学70:516-530, 1998
 
12) Akatsu, T., Takahashi, N., Udagawa, N. et al:Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J. Bone Miner. Res. 6:183-190, 1991
PubMed
13) 小林拓也, 牛首文隆, 成宮 周:受容体ノックアウトマウスを用いた新しい生理機能の解析. 現代医療31:171-184, 1999
 
14) Miyaura, C., Inada, M., Suzawa, T. et al.:Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J. Biol Chem. 275:19819-19823, 2000
PubMed
15) Sakuma, Y., Tanaka, K., Suda, M. et al:Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res. 15:218-227, 2000
PubMed
16) Suzawa, T., Miyaura, C., Inada, M. et al.:The role of prostaglandin E receptor subtypes (EPl EP2, EP3 and EP4) in bone resorption:An analysis using specific agonists for the respective EPs. Endocrinology 141:1554-1559, 2000
 
17) Li, X., Okada, Y., Pilbeam, C. C. et al.:Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141:2054-2061, 2000
PubMed
18) Masuzawa, T., Miyaura, C., Onoe, Y. et al.:Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J. Clin. Invest. 94:1090-1097, 1994
PubMed
19) Miyaura, C., Onoe, Y., Inada, M. et al.:Increased B-lymphopoiesis by interleukin-7 induces bone loss in mice with intact ovarian function:Similarity to estrogen deficiency. Proc. Natl. Acad. Sci. USA 94:9360-9365, 1997
PubMed
20) Onoe, Y., Miyaura, C., Ohta, H. et al.:Expression of estrogen receptor β in rat bone. Endocrinology 138:4509-4512, 1997
 
22) Kanematsu, M., Sato, T., Takai, H. et al.:Prostaglandin E2 induces expression of receptor activator of nuclear factor-πB ligand/osteoprotegrin ligand on pre-B cells:Implications for accelerated osteoclastogenesis in estrgoen deficiency. J. Bone Miner. Res. 15:1321-1329, 2000
 
23) Kawaguchi, H., Pilbeam, C. C., Vargas, S. J. et al.:Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J. Clin. Invest. 96:539-548, 1995
PubMed
21 Asami, T., Inada, M., Mizunuma, H. et al.:Expression of osteoclast differentiation factor (ODF/RANKL/OPG1) in trab β cular bone and bone marrow B-lymphocytes in OVX mice. J. Bone Miner. Res. 14:S152, 1999
 

第3章 骨粗鬆症の病態と診断の分子医学

P.296 掲載の参考文献
1) Eastell, R.:Treatment of postmenopausal osteoporosis. N. Engl. J. Med. 338:736-746, 1998
PubMed
2) Gallagher, J. C.:Estrogen:prevention and treatment of osteoporosis, in Osteoporosis. (Marcus, R., Feldman, D., Kelsery, J. eds. ) Academic Press, San diego, 1996, p.1191-1208
 
3) Eisman, J. A.:Genetics of osteoporosis. Endocr. Rev. 20:788-804, 1999
PubMed
4) Cummings, S. R., Browner, W. S., Bauer, D. et al.:Endogehous hormones and the risk of hip and vertebral fractures among older women. N. Engl. Med. 339:733-738, 1998
PubMed
5) Bilezikian, J. P., Morishima, A., Bell, J. et al.:Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl. J. Med. 339:599-603, 1998
 
6) Carani, C., Qin, K, Simoni, M. et al.:Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med. 337:91-95, 1998
 
7) Fisher, C. R., Graves, K. H., Parlow, A. F. et al.:Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc. Natl. Acad. Sci. USA 495:6965-6970, 1998
 
8) Komm, B. S., Terpening, C. M., Benz, d. J. et al.:Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241:81-84, 1988
PubMed
9) Eriksen, E. F., Colvard, d. S., Berg, N. J. et al.:Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84-86, 1988
PubMed
10) Oursler, M. J., Osdoby, P., Pyfferoen, J. et al.:Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. USA 88:6613-6617, 1991
PubMed
11) Onoe, Y., Miyaura, C., Ohta, H. et al.:Expression of estrogen receptor beta in rat bone. Endocrinology 138:4509-4512, 1997
PubMed
12) Smith, E. P., Bpyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994
 
13) Couse, J. F., Korach, KS.:Estrogen receptor null mice:what have we learned and where will they lead us? Endocr. Rev. 20:358-417, 1999
PubMed
14) Windahl, S. H., Vidal, O., Andersson, G. et al.:Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERβ-/-mice. J. Clin. Invest. 104:895-901, 1999
 
15) Uebelhart, D., Schlemmer, A., Johansen, J. S. et al.:Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J. Clin. Endocrinol. Metab. 72:367-373, 1991
 
16) Calvo, M. S., Eyre, d. R., Gundberg, C. M.:Molecular basis and Clinical application of biological markers of bone turnover. Endocr. Rev. 17:333-368, 1996
PubMed
17) Spelsberg, T. C., Subramaniam, M., Riggs, B. L. et al.:The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol. Endocrinol. 13:819-828, 1999
PubMed
18) Pacifici, R.:Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11:1043-1051, 1996
PubMed
19) Manolagas, S. C., Jilka, R. L:Bone marrow, cytokines, and bone remodeling:emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332:305-310, 1995
PubMed
20) Pacifici, R., Rifas, L, Teitelbaum, S. et al.:Spontaneous release of interleukin l from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc. Natl. Acad. Sci. USA 84:4616-4620, 1987
 
21) Pacifici, R., Rifas, L., McCracken, R. et al.:Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin l release. Proc. Natl. Acad. Sci. USA 86:2398-2402, 1989
 
22) Pacifici, R., Brown, C., Puscheck, E. et al.:Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononeclear cells. Proc. Natl. Acad. Sci. USA 88:5134-5138, 1991
PubMed
23) Kitazawa, R., Kimble, R. B., Vannice, J. L. et al.:Interleukin-l receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94:2397-2406, 1994
 
24) Lorenzo, J. A., Naprta, A., Rao, Y. et al.:Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139:3022-3025, 1998
 
25) Ammann, P., Rizzoli, R., Bonjour, J. P. et al.:Transgenic mice expressing soluble tumor necrosis factor receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 99:1699-1703, 1997
PubMed
26) Kimble, R. B., Srivastava, S., Ross, F. P. et al.:Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1-and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 271:28890-28897, 1996
PubMed
27) Srivastava, S., Weitzmann, M. N., Kimble, R. B. et al.:Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J. Clin. Invest. 102:1850-1859, 1998
 
28) Girasole, G., Jilka, R. L., Passeri, G. et al.:17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro:apotential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89:883-891, 1992
 
29) Jilka, R. L., Hangoc, G., . Girasole, G. et al.:Increased osteoclast development after estrogen loss:mediation by interleukin-6. Science 257:88-91, 1992
PubMed
30) Poli, V., Balena, R., Fattori, E. et al.:Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1189-1196, 1994
PubMed
31) Kawasaki, K., Gao, Y. H., Yokose, S. et al.:Osteoclasts are present in gp130-deficient mice. Endocrinology 138:4959-4965, 1997
PubMed
32) Kawaguchi, H., Pilbeam, C. C., Vargas, S. J. et al.:Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in culturedmouse calvariae. J. Clin. Invest. 96:539-548, 1995
 
33) Miyaura, C., Kusano, K., Masuzawa, T. et al.:Endogenous bone-resorbing factors in estro gendeficiency:cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 10:1365-1373, 1995
 
34) Jilka, R. L, Takahashi, K., Munshi, M. et al.:Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow:evidence for autonomy from factors released during bone resorption. J. Clin. Invest. 101:1942-1950, 1998
PubMed
35) Suda, T., Takahashi, N., Udagawa, N. et al.:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev . 20:345-357, 1999
PubMed
36) Filvaroff, E., derynck, R.:A signaling system for osteoclast regulation. Curr. Biol. 8:R679-R682, 1998
PubMed
37) Roodman, G. D.:Advances in bone biology:the osteoclast. Endocr. Rev. 17:308-332, 1996
PubMed
38) Lacey, D. L., Timms, E., Tan, H. L. et al:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
PubMed
39) Yasuda, H., Shima, N., Nakagawa, N. et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998
PubMed
40) Fuller, K., Wong, B., Fox, S. et al.:TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188:997-1001, 1998
PubMed
41) Kong, Y. Y., Yoshida, H., Sarosi, I. et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
PubMed
42) Hsu, H., Lacey, D. L., Dunstan, C. R. et al.:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96:3540-3545, 1999
PubMed
43) Dougall, W. C., Glaccum, M., Charrier, K. et al.:RANK is essential for osteoclast and lymph node development. Genes Dev. 13:2412-2424, 1999
PubMed
44) Lomaga, M. A., Yeh, W. C., Sarosi, I. et al.:TRAF6 deficiency results in osteopetrosis and defective interleukin-1, Cd-40, and LPS signaling. Genes Dev. 13:1015-1024, 1999
 
45) Simonet, W. S., Lacey, D. L., Dunstan, C. R. et al.:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
PubMed
46) Bucay, N., Sarosi, I., Dunstan, C. R. et al.:Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-1268, 1998
PubMed
47) Kobayashi, K., Takahashi, N., Jimi, E. et al.:Tumor necrosis factor a stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 17:275-286, 2000
 
48) Hofbauer, LC., Khosla, S., Dunstan, C. R. et al.:The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15:2-12, 2000
PubMed
49) Yano, K., Tsuda, E., Washida, N. et al:Immunological characterization of circulating osteo-protegerin/osteoclastogenesis inhibitory factor:increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14:518-527, 1999
 
50) Sato, T., Ikeda, K., Watanabe, K.:Generation of bone-resorbing osteoclasts from B220-positive cells:its role in accelerated osteoclastogenesis in estrogen deficiency. J. Bone Miner. Res. (in press)
 
51) Manolagas, S. C.:Birth and death of bone cells:basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21:115-137, 2000
PubMed
52) Hughes, D. E., Dai, A., Tiffee, J. C. et al.:Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat. Med. 2:1132-1136, 1996
 
53) Kameda, T., Mano, H . ., Yuasa, T. et al:Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186:489-495, 1997
PubMed
54) Kincade, P. W., Medina, K. L, Smithson, G. et al.:Pregnancy:a clue to normal regulation of B lymphopoiesis. Immunol. Today 15:539-544, 1994
PubMed
55) Masuzawa, T., Miyaura, C., Onoe, Y. et al.:Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J. Clin. Invest, 94:1090-1097, 1994
PubMed
56) Miyaura, C., Onoe, Y., Inada, M. et al.:Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function:similarity to estrogen deficiency. Proc. Natl. Acad. Sci. USA 94:9360-9365, 1997
PubMed
57) 浅見哲司ほか:エストロゲン欠乏による骨髄リンパ球造血の亢進と破骨細胞分化誘導因子(ODF)の発現増大の相関. 日本骨代謝学会雑誌17:58, 1999
 
58) Kanematsu, M., Sato, T., Takai, H. et al:Prostaglandin E2 induces expression of RANKL/OPGL on pre-B cells:implications for accelerated osteoclastogenesis in estrogen deficiency. J. Bone Miner. Res. 15:1321-1329, 2000
 
59) Riggs, B. L., Khosla, S., Melton, L. J. III.:Aunitary model for involutional osteoporosis:estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13:763-773, 1998
 
60) Prince, R. L.:Estrogen effects on calcitropic hormones and calcium homeostasis. Endocr. Rev. 15:301-309, 1994
PubMed
61) Colin, E. M., Van Den Bemd, G. J., Van Aken, M. et al.:Evidence for invovlement of 17b-estradiol in intestinal calcium absorption independent of 1,25-dihydrozyvitamin D3 level in the rat. J. Bone Miner. Res. 14:57-64, 1999
 
62) Bolscher, M. T., Netelenbos, J. C., Barto, R. et al.:Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat. J. Bone Miner. Res. 14:1197-1202, 1999
 
63) Slemenda, C. W., Longcope, C., Zhou, L. et al.:Sex steroids and bone mass in older man:positive associations with serum estrogens and negative associations with androgens. J. Clin. Invest. 100:1755-1759, 1997
PubMed
64) Khosla, S., Melton, L. J. III., Atkinson, E. J. et al.:Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women:akey role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83:2266-2274, 1998
 
65) Rodan, G. A.:Mechanical loading, estrogen deficiency, and the coupling of bone formation to bone resorption. J. Bone Miner. Res. 6:527-530, 1991
PubMed
66) Westerlind, K. C., Wronski, T. J., Ritman, E. L. et al.:Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. Proc. Natl. Acad. Sci. USA 94:4199-4204, 1997
PubMed
P.310 掲載の参考文献
1) Riggs, B. L, Khosla, S., Melton, I. J. L.:A unitary model for involutional osteoporosis:Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13:763-773, 1998
 
2) Riggs, B. L, Melton, IIL L. J.:Involutional osteoporosis. N. Engl. J. Med. 314:1676-1686, 1986
 
3) Takahashi, M., Kushida, K., Hoshino, H. et al.:Biochemical markers of bone turnover do not decline after menopause in healthy women. Br. J. Obstet. Gynaecol 106:427-431, 1999
 
4) Theiler, R., Stahelin, H. B., Kranzlin, M. et al.:High bone turnover in the elderly. Arch. Phys. Med. Rehabil. 80:485-489, 1999
PubMed
5) Bollen, A. M., Kiyak, H. A., Eyre, D. R.:Longitudinal evaluation of a bone resorption marker in elderly subjects. Osteoporos. Int. 7:544-549, 1997
PubMed
6) Yoshimura, N., Hashimoto, T., Sakata, K. et al.:Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck:the Taiji study. Calcif. Tissue Int. 65:198-202, 1999
PubMed
7) Dawson-Hughes, B., Harris, S. S., Krall, E. A. et al:Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. Med. 337:670-676, 1997
PubMed
8) D'Ippolito, G., Schiller, P. C., Ricordi, C. et al.:Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J. Bone Miner. Res. 14:1115-1122, 1999
 
9) Bergman, R. J., Gazit, D., Kahn, A. J. et al.:Age-related changes in osteogenic stem cells in mice. J. Bone miner. Res. 11:568-577, 1996
PubMed
10) Jilka, R. L, Weinstein, R. S., Takahashi, K. et al.:Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J. Clin. Invest. 97:1732-1740, 1996
 
11) Kodama, Y., Takeuchi, Y., Suzawa, M. et al.:Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6):relationship to osteopenia with enhanced adipogenesis. J. Bone Miner. Res. 13:1370-1377, 1998
PubMed
12) Kawaguchi, H., Manabe, N., Miyaura, C. et al.:Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J. Clin. Invest. 104:229-237, 1999
PubMed
13) Rosen, C. J.:Growth hormone, insulin-like growth factors, and the senescent skeleton:Ponce de Leon:s Fountain revisited? J. Cell Biochem. 56:348-356, 1994
 
14) Pfeilschifter, J., Diel, I., Pilz, U. et al.:Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age. J. Bone Miner. Res. 8:707-717, 1993
 
15) Fleet, J. C., Cashman, K., Cox, K. et al.:The effects of aging on the bone inductive activity of recombinant human bone morphogenetic protein-2. Endocrinology 137:4605-4610, 1996
PubMed
16) Donahue, H. J., Zhou, Z., Li, Z. et al.:Age-related decreases in stimulatory G protein-coupled adenylate cyclase activity in osteoblastic cells. Am. J. Physiol. 273:E776-E781, 1997
 
17) Poli, V., Balena, R., Fattori, E. et al.:Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1189-1196, 1994
PubMed
18) Lorenzo, J. A., Naprta, A., Rao, Y. et al:Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy[see comments]. Endocrinology 139:3022-3025, 1998
PubMed
19) Ammann, P., Rizzoli, R., Bonjour, J. P. et al:Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 99:1699-1703, 1997
PubMed
20) Anderson, D. M., Maraskovsky, E., Billingsley, W. L. et al:A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (Lond) 390:175-179, 1997
PubMed
21) Lacey, d. L., Timms, E., Tan, H. L. et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
PubMed
22) Wong, B. R., Rho, J., Arron, J. et al.:TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190-25194, 1997
 
23) O'Brien, C. A., Gubrij, I., Lin, S. C. et al.:STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-l but Not 1,25-dihydroxyvitamin D3 or Parathyroid Hormone. J. Biol. Chem. 274:19301-19308, 1999
 
24) Azuma, Y., Kaji, K., Katogi, R. et al.:Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275:4858-4864, 2000
 
25) Kobayashi, K., Takahashi, N., Jimi, E. et al.:Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-286, 2000
 
26) Jimi, E., Nakamura, I., Duong, L. T. et al:Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247:84-93, 1999
PubMed
27) Aerssens, J., Boonen, S., Joly, J. et al.:Variations in trabecular bone composition with anatomical site and age:potential implications for bone quality assessment. J. Endocrinol. 155:411-421, 1997
PubMed
28) Nicolas, V., Prewett, A., Bettica, P. et al.:Age-related decreases in insulin-like growth factor-I and transforming growth factor-β in femoral cortical bone from both men and women:implications for bone loss with aging. J. Clin. Endocrinol. Metab. 78:1011-1016, 1994
 
29) Horst, R. L, Goff, J. P., Reinhardt, T. A.:Advancing age results in reduction of intestinal and bone 1,25-dihydroxyvitamin D receptor. Endocrinology 126:1053-1057, 1990
PubMed
30) Mulroney, S. E., Woda, C., Haramati, A.:Changes in renal phosphate reabsorption in the aged rat. Proc. Soc. Exp. .Biol. Med. 218:62-67, 1998
PubMed
31) Ledger, G. A., Burritt, M. F., Kao, P. C. et al.:Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. J. Clin. Endocrinol. Metab. 79:211-216, 1994
PubMed
32) Haden, S. T., Brown, E. M., Hurwitz, S. et al.:The effects of age and gender on parathyroid hormone dynamics. Clin. Endocrinol. 52:329-338, 2000
PubMed
33) Boonen, S., Aerssens, J., dequeker, J.:Age-related endocrine deficiencies and fractures of the proximal femur. I implications of growth hormone deficiency in the elderly. J. Endocrinol. 149:7-12, 1996
PubMed
34) Sugimoto, T., Nishiyama, K., Kuribayashi, F. et al.:Serum levels of insulin-like growth factor (IGF)1, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J. Bone Miner. Res. 12:1272-1279, 1997
PubMed
35) Marcus, R., Hoffman, A. R.:Growth hormone as therapy for older men and women. Annu. Rev. Pharmacol. Toxicol. 38:45-61, 1998
PubMed
36) Marie, P.:Growth factors and bone formation in osteoporosis:roles for IGF-Iand TGF-β. Rev. Rhum. Engl. Ed. 64:44-53, 1997
 
37) Lamberts, S. W., van den Beld, A. W., van der Lely, A. J.:The endocrinology of aging. Science (Wash. DC) 278:419-424, 1997
 
38) Baulieu, E. E., Thomas, G., Legrain, S. et al.:dehydroepiandrosterone (DHEA), DHEA sulfate, and aging:contribution of the DHEAge Study to a sociobiomedical issue. Proc. Natl. Acad. Sci. USA 97:4279-4284, 2000
PubMed
39) Stephan, J. J., Lachman, M., Zverina, J. et al:Castrated men exhibit bone loss:Effect of calcitonin treatment on biochemical indices of bone remodeling. J. Clin. Endocrinol. Metab. 69:523-527, 1989
 
40) Smith, E. P., Boyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994
 
41) MacGimvray, M. H., Morishima, A., Conte, F. et al.:Pediatric endocrinology update:an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion andbone turnover:lessons from mutations in the genes for aromatase and the estrogen receptor. Horm. Res. 1:2-8, 1998
 
42) Bilezikian, J. B., Morishima, A., Bell, J. et al.:Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 339:599-603, 1998
 
43) Slemenda, C. W., Longcope, C., Zhou, L. et al.:Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J. Clin. Invest. 100:1755-1759, 1997
PubMed
44) Vanderschueren, D., Van-Herck, E., de-Coster, R. et al.:Aromatization of androgens is important for skeletal maintenance of aged male rats. Calcif. Tissue Int. 59:179-183, 1996
PubMed
45) Cummings, S. R., Browner, W. S., Bauer, d. et al:Endogenous hormones and the risk of the hip and vertebral fractures among older women. N. Engl. J. Med. 339:733-738, 1998
 
46) Takeda, T., Hosokawa, M., Takeshita, S. et al.:Anew murine model of accelerated senescence. Mech. Ageing Dev. 17:183-194, 1981
 
47) Takeda, T., Hosokawa, M., Higuchi, K.:Senescence-accelerated mouse (SAM):anovel murine model of accelerated senescence. J. Am. Geriatr. Soc. 39:911-919, 1991
 
48) Matsushita, M., Tsuboyama, T., Kasai, R. et al:Age-related changes in bone mass in the senescence-accelerated mouse (SAM) . SAM-R/3 and SAM-P/6 as new murine models for senile osteoporosis. Am. J. Pathol. 125:276-283, 1986
 
49) Kajkenova, O., Lecka-Czernik, B., Gubrij, I. et al.:Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis andlow turnover osteopenia. J. Bone Miner. Res. 12:1772-1779, 1997
 
50) Ohsumi, J., Miyadai, K., Kawashima, I. et al.:Adipogenesis inhibitory factor. A novel inhibitory regulator of adipose conversion in bone marrow. FASEB J. 288:13-16, 1991
 
51) Kawashima, I., Ohsumi, J., Mita-Honjo, K. et al.:Molecular cloning of cdNA encoding adipogenesis inhibitory factor and identity with interleukin-11. FASEB J. 283:199-202, 1991
 
52) Tohjima, E., Inoue, D., Yamamoto, N. et al.:Analysis of regulatory elements of mouse interleukin-11 gene transcription:insight into the mechanism of impairment of bone formation in senescence-acceleratd mice (SAM) . J. Bone Miner. Res. 14 (suppl.1):S152, 1999
 
53) Kuliwaba, J. S., Findlay, d. M., Atkins, G. J. et al.:Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. J. Bone Miner. Res. 15:332-341, 2000
PubMed
54) Kuro-o, M., Matsumura, Y., Aizawa, H. et al:Mutation of the mouse klotho gene leads to a syndrome resembling ageing[see comments]. Science (Wash. DC) 278:45-51, 1997
 
55) Yasuda, H., Shima, N., Nakagawa, N. et al.:Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):amechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337, 1998
 
56) Simonet, W. S., Lacey, D. L, Dunstan, C. R. et al:Osteoprotegerin:anovel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
 
57) Yano, K., Tsuda, E., Washida, N. et al.:Immunological characterization of circulating osteoprotegerin/ osteoclastogenesis inhibitory factor:increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14:518-527, 1999
 
58) Ducy, P., Amling, M., Takeda, S. et al:Leptin inhibits bone formation through a hypothalamic relay:acentral control of bone mass. Cell 100:197-207, 2000
 
P.323 掲載の参考文献
1) 名和田 新, 高柳淳一, 柳瀬敏彦ほか:グルココルチコイド療法の適応症と治療計画. Mol. Med. 30:592-600, 1993
 
2) 名和田 新:ステロイド性骨粗鬆症. 日本内科学会雑誌89:2116-2121, 2000
 
3) 名和田 新, 高柳涼一, 柳瀬敏彦ほか:副腎皮質ステロイドホルモン過剰による骨変化の分子機構. 分子骨代謝学と骨粗鬆症. (松本俊夫 編)メディカルレビュー社, 東京, 1996, p. 261-269
 
4) 名和田 新, 生山祥一郎, 後藤公宣ほか:内科医からみた慢性関節リウマチにおけるステロイドの功罪. 整形外科, 慢性関節リウマチ34:30-34, 1998
 
5) Hofbauer, L. C., Gori, F., Riggs, B. L. et al.:Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells:Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis. Endocrinology 140:4382-4389, 1999
PubMed
6) Manelli, F.:Glucocorticoid-induced osteoporosis. TEM 11:79-85, 2000
PubMed
7) American College of Rheumatology Task Force on Osteoporosis Guideline:Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 39:1791-1801, 1996
PubMed
8) Eastell, R., Reid, d. M., Compston, J. et al.:AUK consensus group on management of glucocorticoid osteoporosis:an update. J. Int. Med. 244:271-292, 1998
 
9) 名和田 新, 田中誠一:副腎アンドロゲンの骨粗鬆症における役割. 医学のあゆみ165:538-541, 1993
 
10) Nawata, H., Tanaka, S., Tanaka, S. et al:Aromatase in bone cell:association with osteoporosis in postmenopausal women. J. Steroid Biochem. Molec. Biol. 53:165-174, 1995
PubMed
11) Smith, E. P., Boyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen-receptor gene in man. N. Engl. J. Med. 331:1056-1061, 1994
 
12) Morishima, A., Grumbach, M. M., Simpson, E. R. et al:Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogen. J. Clin. Endocrinol. Metab. 80:3689-3698, 1995
PubMed
P.334 掲載の参考文献
1) Wekerle, H., Ketelsen, U. P.:Thymic nurse cells:Ia-bearing epithelium involved in T-lymphocyte differentiation? Nature 283:402-404, 1980
 
2) Wekerle, H., Ketelsen, U. P, Ernst, M.:Thymic nurse cells. Lymphoepitherial cell complexes in murine thymus:Morphological and serological characterization. J. Exp. Med. 151:925-944, 1980
PubMed
3) Iwabuchi, K., Nakayama, K., McCoy, R. L. et al.:Cellular and peptide requirements for in vivo clonal deletion of immature thymocytes. Proc. Natl. Acad. Sci. USA 89:9000-9004, 1992
PubMed
4) Pezzano, M., Li, Y., Phlip, d. et al.:Thymic nurse cells of early Cd4+Cd8+thymocytes from apoptosis. Cell. Mol. Biol. 41:1099-1111, 1995
 
5) Pezzano, M., Phlip, D., Stephenson, S. et al.:Positive selection by thymic nurse cells requires IL-1β and is associated with an increased Bcl-2 expression. Cell. Immunol. 169:174-184, 1996
 
6) Oliveira-dos-Santos, A. J., Penninger, J. M., Rieker-Geley, T. et al.:Thymic heterotypic cellular complexes in gene-targeted mice with defined blocks in T cell development and adhesion molecule expression. Eur. J. Immunol. 28:2882-2892, 1998
 
7) Pezzano, M., King, K. D., Phlip, D. D. et al.:Athymic nurse cell-specific monoclonal antibody. Cell. Immunol. 185:123-133, 1998
 
8) Nakagawa, S., Hata, M., Seki, M. et al.:Interaction of cutaneous stromal cells and γ/δ T cell receptor (TcR)-positive cells. I. Vγ-γ/δTcR T cells migrating from organ-cultured murine skin proliferate by co-culture with cutaneous stromal cells in the presence of interleukin-2. Eur. J. Immunol 23:1705-1710, 1993
 
9) Iwagami, S., Furue, S., Toyosaki, T. et al:Establishment and characterization of nurse cell-like clones from human skin. Nurse cell-like clones can stimulate autologous mixed lymphocyte reaction. J. Immunol. 153:2927-2938, 1994
PubMed
10) Tomita, T., Takeuchi, E., Toyosak-Maeda, T. et al.:Establishment of nurse-like stromal cells from bone marrow of patients with rheumatoid arthritis:indication of characteristic bone marrow microenvironment in patients with rheumatoid arthritis. Rheumatology (Oxford) 38:854-863, 1999
 
11) Takeuchi, E., Tomita, T., Toyosaki-Maeda, T. et al.:Establishment and characterization of nurse-like stromal cell lines from synovial tissues of patients with rheumatoid arthritis. Arthritis Rheum. 42:221-228, 1999
PubMed
12) Shimaoka, Y., Attrep, J. F, Ilirano, T. et al.:Nurse-like cells from bone marrow and synovium of patients with rheumatoid arthritis promotes survival and enhance function of human B cells. J. Clin. Invest. 102:606-618, 1998
 
13) Tanabe, M, Ochi, T., Tomita, T. et al.:Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J. Rheumatol. 21:830-835, 1994
PubMed
14) 越智隆弘, 鈴木隆二, 前田(豊崎)朋子:慢性関節リウマチと骨髄病変. 治療学33:822-824, 1999
 
15) Edwards, J. C. W.:The synovium, in Rheumatology. (Klippel, J. H., dieppe, P. A. eds. ) Mosby, London, Philadelphia, St. Louis, Sydney, Tokyo, 1998, section 5, 6-l
 
16) Toyosaki, T., Tsuruta, Y., Yoshioka, T. et al.:Recognition of rheumatoid arthritis synovial antigen by Cd4+, Cd8-Tcell clones established from rheumatoid arthritis joints. Arthritis Rheum. 41:92-100, 1998
 
17) 鈴木隆二, 冨田哲也, 越智隆弘ほか:リウマチ病変とナース細胞. リウマチ病セミナーVIII. (七川歡次 監)永井書店, 大阪, 1997, p.155-163
 
18) 高野裕史, 冨田哲也, 前田(豊崎)朋子ほか:RA間質(ナース)細胞による末梢血単球の前破骨細胞への変化. リウマチ40:360, 2000
 
19) Higuchi, S., Tabata, N., Tajima, M. et al:Induction of human osteoclast-like cells by treatment of blood monocytes with anti-fusion reguratory protein-1/Cd98 monoclonal antibodies. J. Bone Miner. Res. 13:44-49, 1998
 
20) Tomita, T., Kaneko, M., Nakase, T. et al:Contribution of RA nurse cells to articular cartilage degradation. Arthritis Rheum. 42:S89, 1999
 
21) 冨田哲也, 金子元春, 高野裕史ほか:慢性関節リウマチ間質(ナース)細胞による軟骨破壊. リウマチ40:364, 2000
 
P.347 掲載の参考文献
1) Krolner, B., Toft, B., PorsNielsen, S. et al.:Physical exercise as prophylaxis against involutional vertebral bone loss:acontrolled trial. Clin. Sci. 64:541-546, 1983
 
2) Kodama, Y., Nakayama, K., Fuse, H. et al.:Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J. Bone Miner. Res. 12:1058-1067, 1997
PubMed
3) Sakata, T., Sakai, A., Tsurukami, H. et al.:Trabecular bone turnover and bone marrow cell development in tail-suspended mice. J. Bone Miner. Res. 14:1596-1604, 1999
PubMed
4) Morey, E. R., Baylink, D. J.:Inhibition of bone formation during space flight. Science 201:1138-1141, 1978
PubMed
5) Vico, L, Chappard, D., Alexandre, C. et al:Effects of weightlessness on bone mass and osteoclast number in pregnant rats after a five day space flight (Cosmos 1514) . Bone 8:95-103, 1987
 
6) Bassett, C. A. L., Becker, R. O.:Generation of electric potentials in bone ip response to mechanical stress. Science 137:1063-1064, 1962
 
7) Somjen, D., Binderman, I., Berger, E. et al.:Bone remodelling induced by physical stress is prostaglandin E2 mediated. Biochim. Biophys. Acta 627:91-100, 1980
PubMed
8) Binderman, I., Shimshoni, Z., Somjen, d.:Biochemical pathways involved in the translation of physical stimulus into biological message. Calcif. Tissue Int. 36 (Suppl.):S82-S85, 1984
 
9) Sandy, J. R., Meghji, S., Farndale, R. W. et al.:dual elevation of cyclic AMP and inositol phosphates in response to mechanical deformation of murine osteoblasts. Biochim. Biophys. Acta 1010:265-269, 1989
PubMed
10) Burr, D. B., Milgrom, C., Fyhrie, D. et al.:In vivo measurement of human tibial strains during vigorous activity. Bone 18:405-410, 1996
PubMed
11) Owan, I., Ibaraki, K., Duncan, R. L. et al.:Which activates mechanotransduction in bone-extracellular fluid flow or mechanical strain? Mechanical Loading of Bones and Joints. (Takahashi, H. E. ed. ) Springer-Verlag, Tokyo, Berlin, Heidelberg, New York, 1999, p.303-309
 
12) Hillsley, M. V., Frangos, J. A.:Alkaline phosphatase in osteoblasts is down-regulated by pulsatile fluid flow. Calcif. Tissue Int. 60:48-53, 1997
PubMed
13) Otter, M. W., Palmieri, V. R., Wu, D. D. et al.:A comparative analysis of streaming potentials in vivo and in vitro. J. Orthop. Res. 10:710-719, 1992
 
14) Joldersma, M., Burger, E. H., Semeins, C. M.:Mechanical stress induces COX-2 mRNA expression in bone cells from elderly women. J. Biomech. 33:53-61, 2000
PubMed
15) Reich, K. M., Gay, C. V., Frangos, J. A.:Fluid shear stress as a mediator of osteoblast cyclic adenosine monophosphate production. J. Cell. Physiol. 143:100-104, 1990
PubMed
16) Reich, K. M., Frangos, J. A.:Protein kinase C mediates flow-induced prostaglandin E2 production in osteoblasts. Calcif. Tissue Int. 52:62-66, 1993
PubMed
17) Johnson, d. L., McAllister, T. N., Frangos, J. A.:Fluid flow stimulates rapid and continuous release of nitric oxide in osteoblasts. Am. J. Physiol. 271:E205-E208, 1996
PubMed
18) Donahue, H. J., McLeod, K. J., Rubin, C. T. et al.:Cell-to-cell communication in osteoblastic networks:cell line-dependent hormonal regulation of gap junction function. J. Bone Miner. Res. 10:881-889, 1995
PubMed
19) Doty, S. B.:Morphological evidence of gap junctions between bone cells. Calcif. Tissue Int. 33:509-512, 1981
PubMed
20) Mason, D. J., Suva, L. J., Genever, P. G. et al.:Mechanically regulated expression of a neural glutamate transporter in bone:a role for excitatory amino acids as osteotropic agents? Bone 20:199-205, 1997
 
21) Skerry, T. M.:Identification of novel signaling pathways during functional adaptation of the skeleton to mechanical loading:the role of glutamate as a paracrine signaling agent in the skeleton. J. Bone Miner. Metab. 17:66-70, 1999
PubMed
22) Klein-Nulend, J., van der Plas, A., Semeins, C. M. et al.:Sensitivity of osteocytes to biomechanical stress in vitro. FASEB J. 9:441-445, 1995
PubMed
23) Chambers, T. J., Fox, S., Jagger, C. J. et al.:The role of prostaglandins and nitric oxide in the response of bone to mechanical forces. Osteoarthritis Cartilage 7:422-423, 1999
PubMed
24) Kawata, A., Mikuni-Takagaki, Y.:Mechanotransduction in stretched osteocytes-temporal expression of immediate early and other genes. Biochem. Biophys. Res. Commun. 246:404-408, 1998
PubMed
25) Mikuni-Takagakl, Y.:Mechanical responses and signal transduction pathways in stretched osteocytes. J. Bone Miner. Metab. 17:57-60, 1999
 
26) Matsumoto, T., Nakayama, K., Kodama, Y. et al.:Effect of mechanical unloading and reloading on periosteal bone formation and gene expression in tail-suspended rapidly growing rats. Bone 22:89S-93S, 1998
PubMed
27) Turner, C. H., Akhter, M. P.:The mechanics of bone adaptation, in Mechanical Loading of Bone and Joints. (Takahashi, H. E. ed. ) Springer-Verlag, Tokyo, Berlin, Heidelberg, New York, 1999, p. 79-91
 
28) Forwood, M. R.:Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J. Bone Miner. Res. 11:1688-1693, 1996
PubMed
29) Chow, J. W., Chambers, T. J.:Indomethacin has distinct early and late actions on bone formation induced by mechanical stimulation. Am. J. Physiol. 270:E287-E292, 1994
 
30) Fox, S. W., Chambers, T. J., Chow, J. W.:Nitric oxide is an early mediator of the increase in bone formation by mechanical stimulation. Am. J. Physiol. 270:E955-E960, 1996
PubMed
31) Turner, C. H., Takano, Y., Owan, I. et al:Nitric oxide inhibitor L-NAME suppresses mechanically-induced bone formation in rats. Am. J. Physiol. 270:E634-E639, 1996
PubMed
32) Zhang, R., Supowit, S. C., Klein, G. L. et al.:Rat tail suspension reduces messenger RNA level for growth factors and osteopontin and decreases the osteoblastic differentiation of bone marrow stromal cells. J. Bone Miner. Res. 10:415-423, 1995
PubMed
33) Machwate, M., Zerath, E., Holy, X. et al.:Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. Endocrinology 134:1031-1038, 1994
PubMed
34) Rubin, J., Biskobing, D., Fan, X. et al:Pressure regulates osteoclast formation and MCSF expression in marrow culture. J. Cell. Physiol. 170:81-87, 1997
PubMed
35) Armstrong, J. W., Balch, S., Chapes, S. K. et al:Interleukin-2 therapy reverses some immunosuppressive effects of skeletal unloading. J. Appl. Physiol. 77:584-589, 1994
PubMed
36) Grewal, T. S., Genever, P. G., Brabbs, A. C. et al:Best5:a novel interferon-inducible gene expressed during bone formation. FASEB J. 14:523-531, 2000
PubMed
37) Burkhart, J. M., Jowsey, J.:Parathyroid and thyroid hormones in the development of immobilization osteoporosis. Endocrinology 81:1053-1062, 1967 38) Lindgren, U.:The effect of thyroparathyroidectomy:development of disuse in adult rats. Clin. Orthop. 118:251-256, 1976
 
39) Sakai, A., Nakamura, T., Tsurukami, H. et al.:Bone marrow capacity for bone cells and trabecular bone turnover in immobilized tibia after sciatic neurectomy in mice. Bone 18:479-486, 1996
PubMed
40) Shaker, J. L, Fallon, M. D., Goldfarb, S. et al.:WR-2721 reduces bone loss after hindlimb tenotomy in rats. J. Bone Miner. Res. 4:885-890, 1989
PubMed
41) Chow, J. W., Fox, S., Jagger, C. J. et al:Role for parathyroid hormone in mechanical responsiveness of rat bone. Am. J. Physiol. 274:E146-E154, 1998
PubMed
42) Sakai, A., Sakata, T., Ikeda, S. et al.:Intermittent administration of human parathyroid hormone (1-34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice. J. Bone Miner. Res. 14:1691-1699, 1999
PubMed
43) Bikle, D. D., Harris, J., Halloran, B. P. et al.:Skeletal unloading induces resistance to insuline-like growth factor I. J. Bone Miner. Res. 9:1789-1796, 1994
 
44) Thompson, D. D., Rodan, G. A.:Indomethacin inhibition of tenotomy-induced bone resorption in rats. J. Bone Miner. Res. 4:409-414, 1988
PubMed
45) Fiorentino, S., Melillo, G., Fedele, G. et al.:Ketoprofen lysine salt inhibits disuse-induced osteopenia in a new non-traumatic immobilization model in rat. Pharmacol. Res. 33:277-281, 1996
 
46) Halloran, B. P., Bikle, d. D., Harris, J. et al:Skeletal unloading induces selective resistance to the anabolic actions of growth hormone on bone. J. Bone Miner. Res. 10:1168-1176, 1995
 
P.364 掲載の参考文献
1) Feldkamp, L. A., Goldstein, S. A., Parfitt, A. M. et al.:The direct examination of three-dimensional bone architecture in vitro by computed tomography. J. Bone Miner. Res. 4:3-ll, 1989
PubMed
2) Bonse, U., Busch, F., Gunnewig, O. et al:3D computed X-ray tomography of human cancellous bone at 8mm spatial and 10-4 energy resolution. Bone Miner. 25:25-38, 1994
 
3) Kinney, J. H., Lane, N. E., Haupt, D. L.:In vivo, three-dimensional microscopy of trabecular bone. J. Bone Miner. Res. 10:264-270, 1995
PubMed
4) Ruegesegger, P., Koller, B., Muller, R. et al:A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int. 58:24-29, 1996
 
5) Parfitt, A. M., Mathews, C. H., Villanueva, A. R. et al.:Relationships between surface, volume and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J. Clin. Invest. 72:1396-1409, 1983
PubMed
6) Hildebrand, T., Ruegsegger, P.:A new method for the model independent assessment of thickness in three-dimensional images. J. Microsc. 185:67-75, 1997
 
7) Hildebrand, T., Ruegsegger, P.:Quantificatin of bone microarchitecture with the structurc model index. CMBBE 1:15-23, 1997
PubMed
8) Hahn, M., Vogel, M., Pompesius-Kempa, M. et al:Trabecular bone pattern factor:a new parameter for simple quantification of bone microarchitecture. Bone 13:327-330, 1992
PubMed
9) DeHoff, R. T., Aigeltinger, E. H., Craig, K. R. et al:Experimental determination of the topological properties of three-dimensional microstructure. J. Microsc. 95:69, 1972
 
10) Odgaard, A., Gundersen, H. J. G.:Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions. Bone 14:173-182, 1993
 
11) Garrahan, N. J., Mellish, R. W., Compston, J. E.:A new method for the two-dimensional analysis of bone structure in human iliac crest biopsies. J. Microsc. 142:341-349, 1986
PubMed
12) Vesterby, A.:Star volume of marrow space and trabeculae in iliac crest:sampling procedure and correlation to star volume of first lumbar vertebra. Bone 11:149-155, 1990
PubMed
13) Muller, R., Hildebrand, T., Ruegesegger, P. et al.:Structural bone properties from different sites of the human skeleton assessed by micro-computed tomography. Osteoporosis Int, 7:271, 1997
 
14) Hildebrand, T., Laib, A., Mueller, R. et al.:Direct three-dimensionalmorphometric analysis of human cancellous bone:Microstructural data from spine, femur iliac crest, and calcaneus. J. Bone Miner. Res. 14:1167-1174, 1999
 
15) 伊東昌子ほか:ヒト腸骨三次元骨梁構造の加齢変化. 1999年 代謝性骨疾患研究会にて報告.
 
16) Ito, M., Nakamura, T., Matsumoto, T. et al.:Analysis of trabecular microarchitecture of human iliac bone using microcomputed tomography in patients with hip arthrosis with or without vertebral fracture. Bone 23:163-169, 1998
 
17) Kinney, J. H., Ladd, A. J. C.:The relationship between three-dimensional connectivity and the elastic properties of trabecular bone. JJBMR 13:839-845, 1998
 
18) Uchiyama, T., Tanizawa, T., Muramatsu, H. et al.:Three-dimensional microstructural analysis of human trabecular bone in relation to its mechanical properties. Bone 25:487-491, 1999
PubMed
19) lto, M.:Symposium of The Bone Architecture and the Competence of Bone. Montry, USA May7, 2000
 
20) Majumdar, S., Genant, H. K.:Assessment of trabecular structure using high resolution magnetic resonance imaging. Stud. Health Technol. Inform. 40:81-96, 1997
PubMed
21) Sharp, J. C., Copps, J. C., Liu, Q. et al.:Analysis of ovariectomy and estrogen effects on body composition in rats by X-ray and magnetic resonance imaging techniques. J. Bone Miner. Res. 15:138-146, 2000
PubMed
22) Peyrin, F., Salome, M., Cloetens, P. et al.:Micro-CT examinations of trabecular bone samples at different resolutions:14, 7 and 2 micron level. Technol. Health Care 6:391-401, 1998
PubMed
23) Gomez, S., Rizzo, R., Pozzi-Mucelli, M. et al.:Zinc mapping in bone tissue by histochemistry and synchrotron radiation-induced X-ray emission:Correlation with the distribution of alkaline phosphatase. Bone 25:33-38, 1999
PubMed
P.376 掲載の参考文献
1) Lajeunesse, D., Frondoza, C., Schoffield, B. et al.:Osteocalcin secretion by the human osteosarcoma cell line MG-63. J. Bone Miner. Res. 5:915-922, 1990
PubMed
2) Garnero, P., Grimaux, M., Seguin, P. et al.:Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Miner. Res. 9:255-264, 1994
PubMed
3) Hosoda, K., Eguchi, H., Nakamoto, T. et al.:Sandwich immunoassay for intact human osteocalcin. Clin. Chem. 38:2223-2338, 1992
 
4) Takahashi, M.:Investigation of the performance of ELISA for N-terminal mid-fragment of osteocalcin. J. Bone Miner. Metab. 15:132, 1997
 
5) Vergnaud, P., Garnero, P., Meunier, P. J. et al.:Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women:The EPIDOS Study. J. Clin. Endocrinol. Metab. 82:719-724, 1997
PubMed
6) Kanzaki, S., Hosoda, K., Moriwake, T. et al.:Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency:A potential marker of bone growth and response to GH therapy. J. Clin. Endocrinol. Metab. 75:1104-1109, 1992
PubMed
7) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996
PubMed
8) Boskey, A. L., Gadaleta, S., Gundberg, C. et al.:Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 23:187-196, 1998
PubMed
9) Knoll, B. J., Rothblum, K. N., Longley, M..:Nucleotide sequence of human placental alkaline phosphatase gene. Evolution of the 5' flanking region by deletion/substitution. J. Biol. Chem. 263:12020-12027, 1988
PubMed
10) Stein, G. S., Lian, J. B., Owen, T. A.:Relationship of cell growth to the regulation of tissue-specific gene espression during osteoblast differentiation. Faseb. J. 4:3111-3123, 1990
 
11) Ohlsson, C., Isgaard, J., Tornell, T. et al.:Endocrine regulation of longitudinal bone growth. Acta Paediatr. Suppl. 82(Suppl. 391):33-40, 1993
 
12) Garnero, P., delmas, P. D.:Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 77:1046-1053, 1993
PubMed
13) Hata, K., Tokuhiro, H., Nakatsuka, K. et al.:Measurement of bone-specific alkaline phosphatase by an immunoselective enzyme assay method. . Ann. Clin. Biochem.33:127-133, 1996
PubMed
14) Tobiume, H., Kanzaki, S., Hida, S. et al.:Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency:A potential marker for bone formation and response to GH therapy. J. Clin. Endocrinol. Metab. 82:2056-2061, 1997
PubMed
15) Stepan, J. J., Tesarova, A., Harvanek, T. et al.:Age and sex dependency of the biochemical indices of bone remodelling. Clin. Chim. Acta 151:273-283, 1985
 
16) Moss, D. W., Eaton, R. H., Smith, J. K. et al.:Association of inorganic-pyrophjosphatase activity with human alkaline phosphatase preparations. Biochem. J. 102:53-57, 1967
PubMed
17) Prockop, D. J., Kivirikko, K. I., Tuderman, L. et al.:The biosynthesis of collagen and its disorders. N. Engl. J. Med. 301:13-23, 1979
PubMed
18) Melkko, J., Niemi, S., Risteli, L. et al.:Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 36:1328-1332, 1990
PubMed
19) Kubo, T., Tanaka, H., Inoue, M. et al.:Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children and children with growth hormone (GH) deficiency during GH therapy. Bone 17:397-401, 1995
PubMed
20) Garnero, P., Shih, W. J., Gineyts, E. et al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endcrinol. Metab. 79:1693-1700, 1994
 
P.388 掲載の参考文献
1) Minkin, C.:Bone acid phosphatase:Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif. Tissue Int. 34:285-290, 1982
PubMed
2) de la Piedra, C., Torre, R., Rapado, A. et al.:Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int. 45:58-60, 1989
 
3) Stepan, J. J., Pospichal, J., Presl, J. et al.:Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8:279-284, 1987
PubMed
4) Kraenzlin, M. E, Lau, K.-H. W., Liang, L. et al:Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J. Clin. Endocrinol. Metab. 71:442-451, 1990
 
5) Calvo, M. S., Eyre, D. R., Gundberg, C. M.:Molecular basis and Clinical application of biological markers of bone turnover. Endocr. Rev. 17:333-368, 1996
PubMed
6) Ebeling, P. R., Peterson, J. M., Riggs, B. L:Utility of type I procollagen propeptide assay for assessing abnormalities in metabolic bone diseases. J. Bone Miner. Res. 7:1243-1250, 1992
PubMed
7) Smedsrod, B., Melkko, J., Risteli, J. et al.:Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem. J. 271:345-350, 1990
PubMed
8) Atley, L. M., Mot, J. S., Lalumiere, M. et al.:Proteolysis of human bone collagen by cathepsin K:Characterization of the cleavage sites generative the cross-linked N-telopeptide neoepitope. Bone 26:241-247, 2000
 
9) Eyre, D.:Collagen cross-linking amino acids. Methods Enzymology 144:115-139, 1987
 
10) Seyedin, S. M., Kung, V. T., Daniloff, Y. N. et al.:Immunoassay for urinary pyridinoline:The new marker of bone resorption. J. Bone Miner. Res. 8:635-641, 1993
PubMed
11) Black, D., Duncan, A., Robins, S.:Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography. Anal. Biochem. 169:197-203, 1988
PubMed
12) Robins, S. P., Duncan, A., Riggs, B. L.:Direct measurement of free hydroxypyridinium crosslinks of collagen in urine as a new marker of bone resorption in osteoporosis. Osteoporosis. (Christiansen, C., Overgaad, K. eds.) Osteoporosis Aps, Copenhagen, 1990, p.465-468
 
13) Hanson, D. A., Weis, M. A., Bollen, A.-M. et al.:A specific immunoassay for monitoring human bone resorption:Quantitation of type I collagen crosslinked N-telopeptides in urine. J. Bone Miner. Res. 7:1251-1258, 1992
PubMed
14) Beardsworth, L. J., Eyre, D. R., Dickson, I. R.:Changes with age in the urinary excretion of lysyl and hydroxylysyl-pyridinoline, two new markers of bone collagen turnover. J. Bone Miner. Res. 5:671-676, 1990
PubMed
15) Delmas, P. D., Schelemmer, A., Gineyts, E. et al.:Urinary excretion of pyridinoline crosslinks correlated with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J. Bone Miner. Res. 6:639-644, 1991
 
16) Eriksen, E. F., Charles, P., Melsen, F. et al.:Serum markers of type I collagen formation and degradation in metabolic bone disease:Correlation with bone histomorphometry. J. Bone Miner. Res. 8:127-132, 1993
PubMed
17) Uebelhart, D., Schlemmer, A., Johansen, J. S. et al.:Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J. Clin. Endocrinol. Metab. 72:367-373, 1991
PubMed
18) Seibel, M. J., Woitge, H., Scheidt-Nave, C. et al.:Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis:Results of a pilot study. J. Bone Miner. Res. 9:1433-1440, 1994
PubMed
19) McLaren, A. M., Hordon, L. D., Bird, H. A. et al.:Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann. Rheum. Dis. 51:648-651, 1992
PubMed
20) Akesson, K., Vergnaud, P., Gineyts, E. et al.:Impairment of bone turnover in elderly women with hip fracture. Calcif. Tissue Int. 53:162-169, 1993
PubMed
21) Civitelli, R., Gonnelli, S., Zacchei, F. et al.:Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J. Clin. Invest. 82:1268-1274, 1988
PubMed
22) Rossini, M., Gatti, D., Zamberlan, N. et al.:Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J. Bone Miner. Res. 9:1833-1837, 1994
PubMed
23) Prestwood, K. M., Pilbeam, C. C., Burleson, J. A. et al.:The short term effects of conjugated estrogen on bone turnover in older women. J. Clin. Endocrinol. Metab. 79:366-371, 1994
 
24) Hassager, C., Jensen, L. T., Podenphant, J. et al.:The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption:The effect of nandrolone decanoate and hormone replacement therapy. Calcif. Tissue Int. 54:30-33, 1994
PubMed
25) Harris, S. T., Gertz, B. J., Genant, H. K. et al.:The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J. Clin. Endocrinol. .Metab. 76:1399-1406, 1993
PubMed
26) Chesnut, III. C. H., McClung, M. R., Ensrud, K. E. et al.:Alendronate treatment of the postmenopausal osteoporotic women:Effect of multiple dosages on bone mass and bone remodeling. Am. J. Med. 99:144-151, 1995
 
27) Garnero, P., Shin, W. J., Gineyts, E. et al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79:1693-1700, 1994
 
28) Garnero, P., Gineyts, E., Arbault, P. et al.:Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J. Bone Miner. Res. 10:641-649, 1995
 
29) Mallinak, N. J. S., Chemens, J. D.:Cross-linked N-telopeptides of bone collagen:A marker of bone resorption. J. Clin. Ligand Assay 21:111-117, 1998
 
30) Woitge, H., Pecherstorfer, M, Li, Y. et al.:Novel serum markers of bone resorption:Clinical assessment and comparison with established urinary indices. J. Bone Miner. Res. 14:792-801, 1999
PubMed
31) Eastell, R., Mallinak, N., Weiss, S. et al.:Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J. Bone Miner. Res. 15:594-598, 2000
PubMed
32) Sone, T., Miyake, M., Takeda, N. et al.:Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults:Age-and sex-related changes and reference limits. Bone 17:335-339, 1995
PubMed
33) Chesnut, III. C. H., Bell, N. H., Chark, G. S. et al.:Hormone replacement therapy in postmenopausal women:Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am. J. Med. 102:29-37, 1997
 
34) Greenspan, S. L., Parker, R. A., Ferguson, L. et al:Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women:A randamized Clinical trial. J. Bone Miner. Res. 13:1431-1438, 1998
 
35) Bauer, D. C., Sklarin, P. M., Stone, K. L. et al:Biochemical markers of bone turnover an prediction of hip bone loss in older women:The study of osteoporotic fractures. J. Bone Miner. Res. 14:1404-1410, 1999
 
36) Bonde, M., Qvist, P., Fledelius, C. et al.:Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin. Chem. 40:2022-2025, 1994
PubMed
37) Garnero, P., Gineyts, E., Riou, J. P. et al:Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 79:780-785, 1994
PubMed
38) Bonde, M., Qvist, P., Fledelius, C. et al.:Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps):Follow-up on hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 80:864-868, 1995
PubMed
39) Garnero, P., Hausherr, E, Chapuy, M.-C. et al.:Markers of bone resorption predict hip fracture in elderly women:The EPIDOS study. J. Bone Miner. Res. 11:1531-1538, 1996
PubMed
40) Garnero, P., Dargent-Molina, P., Hans, D. et al.:Do markers of bone resorption add to bone mineral density and ultrasonographic heal measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporosis Int. 8:563-569, 1998
 
41) Fledelius, C., Johnsen, A. H., Cloos, P. A. C. et al.:Characterization of urinary degradation products derived from type I collagen:Identification of aβ-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J. Biol. Chem. 272:9755-9763, 1997
 
42) Cloos, P. A. C., Fledelius, C.:Collagen fragments in urine derived from bone resorption are highly racemized and isomerized:A biological clock of protein aging with Clinical potential. Biochem. J. 345:473-480, 2000
 
43) Hoshino, H., Takahashi, M., Kushida, K. et al.:The relationships between the degree of β-isomerization of type I collagen degradation products in the urine and aging, menopause and osteoporosis with fractures. Osteoporosis Int. 9:405-409, 1999
 
44) Bonde, M., Garnero, P., Fledelius, C. et al.:Measurement of bone degradation products in serum using antibodies reactive with a isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J. Bone Miner. Res. 12:1028-1034, 1997
 
45) Risteli, J., Elomaa, I., Niemi, S. et al.:Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen:A new serum marker of bone collagen degradation. Clin. Chem. 39:635-640, 1995
 
46) 清原 剛, 黒江謙治, 秩父賢司ほか:RIA法による血中ICTP(l型コラーゲン-C-テロペプチド)の測定. ホルモンと臨床42:1189-1193, 1994
 
47) Takahashi, M., Kushida, K., Kawana, K. et al.:Discrimination ability of pyridinoline crosslinks related markers for bone resorption in post-menopause and osteoporosis. Endocr. Res. 21:105-117, 1997
 
48) Guerrero, R., Martin, M. A. D., Diaz Diego, E. M. et al.:New biochemical markers of bone resorption derived from collagen . breakdown in the study of postmenopausal osteoporosis. Osteoporosis Int. 6:297-302, 1996
 
49) Kushida, K., Takahashi, M., Kawana, K. et al.:Comparison of markers for bone formation and resorption in pre-menopausal subjects, and osteoporotic patients. J. Clin. Endocrinol. Metab. 80:2447-2450, 1995
 
50) Elomaa, I., Virkkunen, L, Risteli, L. et al.:Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br. J. Cancer 66:337-341, 1992
 
51) Koizumi, M., Yamada, Y., Takiguchi, T. et al.:Bone metabolic markers in bone metastases. J. Cancer Res. Clin. Oncol. 121:542-548, 1995
PubMed
52) Maeda, H., Koizumi, M., Yoshimura, K. et al.:Correlation between bone metabolic markers and bone scan in prostatic cancer. J. Urology 157:539-543, 1997
PubMed
53) Aruga, A., Koizumi, M., Hotta, R. et al.:Usefulness of bone metaboic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br. J. Caner 76:760-764, 1997
 
54) Nishi, Y., Atley, L., Eyre, d. E. et al.:determination of bone markers in pycnodysostosis:Effects of cathepsin K deficiency on bone matrix degradation. J. Bone Miner. Res. 14:1902-1908, 1999
 
P.399 掲載の参考文献
1) Kanis, J. A., Melton, L. J. III., Christiansen, C. et al.:The diagnosis of osteoporosis. J. Bone Miner. Res. 9:1137-1141, 1994
 
2) Pocock, N. A., Eisman, J. A., Hopper, J. L. et al.:Genetic determinants of bone mass in adults. A twin study. J. Clin. Invest. 80:706-710, 1987
PubMed
3) Slemenda, C. W., Christian, J. C., Williams, C. J. et al.:Genetic determinants of bone mass in adult women:areevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J. Bone Miner. Res. 6:561-567, 1991
 
4) 折茂 肇, 杉岡洋-ほか:原発性骨粗鬆症の診断基準 (1996年改訂版) . Osteoporosis Jpn. 4:643-652, 1996
 
5) Giguere, Y., Rousseau, F.:The genetics of osteoporosis:`complexities and difficulties:. Clin. Genet. 57:161-169, 2000
PubMed
6) O'Donovan, M. C., Oefner, P. J., Roberts, S. C. et al.:Blind analysis of denaturing high performance liquid chromatography as a tool for mutation detection. Genomics 52:44-49, 1998
PubMed
7) Morrison, N. A., Qi, J. C., Tokita, A. et al.:Prediction of bone density from vitamin D receptor alleles. . Nature 367:284-287, 1994
PubMed
8) Nguyen, T. A., Morrison, N. A., Sambrook, P. N. et al.:vitamin D receptor gene and osteoporosis. J Clin. Endocrinol. Metab. 81:1674-1675, 1996
 
9) Eisman, J. A.:vitamin D receptor gene alleles and osteoporosis:an affirmative view. J. Bone Miner. Res. 10:1289-1293, 1995
 
10) Peacock, M.:vitamin D receptor gene alleles and osteoporosis:acontrasting view. J. Bone Miner. Res. 10:1294-1297, 1995
 
11) Cooper, G. S., Umbach, d. M.:Are vitamin D receptor polymorphisms associated with bone mineral density ? A meta-analysis. J. Bone Miner. Res. 11:1841-1849, 1996
PubMed
12) Gross, C., Eccleshall, T. R., Malloy, P. J. et al.:The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-Amarican women. J. Bone Miner. Res. 11:1850-1855, 1996
 
13) Arai, H., Miyamoto, K., Taketani, Y. et al.:Avitamin D receptor gene polymorphism in the translation initiation codon:effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 12:915-921, 1997
 
14) Harris, S. S., Eccleshall, T. R., Gross, C. et al.:The vitamin D receptor start codon polymorphism (Fok1) and bone mineral density in premenopausal American black and white women. J. Bone Miner. Res. 12:1043-1048, 1997
 
15) Sano, M., Inoue, S., Hosoi, T. et al:Association of estrogen receptor dinucleotide repeat polyinorphism with osteoporosis. Biochem. Biophys. Res. Commun. 217:378-383, 1995
PubMed
16) Kobayashi, S., Inoue, S., Hosoi, T. et al.:Association of bone mineral density with polymorphism of the estrogen receptor gene. J. Bone Miner. Res. 11:306-311, 1996
 
17) Mizunuma, H., Hosoi, T., Okano, II. et al.:Estrogen receptor gene polymorphism and bone mineral density at the lumbar spine of pre-and postmenopausal women. Bone 21:379-383, 1997
 
18) Shiraki, M., Shiraki, Y., Aoki, C. et al.:Association of bone mineral density with apolipoprotein E phenotype. J. Bone Miner. Res. 12:1438-1445, 1997
PubMed
19) Hosoi, T., Miyao, M., Inoue, S. et al.:Association study of parathyroid hormone gene polymorphism and bone mineral density in Japanese postmenopausal women. Calcif. Tissue Int. 64:205-208, 1999
PubMed
20) Miyao, M., Hosoi, T., Emi, M. et al.:Association of bone mineral density with a dinucleotide repeat polymorphism at the calcitonin (CT) locus. J. Human Genetics (in press)
 
21) Tsukamoto, K., Orimo, H., Hosoi, T. et al:Association of bone mineral density with polymorphism of the human matrix Gla protein locus in elderly women. J. Bone Miner. Metab. 18:27-30, 2000
PubMed
22) Langdahl, B. L, Knudsen, J. Y., Jensen, H. K. et al.:A sequence variation:713-8delC in thetransforming growth factor-β1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 20:289-294, 1997
 
23) Yamada, Y., Hosoi, T., Makimoto, F. et al.:Transforming growth factor β-l gene polymorphism and bone mineral density in Japanese adolescents. Am. J. Med. 106:477-479, 1999
 
24) Miyao, M., Morita, H., Hosoi, T. et al.:Association of methylenetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women. Calcif. Tissue Int. 66:190-194, 2000
 
25) Utterlinden, A. G., Burger, H., Huang, Q. et al.:Relation of alleles of the collagen type I α 1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N. Engl J.:Med. 338:1016-1021, 1998
 
26) Nakajima, T., Ota, N., Shirai, Y. et al.:Ethnic difference in contribution of Sp 1 site variation of COLIA 1 gene in genetic predisposition to osteoporosis. Calcif. Tissue Int. 65:352-353, 1999
 
27) Han, K. O., Moon, I. G., Hwang, C. S. et al.:Lack of an intronic Sp 1 binding-site polymorphism at the collagen type I alpha 1 gene in healthy Korean women. Bone 24:135-137, 1999
 
28) Ota, N., Hunt, S. C., Nakajima, T. et al.:Linkage of interleukin glocus to human osteopenia by sibling pair analysis. Hum. Genet. 105:253-257, 1999
 
29) Ota, N., Hunt, S. C., Nakajima, T. et al.:Linkage of human tumor necrosis factor-alpha to human osteoporosis by sib-pair analysis Genes. and Immunity 1:261-265, 2000
 
30) Koller, d. L., Econs, M. J., Morin, P. A. et al.:Genome screen for QTLs contributing to normal variation in bone mineral density and osteoporosis. J. Clin. Endocrinol. Metab. 85:3116-3120, 2000
 

第4章 骨粗鬆症治療薬の作用機序と効果

P.414 掲載の参考文献
1) Polatti, F., Capuzzo, E., Viazzo, F. et al.:Bone mineral density during and after lactation Obstet. Gynecol. 94:52-56, 1999
PubMed
2) Chiv, K. M., Ju, J., Mayes, d. et al.:Changes in bone resorption during the menstrual cycle. J. Bone Miner. Res. 14:609-615, 1999
 
3) Smith, E. P., Boyd, J., Frank, G. P. et al:Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994
 
4) Gillberg, P., Johansson, A. G., Ljunghall, S.:decreased estradiol level and free androgen and elevated sex hormone binding globulin levels in male idiopathic osteoporosis. Calcif Tissue Int. 64:209-213, 1999
PubMed
5) Riggs, B. L., Khosla, S., Melton, L. IIL:Aunitary model for involutional osteoporosis.:Estrogen deficiency causes both type I and type II osteoporosis in post-menopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13:763-773, 1998
 
6) Vanderschueren, D., Van Herck, E., Nijs, J. et al.:Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Bone 21:49-56, 1997
 
7) Bertelloni, S., Baroncelli, G. I., Sorrentino, M. C. et al.:Androgen-receptor blockade does not impair bone mineral density in adolescent females. Calcif. Tissue Int. 61:1-5, 1997
 
8) Hansen, M. A., Overgaad, K., Christiansen, C.:Spontaneous postmenopausal bone loss in different skeletal areas-Follow up for 15 years. J. Bone Miner. .Res. 10:205-210, 1995
 
9) Mazzuoli, G., Acca, M., Pisani, d . et al.:Annual skeletal balance and metabolic bone marker changes in healthy early postmenopausal women:Results of a prospective study. Bone 26:381-386, 2000
PubMed
10) Melton, L. J. III., Atkinson, E. J., O'Connor, M. K. et al.:determinants of bone loss from the femoral neck in women of different ages. J Bone Miner. Res. 15:24-31, 2000
 
11) Gennari, C., Agnusdei, D., Civitelli, R. et al.:Effects of estrogens on vitamin D in metabolism in postmenopausal osteoporotic women. Postmenopausal hormone therapy:benefits and risks. (Fioretti, P. et al. ed. ) Raven Press, New York, 1987, p. 243-253
 
12) Gallagher, J. C., Nordin, B. E. C.:Oestrogen and calcium metabolisnl. Aging and estrogens. vol. 2. Frontiers of Hormone Research. (Van Keep, P. A., Lauritzen, C. K. eds. ) 1973, p. 98-117
 
13) Liel, Y., Shany, S., Smimoff, P. et al:Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 140:280-285, 1999
PubMed
14) Schulz, S. R., Morris, II. A.:Ionized calcium and bone turnover in the estrogen-deficient rat. Calcif. Tissue Int. 65:78-82, 1999
 
15) Colin, E. M., Vand, B. G., Van Aken, M. et al.:Evidence for involvement of 17 beta-estradiol in intestinal calcium absorptioll independent of 1,25-dihydroxyvitamin D3 level in the rat. J. Bone Miner. Res. 14:57-64, 1999
 
16) Arts, J., Kuiper, G. G., Janssen, J. M. et al.:differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138:5067-5070, 1997
 
17) Onoe, Y., Miyaura, C., Ohta, H. et al.:Expression of estrogen receptor β in rat bone. Endocrinology 138:4509-4512, 1997
 
18) Lim, S. K., Won, Y. J., Lee, H. C. et al.:APCR analysis of ER alpha and ER beta mRNA abundance in rats and the effect of ovariectomy. J.Bone Miner. Res. 14:1189-1196, 1999
 
19) Hoyland, J. A., Baris, C., Wood, L. et al.:Effect of ovarian steroid deficiency on oestrogen receptor alpha expression in bone. J. Pa thol. 188:294-303, 1999
 
20) Pan, L. C., Ke, H. Z., Simmons, H. A. et al.:Estrogen receptor-alpha knockout (ERKO) mice lose trabecular and cortical bone following ovariectomy. J. Bone Miner. Res. 12:S134, 1997
 
21) Windel, S. H., Vidal, O., Andersson, G. et al.:Increased cortical bone mineral content but unchanged trabecular bone density in female ER beta (-/-) mice. J. Clin.Invest. 104:895-901, 1999
 
22) Pacifici, R., Rifas, L, McCracken, R. et al:Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc. Natl. Acad. Sci. USA 86:2398-2402, 1989
PubMed
23) Jilka, R. L., Hangoc, C., Girasole, G. et al.:Increased osteoclast development after estrogen Ioss:Mediation by interleukin-6. Science 257:88-91, 1992
 
24) Ishimi, Y., Miyaura, C., Jim, C. et al.:IL-6 is produced by osteoblasts and induces bone resorption. J.Immunol. 145:3297-3303, 1990
 
25) Girasole, G., Givliani, N., Modena, A. B. et al.:Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro. Clin. Endocrinol. 51:801-807, 1999
PubMed
26) Tamura, T., Udagawa, N., Takahashi, N. et al.:Soluble interleukin-6 receptor trigger osteoclast formation by interleukin-6. Proc. Natl. Acad. Sci. USA 490:11924-11928, 1993
 
27) Lewis, d. B., Liggitt, H. D., Effman, E. L. et al:Osteoporosis induced in mice by overproduction of interleukin-4 Proc. Natl. Acad. Sci. USA 90:11618-11622, 1993
 
28) Girasole, G., Paseri, G., Knutson, S. et al.:A distinct and hierarchically central role of interleukin-11 among other cytokines in osteoclast development. J. Bone Miner. Res. 8:117-123, 1993
 
29) Kimble, R. B., Srivastava, S., Ross, F. P. et al.:Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 271:28890-28897, 1996
PubMed
30) Wimalawansa, S. J.:Restoration of ovariectomy-induced osteopenia by nitroglycerin. Calcif.Tissue Int. 66:56-60, 2000
PubMed
31) Armour, K. E., Ralston, S. H.:Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. Endocrinology 139:799-802, 1998
PubMed
32) Hughes, d. E., dai, A., Triffee, J. C. et al.:Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nature Med. 2:1132-1136, 1996
 
33) Tompkinson, A., Gevers, E. F., Wit, J. M. et al:The role of estrogen in the control of rat osteocyte apoptosis. J. Bone. Miner. Res. 13:1243-1250, 1998
 
34) Powers, M. S., Schenkel, L, darley, P. E. et al.:Pharmacokinetics and pharmacodynamics of transdermal dosage form of 17β-estradiol:comparison with conventional oral estrogens used for hormone replacement. Am. J. Obstet. Gynecol. 152:1099-1106, 1985
 
35) Persson, I., Adami, H. O., Bergkvist, L. et al.:Risk of endometrial cancer after treatment with estrogens alone or in conjunction with progestogens:results of a prospective study. . Br. Med. J. 298:147-151, 1989
PubMed
36) Minaguchi, H., Uemura, T., Shirasu, K. et al.:Effect of estriol on bone loss in postmenopausal Japanese women:Amulticenter prospective open study. J. Obstet. Gynecol. Res. 22:259-265, 1996
 
37) Ettinger, B., Genant, H. K., Steigen, P. et al:Low dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am. J. Obstet. Gynecol. 166:479-488, 1992
 
38) O'sullivan, A. J., Cramptor, L. J., Frend, J. et al.:The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 102:1035-1040, 1998
 
39) Stevenson, J. C., Cust, M. P., Ganger, K. F. et al:Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 336:265-269, 1990
 
40) PEPI Study Group:Effects of hormone replacement therapy on bone mineral density:results from the postmenopausal. estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 276:1389-1396, 1996
 
41) Munk Jensen, N., Nielsen, S. P., Obel, E. P. et al:Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen:adouble blind placebo controlled study. Br. Med. J. 296:1150-1152, 1988
 
42) Ettinger, B., Genant, H. K., Cann, C. E.:Long term oestrogen replacement therapy prevents bone loss and fractures. Ann. Intern. Med. 102:319-324, 1985
PubMed
43) Bone, H. G, Greenspan, S. L, McKeever, C. et al.:Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J. Clin. Endocrinol. Metab. 85:720-726, 2000
PubMed
P.432 掲載の参考文献
1) Jones, C. D., Blaszczak, L. C., Goettel, M. E. et al.:Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3, 4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl) ethoxy]-phenyl] methanone. J. Med. Chem. 35 (5):931-938, 1992
PubMed
2) Brzozowski, A. M., Pike, A. C., dauter, Z. et al:Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (6652):753-758, 1997
PubMed
3) Sato, M., Grese, T:. A., Dodge, J. A. et al.:Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J. Med. Chem. 42 (1):1-24, 1999
PubMed
4) Sato, M., McClintock, C., Kim, J. et al.:dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J. Bone Miner. Res. 9 (5):715-724, 1994
PubMed
5) Sato, M., Bryant, H. U.:Raloxifene efficacy in nonreproductive and reproductive tissues in rat models in vivo and in vitro. In Vitro Biology of Sex Steroid Hormones Action. (Kuramoto, H., Gurpide, E. eds. ) Livingstone, Tokyo, Churchill, 1996, p. 406-421
 
6) Sato, M.:Comparative x-ray densitometry of bones from ovariectomized rats. Bone 17 (4 Suppl):157S-162S, 1995
 
7) Turuer, C. H., Sato, M., Bryant, H. U.:Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135 (5):2001-2005, 1994
 
8) Sato, M., Kim, J., Short, L. L. et al.:Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J. Pharmcol Exp. Ther. 272:1252-1259, 1995
 
9) Bryant, H. U., Turner, C. H., Frolik, C. A. et al.:Long-term effects of raloxifene on bone, cholesterol alld uterus in ovariectomized rats. Bone 16 (Suppl):116S, 1995
 
10) Onoe, Y., Miyaura, C., Ito, M. et al:Comparative effects of estrogen alld raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J. Bone Miner. Res. 15 (3):541-549, 2000
 
11) Yang, N. N., Bryant, H. U., Hardikar, S. et al:Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone:apotential mechanism for estrogen-or raloxifene-mediated bone maintenance. Endocrinology 137 (5):2075-2084, 1996
 
12) Yang, N. N., Venugopalan, M., Hardikar, S. et al:Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene [see comments][published erratum appears in Science 275 (5304):1249, 19971 Science 273:1222-1225, 1996
 
13) Frolik, C. A., Bryant, H. U., Black, E. C. et al.:Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats:Effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 18 (6):621-627, 1996
PubMed
14) Sato, M., Bryant, H. U., Iversen, P. et al:Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J.Pharmacol. Exp. Ther. 279 (1):298-305, 1996
PubMed
15) Turner, A. S., Hannan, M. K., Bouxsein, M. L. et al.:Effects of raloxifene on bone density and bone strength in aged, ovariectomized ewes. 45th Annual Orthopaedic Research Society Program Proceedings 230, 1999
 
16) Jerome, C. P., Lees, C. J., Register, T. C. et al.:lliac and lumbar vertebral histomorphometry, bone densitometry and bone biomarker data from raloxifene-treated macaques-ASBMR 19th Annual Meeting. J. Bone Miner. Res. 12 (1):347, 1997
 
17) Delmas, P. D., Bjarnason, N. H., Mitlak, B. H. et al.:Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337 (23):1641-1647, 1997
 
18) Delmas, P. D., Bjarnason, N., Mitlak, B. H. et al.:Raloxifene HCl prevents bone loss and lowers serum cholesterol without endometrial stimulation in early postmenopausal women. The Endocrine Society 79th annual meeting program. 67, 1999
 
19) Prestwood, K. M., Gunness, M., Muchmore, d. B. et al.:A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J. Clin. Endocrinol. Metab. 85 (6):2197-2202, 2000
 
20) Evans, G., Bryant, H. U., Magee, d. et al.:The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134 (5):2283-2288, 1994
PubMed
21) Ettinger, B., Black, d. M., Mitlak, B. H. et al:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:Results from a 3-year randomized Clinical trial. J. Am. Med. Assoc. 282 (7):637-645, 1999
 
22) Melton, L. J., Khosla, S., Atkinson, E. J. et al.:Relationship of bone turnover to bone density and fractures. J. Bone Miner. Res. 12 (7):1083-1091, 1997
PubMed
23) Black, L. J., Sato, M., Rowley, E. R. et al.:Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93 (1):63-69, 1994
PubMed
24) Kauffman, R. F, Bensch, W. R., Roudebush, R. E. et al:Hypocholesterolemic activity of raloxifene (LY13948d:pharmacological characterization as a selective estrogen receptor modulator. J. Pharmacol. Exp. Ther. 280 (1):146-153, 1997
PubMed
25) Bjarnason, N. H., Haarbo, J., Byrjalsen, I. et al.:Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 96 (6):1964-1969, 1997
PubMed
26) Clarkson, T. B., Anthony, M. S., Jerome, C. P.:Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 83 (3):721-726, 1998
PubMed
27) Zuckerman, S. H., Bryan, N.:Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HC1) . Atherosclerosis 126 (1):65-75, 1996
 
28) Wiernicki, T., Glasebrook, A., Phillips, d. L. et al:Estrogen and a novel tissue selective estrogen receptor modulator raloxifene directly modulate vascular smooth muscle cell functions:Implications in the cardioprotective mechanism of estrogen. Circulation 94 (8 suppl. d:1278, 1996
 
29) Rahimian, R., Laher, I., Dube, G. et al.:Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta. J. Pharmacol. Exp. Ther. 283 (1):116-122, 1997
PubMed
30) Simoncini, T., de Caterina, R., Genazzani, A. R.:Selective estrogen receptor modulators:different actions on vascular cell adhesion molecule-1 (VCAM-d expression in human endothelial cells. J. Clin. . Endocrinol. Metab. 84 (2):815-818, 1999
 
31) Zoma, W. D., Baker, R. S., Clark, K. E.:Coronary and uterine vascular responses to raloxifene in the sheep. Am. J. Obstet. Gynecol. 182 (3):521-528, 2000
PubMed
32) Walsh, B., Paul, S., Wild, R. A. d. R. et al.:Effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in postmenopausal women:a randomized, controlled trial J. Endocrinol. Metab. 85 (1):214-218, 2000
 
33) Walsh, B. W., Kuller, L. H., Wild, R. A. et al.:Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc. 279 (18):1445-1451, 1998
 
34) Hulley, S., Grady, D., Bush, T. et al.:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J. Am. Med. Assoc. 280 (7):605-613, 1998
 
35) Press Release of the Women's Health Initiative (WHI) Study. Hormone replacement study finds slight rise in heart problems. The Washington Post via DowVision A Section, The. Washington Post Co. A08, 2000
 
36) Barrett-Connor, E., Wenger, N. K., Grady, d. et al.:Coronary heart disease in women, randomized Clinical trials, HERS and RUTH. Maturitas 31(1):l-7, 1998
 
37) Black, L. J., Jones, C. D., Falcone, J. F.:Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 32 (9):1031-1036, 1983
PubMed
38) Fuchs-Young, R., Magee, d. E., Cole, H. W. et al.:Raloxifene is a tissue specific antiestrogen that blocks tamoxifen or estrogen stimulated uterogenic effects. Endocrinology 136:37, 1995
 
39) Bryant, H. U., Wilson, P. K., Adrian, M. d. et al.:Selective estrogen receptor modulators:Pharmacological profile in the rat uterus. J. Soc. Gynecol. Invest. 3 (2):152, 1996
 
40) Sato, M., Rippy, M. K., Bryant, H. U.:Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10:905-912, 1996
PubMed
41) Swisher, d. K., Tague, R. M., Seyler, d. E.:Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats. drug d ev. .Res. 36:43-45, 1995
 
42) Fanning, P. M., Kuehl, T. J., Lee, R. et al.:Video mapping to assess efficacy of an antiestrogen (raloxifene) on spontaneous endometriosis in the rhesus monkey. Fertility and Sterility 67 (5 Suppl. ):38, 1997
 
43) Porter, K. B., Tsibris, J. C. M., Porter, G. W. et al.:Effects of raloxifene in a guinea pig model for leiomyomas. Am. J. Obstet. Gynecol. 179 (5):1283-1287, 1998
 
44) PEPI Trial Writing Group:Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. J. Am. Med. .Assoc. 275 (5):370-375, 1996
 
45) Grady, D., Gebretsadik, T., Kerlikowske, K. et al:Hormone replacement therapy and endometrial cancer risk:ameta-analysis. Obstet. Gynecol 85 (2):304-313, 1995
 
46) Hahn, R. G.:Compliance considerations with estrogen replacement:withdrawal bleeding and other factors. Am. J. Obstet. Gynecol. 161 (6 Pt 2):1854-1858, 1989
 
47) Cummings, S., Eckert, S., Krueger, K. et al.:The effect of raloxifene on risk of breast cancer in postmenopausal women. J.Am. Med. Assoc. 281 (23):2189-2197, 1999
 
48) Goldstein, S. R., Scheele, W. H., Rajagopalan, S. K. et al.:A12-month comparative study of raloxifene, estrogen, and placebo (m the postmenopausal endometrium. Obstet. Gynecol. 95:95-103, 2000
 
49) Fugere, P., Scheele, W. H., Shah, A. et al:Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmellopausal women. Am. J. Obstet. Gynecol. 182 (3):568-574, 2000
PubMed
50) Cohen, F. J., Watts, S., Shah, A. et al.:Uterine effects of three-year raloxifene therapy in postmenopausal women under age 60. Obstet. Gynecol. 95:104-110, 2000
 
51) Sato, M., Glasebrook, A. L., Bryant, H. U.:Raloxifene:aselective estrogen receptor modulator. J. Bone Miner. Metab. 12:9-20, 1994
 
52) Schairer, C., Lubin, J., Troisi, R. et al:Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J. Am. Med. Assoc. 283:485-491, 2000
 
53) Barrett-Connor, E.:Hormone replacement and cancer. Br. Med. Bull. 48:345-355, 1992
PubMed
54) Fuchs-Young, R., Iversen, P., Shelton, P. et al.:PreClinical demonstration of specific and potent inhibition of mammary tumor growth by new selective estrogen receptor modulators (SERMs)-88th Annual Meeting. Proc. Am. Assoc. Cancer Res. 38:573, 1997
 
55) Clemens, J. A., Bennett, D. R., Black, L. J. et al.:Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32:2869-2875, 1983
PubMed
56) Daniel, C. W., Silberstein, G. B., Strickland, P.:direct action of 17β-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Res. 47 (22):6052-6057, 1987
 
57) Short, L. L., Glasebrook, A. L., Adrian, M. d. et al.:distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferation. J. Bone Miner. Res. 11(1):S482, 1996
 
58) Thompson, E. W., Reich, R., Shima, T. B. et al.:differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 48 (23):6764-6768, 1988
PubMed
59) Labrie, F, Veilleux, R., Fournier, A.:Glucocorticoids stimulate the growth of mouse mammary carcinoma shionigi cells in culture. Mol. Cell Endocrinol. 58 (2-3):207-211, 1988
 
60) Anzano, M. A., Peer, C. W., Smith, J. M. et al:Chemoprevention of mammary carcinogenesis in the rat:combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer.Inst. 88:123-125, 1996
PubMed
61) Cauley, J. A., Lucas, F. L, Kuller, L. H. et al.:Elevated serum estradiol and testosteron concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 130:270-277, 1999
 
62) Collaborative Group on Hormonal Factors in Breast Cancer:Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047-1059, 1997
 
63) Lufkin, E. G., Whitaker, M. D., Nickelsen, T. et al.:Treatment of established postmenopausa osteoporosis with raloxifene:arandomized trial. J. Bone Miner. Res. 13(11):1747-1754, 1998
 
64) Draper, M. W., Flowers, d. E., Huster, W. J. et al.:Acontrolled trial of raloxifene (LY13948d HCI) impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11:835-842, 1996
 
65) Polo-Kantola, P., Portin, R., Polo, O. et al.:The effect of short-term estrogen replacement therapy on cognition:a randomized, double-blind, cross-over trial in postmenopausal women. Obstet. Gynecol. 91 (3):459-466, 1998
PubMed
66) Merchenthaler, I., Lane, L. V., Shughrue, P. J.:The comparative distribution of estrogen receptor (and) mRNA-expressing neurons in the rat central nervous system:An in situ hybridization study. Soc. Neurosci. Abstr. 23:1683, 1997
 
67) Simard, J., Labrie, F.:Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. Mol. Cell. Endocrinol. 39:141-144, 1985
PubMed
68) Wu, X., Glinn, M., Su, Y. et al.:Raloxifene increases hippocampal cholineacetyltransferase activity in ovariectomized rats. So6. Neurosci. Abstr. 24 (1):732, 1998
 
69) Wu, X., Glinn, MA, Ostrowski, N. L. et al.:Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res. 847:98-104, 1999
PubMed
70) Kawas, C., Resnick, S., Morrison, A. et al.:A prospective study of estrogen replacement therapy and the risk of developing Alzheimer:s disease:the Baltimore Longitudinal Study of Aging [published erratum appears in Neurology 51 (2):654, 1998]. Neurology 48 (6):1517-1521, 1997
 
71) Brenner, d. E., Kukull, W. A., Stergachis, A. et al.:Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease:a population-based case-control study. Am. J. Epidemiol. 140 (3):262-267, 1994
PubMed
72) Haskell, S. G., Richardson, E. D., Horwitz, R. I. et al.:The effect of estrogen replacement therapy on cognitive function in women:a critical review of the literature. J. Clin. Epidemiol. 50 (1):1249-1264, 1997
 
73) Yaffe, K., Sawaya, G., Lieberburg, I. et al.:Estrogen therapy in postmenopausal women:effects on cognitive function and dementia. J. Am. Med. Assoc. 279 (9):688-695, 1998
 
74) Lakshmanan, M., Bryant, H. U., Paul, S. M. et al.:Central nervous system effects of raloxifene:evidence from animal models and controlled Clinical trials in postmenopausal women. Climacteric 2 (Suppl. 1):331, 1999
 
75) Nickelsen, T., Lufkin, E. G., Riggs, B. L. et al.:Raloxifene hydrochloride, a selective estrogen receptor modulator:safety assessment of effects on cognitive function and mood in postmenopausal women. Psychonezaroendocrinology 24:115-128, 1999
PubMed
76) Fleisch, H.:Bisphosphonates in Bone disease:From the Laboratory to the Patient. Partheonon Publishing, 1997
 
77) Liberman, U. A., Weiss, S. R., Broll, J. et al.:Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N. Engl. J. Med. 333:1437-1443, 1995
 
78) Rodan, G. A., Fleisch, H. A.:Bisphosphonates:mechanisms of action. J. Clin. Invest. 97 (12):2692-2696, 1996
PubMed
79) Pizzani, E., Valenzuela, G.:Esophagitis associated with alendronate sodium. Va. Med. Q. 124 (3):181-182, 1997
PubMed
80) Gertz, B. J., Holland, S. D., Kline, W. F. et al.:Clinical pharmacology of alendronate sodium. Osteoporos. Int. 3:13-16, 1993
 
81) Chavassieux, P. M., Arlot, M. E., Reda, C. et al.:Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100:1475-1480, 1997
 
82) Burr, d. B., Forwood, M. R., Fyhrie, d. P. et al.:Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J. Bone Miner. Res. 12 (1):6-15, 1997
PubMed
83) Fisher, B., Costantino, J. P., Wickerham, d. L. et al.:Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90 (18):1371-1388, 1998
PubMed
84) Hemminki, K., Rajaniemi, H., Lindahl, B. et al.:Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56 (19):4374-4377, 1996
 
85) Bauer, d. C., Black, D., Ensrud, K. et al.:Upper gastrointestinal tract safety profile of alendronate:the fracture intervention trial. Arch. Intern. Med. 160:517-525, 2000
PubMed
86) Ettinger, B., Pressman, A. R., Schein, J. et al.:Alendronate use among 812 women:prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J. Managed Care Pharm. 4:488-492, 1998
 
87) 中澤隆弘, Bryant, H. U.:ラロキシフェン:骨への選択的作用とそのメカニズム. The Bone 11(1):89-102, 1997
 
88) Davies, G. C., Huster, W. J., Lu, Y. et al:Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet. Gynecol. 93 (4):558-565, 1999
PubMed
89) Umland, E. M., Rinaldi, C., Parks, S. M. et al.:The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann. Pharmacother. 33:1315-1328, 1999
PubMed
90) Love, R. R., Wiebe, d. A., Newcomb, P. A. et al.:Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 115:860-864, 1991
PubMed
91) Yang, N. N., Bryant, H. U., 中澤隆弘:ラロキシフェンの組織特異的作用の分子機構. Mol. Med. 35 (4):520-526, 1998
 
92) Bryant, H. U., 福山隆子, 中澤隆弘:ラロキシフェンとエストロゲンの骨作用における類似性. 蛋白質核酸酵素45 (6):1102-1108, 2000
 
P.443 掲載の参考文献
1) Copp, d. H., Cameron, E. C., Cheney, B. A. et al:Evidence for calcitonin-a new hormone from the parathyroid that lowers blood calcium. Endocrinology 70:638-649, 1962
PubMed
2) Rosenfeld, M. G., Mermod, J. J., Amara, S. G. et al.:Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304:129-135, 1983
PubMed
3) Brown, E. M., Gamba, G., Riccardi, d. et al.:Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
PubMed
4) Garrett, J. E., Tamir, H., Kifor, O. et al.:Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 136:5202-5211, 1995
PubMed
5) Freichel, M., Zink-Lorenz, A., Holloschi, A. et al.:Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion Endocrinology 137:3842-3848, 1996
 
6) Naveh-Many, T., Raue F, Grauer, A. et al:Regulation of calcitonin gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J. Bone Miner. Res. 7:1233-1237, 1992
 
7) Lin, H. Y., Harris, T. L, Flannery, M. S. et al.:Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254:1022-1024, 1991
PubMed
8) Segre, G. V., Goldring, S. R.:Receptors for secretin, calcitonin, parathyroid hormone/PTH-related peptide, vasoactive intestinal peptide, glucagon-like peptide 1, growth hormone-releasing hormone and glucagon belong to a newly discovered G-protein linked receptor family. 7 Trends Endocrinol. Metabtab. 4:309-314, 1993
 
9) Gorn, A. H., Lin, H. Y., Yamin, M. et al.:Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J. Clin. .rnvest. 90:1726-1735, 1992
 
10) Gorn, A. H., Rudolph, S. M., Flannery, M. R. et al.:Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction. J. Clin. Invest. 95:2680-2691, 1995
PubMed
11) Lee, S. K., Galson, d. L. et al.:Calcitonin downregulates calcitonin receptor mRNA expression in osteoclast-like cells (OLC) generated from hematopoietic stem cell lines. J. Bone Miner. Res. 11:S277, 1996
 
12) Ikegame, M., Rakopoulos, M., Martin, T. J. et al.:Effects of continuous calcitonin treatment on osteoclast-like cell development and calcitonin receptor expression in mouse bone marrow cultures. J. Bone Miner. Res 11:456-465, 1996
PubMed
13) Takahashi, S., Goldring, S., Katz, M. et al:down regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J. Clin. Invest. 95:167-171, 1995
PubMed
14) Wada, S., Martin, T. J., Findlay, d. M.:Homologous regulation of the calcitonin receptor in mouse osteoclast-like cells and human breast cancer T47D cells. Endocrinology 136:2611-2621, 1995
PubMed
15) Orcel, P., Takahashi, K. et al.:Identification and characterization of two Gs protein-coupling sequences in the porcine calcitonin.Bone 16(Suppl. 1):87S, 1995
 
16) Teti, A., Paniccia, R., Goldring, S. R.:Calcitonin increases cytosolic free calcium concentration via capacitative calcium influx. J. Biol. Chem. 270:16666-16670, 1995
PubMed
17) Ikegame, M., Ejiri, S., Ozawa, H.:Histochemical and autoradiographic studies on elcatonin internalization and intracellular movement in osteoclasts. J. Bone Miner. Res. 9:25-37, 1994
PubMed
18) Suda, T., Nakamura, N., Jimi, E. et al.:Regulation of osteoclast function. J. Bone Miner. Res. 12:869-879, 1997
 
19) Clementi, G., Amico-Roxas, M., Rapisarda, E. et al.:The analgesic activity of calcitonin and the central serotonergic system. Eur. J. Pharmacol. 108:71-75, 1985
PubMed
20) Rico, H., Revilla, M., Hernandez, E. R. et al:Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin:aprospective study. Calcif Tissue Int. 56:181-185, 1995
 
21) Mazzuoli, G. F., Passeri, M., Gennari, C. et al.:Effects of salmon calcitonin in postmenopausal osteoporosis:acontrolled double-blind Clinical study. Calcif. Tissue Int. 38:3-8, 1986
 
22) Reginster, J. Y., denis, D., deroisy, R. et al.:1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481-1483, 1987
PubMed
23) Reginster, J. Y., deroisy, R., Lecart, M. P. et al.:Adouble-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am. J. Med. 98:452-458, 1995
 
24) Overgaard, K., Riis, B. J., Christiansen, C. et al:Effect of salcatonin given intranasally on early postmenopausal bone loss. B. M. J. 299:477-479, 1989
 
25) Overgaard, K., Riis, B. J., Christiansen, C. et al.:Nasal calcitonin for treatment of established osteoporosis. Clin. Endocrinol. 30:435-442, 1989
PubMed
26) Overgaard, K.:Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women:adose-response study. Calcif. Tissue In t. 55:82-86, 1994
 
27) Orimo, H., Morii, H., Inoue, T. et al.:Effect of elcatonin on involutional osteoporosis. J. Bone Miner. Metab. 14:73-78, 1996
 
28) 藤田拓男, 井上哲郎ほか:骨粗鬆症に対するエルカトニンの効果:プラセボを対照薬とした多施設二重盲検比較試験. 医学のあゆみ152:261-282, 1990
 
29) Kanis, J. A., delmas, P., Burckhardt, P. et al.:Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int. 7:390-406, 1997
PubMed
30) 三浦隆行, 井上哲郎ほか:骨粗鬆症に伴う腰背痛に対するエルカトニン長期投与の臨床効果. 診断と新薬 32:110-131, 1995
 
31) Fujita, T., Fukase, M., Shimada, T. et al:Treatment of established osteoporosis with la (OH) vitamin D3 and low dose intermittent elcatonin (eel calcitonin derivative) . J. Bone Miner. Metab. 10:37-40, 1992
 
P.456 掲載の参考文献
1) Gural, R. P., Chungi, V. S., Shewsbury, R. P. et al:dose-dependent absorption of disodium etidronate. J. Pharm. 37:443-445, 1985
 
2) Gertz, B. J., Holland, S. D., Kline, W. F. et al:Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther. 58:288-298, 1995
PubMed
3) Kasting, G. B., Francis, M. d.:Retention of etidronate in human, dog and rat. J. Bone Miner. Res. 7:513-522, 1992
 
4) Sato, M., Grasser, W., Endo, N. et al.:Alendronate localization in rat bone and effects on osteoclast structure. J. Clin. Invest. 88:2095-2105, 1991
 
5) Shinoda, H., Adamek, G., Felix, R. et al.:Structure-activity relationships of various bisphosphonates. Calcif. Tissue Int. 35:87-99, 1983
PubMed
6) Flanagan, A. M., Chambers, T. J.:dichloromethylenebisphosphonate (CI2MBP) inhibits bone resorption through injury to osteoclasts that resorb C12MBP-coated bone. Bone Miner. 6:33-43, 1989
 
7) Flanagan, A. M., Chambers, T. J.:Inhibition of bone resorption by bisphosphonates:interactions between bisphosphonates, osteoclasts, and bone. Calcif. Tissue Int. 49:407-415, 1991
PubMed
8) Murakami, H., Takahashi, N., Sasaki, T. et al.:A possible mechanism of the specific action of bisphosphonates on osteoclasts:tildronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17:137-144, 1995
 
9) Hughes, d. E., Macdonald, B. R., Russell, R. G. G. et al.:Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. Clin. Invest. 83:1930-1935, 1989
 
10) Skorey, K., Ly, H. D., Kelly, J. et al.:How does alendronate inhibit protein-tyrosine phosphatases? J. Biol. Chem. 272:22472-22480, 1997
PubMed
11) Schmidt, A., Rutledge, S. J., Endo, N. et al.:Protein-tyrosine phosphatase activity regulate osteoclast formation and function:inhibition by alendronate. Proc. Natl.Acad. Sci. 93:3068-3073, 1996
PubMed
12) Murakami, H., Takahashi, N., Tanaka, S. et al.:Tiludronate inhibits protein tyrosine phosphatase activity in osteoclast. Bone 20:399-404, 1997
PubMed
13) Opas, E. E., Rutledeg, S. J., Golub, E. et al.:Alendronate inhibition of protein-tyrosine phosphatase-megl. Biochem. Pharm. 54:721-727, 1997
 
14) Soriano, P., Montgomery, C., Geske, R. et al.:Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702, 1991
 
15) Hughes, d. E., Wright, K. R., Uy, H. L. et al.:Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1478-1487, 1995
PubMed
16) Luckman, S. P., Hughes, d. E., Coxon, F. P. et al.:Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13:581-589, 1998
 
17) Zhang, F. L., Casey, P. J.:Protein prenylation:Molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:241-269, 1996
PubMed
18) van Beek, E., Pieterman, E., Cohen, L. et al.:Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264:108-lll, 1999
PubMed
19) Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J. et al.:Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373:231-241, 2000
PubMed
20) van beek, E., Lowik, C., van der Pluijm, G. et al.:The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro:Aclue to the mechanism of action of nitrogen-containing bisphosphonates. J. Bone Miner. Res. 14:722-729, 1999
 
21) Benford, H. L, Frith, J. C., Auriola, S. et al:Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol. 56:131-140, 1999
PubMed
22) Rogers, M. J., Brown, R. J., Hodkin, V. et al.:Bisphosphonates are incorporated into adenine nucleotides by human amino-acyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. 224:863-869, 1996
PubMed
23) Frith, J. C., Monkkonen, J., Blackburn, G. M. et al.:Clodronate and lioposome-encapsulated clodronate are metabolized to a toxic ATP analog, Adenosine 5:-β, γ-dichloromethylene triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 12:1358-1367, 1997
 
24) david, P., Nguyen, H., Barbier, A. et al.:The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H (+)-ATPase. J. Bone Miner. Res. 11:1498-1507, 1996
 
25) 藤田拓男, 折茂 肇, 井上哲郎ほか:退行期骨粗鬆症に対するアルファカルシドールを対照としたエチドロン酸二ナトリウム(EHDP)の二重盲検比較試験. Clin. Eval. 20:261-302, 1993
 
26) Storm, T., Kollerup, G., Thamsborg, G. et al.:Five years of Clinical experience with intermittent cyclical etidronate for post menopausal osteoporosis. J. Rheumatol. 23:1560-1564, 1996
PubMed
27) Lufkin, E. G., Argueta, R., Whitaker, M. d. et al.:Pamidronate:An unrecognized problem in gastro intestinal tolerability. Osteoporosis Int. 4:320-322, 1994
 
28) Black, d. M., Cunnings, S. R., Karpf, d. B. et al.:Randamized trial of effect of alendronate on risk of fracture in women existing vertebral fractures. Lancet 348:1535-1541, 1996
 
29) Schweitzer, d. H., Oostendorp-van de Ruit, M., Van der Pluijm, G. et al:Interleukin-6 and the acute phase response during treatment of patient with Paget:disease with the nitrogen-containing bisphosphonate dimethylamino hydroxypropylidene bisphosphonate. J. Bone Miner. Res. 10:956-962, 1995
 
30) Bounameaux, H. M., Schfferli, J., Montani, J. P. et al.:Renal failure associated with intravenous bisphosphonates. Lancet 1:471, 1983
 
31) dumon, J. C., Magritte, A., Body, J. J.:Efficacy and safety of the bisphophonate tiludronate for the treatment of tumor associated hypercalcemia. Bone Miner. 15:257-266, 1991
 
32) Francis, M. D., Slough, C.:Acute intravenous infusion of disodium dihydrogen (1-hydroxy-ethylidene) diphosphonate:Mechanism of cytotoxicity. J. Pharm. Sci. 73:1097-1100, 1983
 
33) Fleisch, H.:Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. drugs 42:919-944, 1991
PubMed
34) Pecherstorfer, M., Ludwig, H., Schlosser, K. et al.:Administration of the bisphosphonate ibandronate (BM21. 0955) by intravenous bolus injection. J. Bone Miner. Res. 11:587-593, 1996
PubMed
35) Watts, N. B., Harris, S. T., Genant, H. K. et al.:Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 323:73-79, 1990
PubMed
36) libermann, U. A., Weiss, S. R., Broll, J. et al.:Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333:1437-1443, 1995
 
37) Pols, H. A. P., Felsenberg, D., Hanley, d. A. et al.:Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass:results of FOSIT study. Osteoporosis Int. 9:461-468, 1999
 
38) Cummings, S. R., Black, d. M., Thompson, d. E. et al.:Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082, 1998
PubMed
P.469 掲載の参考文献
1) Reid, I.:vitamin D and its metabolites in the management of osteoporosis, in Osteoporosis. (Marcus, R., Feldman, D., Kelsey, J. eds. ), Academic Press, San diego, London, Boston, New York, Sydney, Tokyo, Toront, 1996, p. 1169-1190
 
2) Rosen, C.:vitamin D and bone health in adults and the elderly, in vitamin D:Physiology, molecular biology, and Clinical applications. (Holick, M. ed. ) Humana Press, Totowa, 1999, p. 287-305
 
3) 板橋 明:原発性骨粗鬆症. 病態生理. 最新内科学体系73 骨疾患. (坂根 剛, 森井浩世 編)中山書店, 東京, 1995, p. 146-154
 
4) 板橋 明:骨粗鬆症と骨軟化症. 内科学. (黒川 清, 松澤佑次 編) 文光堂, 東京, 1999, p. 1195-1199
 
5) Holick, M.:Evolution, Biologic functions, and recommend and dietary allowances for vitamin D, in vitamin D:Physiology, molecular biology, and Clinical applications. (Holick, M. ed. ) Humana Press, Totowa, 1999, p. l-16
 
6) Utiger, R.:The Need for More vitamin D. N. Engl. J. Med. 338:828-829, 1998
PubMed
7) Holick, M., Matsuoka, L., Wortsman, J.:Age, vitamin D, and solar ultraviolet radiation. Lancet 4:1104-1105, 1989
 
8) Tsai, K.-S., Heath, HI, H., Kumar, R. et al.:Impaired vitamin D Metabolism with Aging in women. Possible Role in Pathogenesis of Senile osteoporosis. J. Clin. Invest. 73:1668-1672, 1984
 
9) Ebeling, P., Sandgren, M., diMagno, E. et al.:Evidence of an age-related decrease in intestinal responsiveness to vitamin D:Relationship between serum 125-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. J. Clin. Endocrinol. Metab. 75:176-182, 1992
 
10) Vieth, R.:vitamin D supplementation, 25-hydrovitamin D concentrations, and safety. Am. J. Clin. Nutr. 69:842-856, 1999
 
11) Andersson, S., davis, D., dahlback, H. et al.:Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme. J. Biol. Chem 2. 264:8222-8229, 1989
 
12) Usui, E., Noshiro, M., Okuda, K.:Molecular cloning of cdNA for vitamin D 25-hydroxylase from rat liver mitochondria. FEBS Lett. 262:135-138, 1990
 
13) Slovik, D., Adams, J., Neer, R. et al.:deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic Patients. N. Engl. J. Med. 305:372-374, 1981
PubMed
14) Kinyamu, H., Gallagher, J., Prahl, J. et al.:Association between intestinal vitamin D receptor, calcium absorption, and serum 1,25-dihydroxyvitamin D ip normal young and elderly women. J. Bone Miner. Res. 12:922-928, 1997
 
15) Horst, R., Goff, J., Reinhardt, T.:Advancing age results in reduction of intestinal and bone 1,25dihydroxyvitamin D receptor. Endocrinology 126:1053-1057, 1990
PubMed
16) Armbrecht, H., Boltz, M., Christakos, S. et al.:Capacity of 1, 25dihydroxyvitamin D to stimulate expression of calbindin d changes with age in the rat. Arch. Biochem. Biophys. 352:159-164, 1998
PubMed
17) Optimal calcium intake. NIH consensus development panel on optimal calcium intake. JAMA 272:1942-1948, 1994
PubMed
18) dawson-Hughes, B., Dallal, G., Krall, E. et al.:Acontrolled trial of the effect of calcium supplementation on bone density in postmenopausal women. N. Engl. J. Med. 323:878-883, 1990
 
19) Reid, I., Ames, R., Evans, M. et al.:Effect of calcium supplementation on bone loss in postmenopausal women. N. Engl. J. Med. 328:460-464, 1993
 
20) Riggs, B., O'Fallon, W., Muhs, J. et al.:Longterm effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women.J. Bone Miner. Res. 13:168-174, 1998
PubMed
21) Chapuy, M., Arlot, M., Duboeuf, F. et al.:vitamin D3 and calcium to prevent hip fracture in elderly women. N. Engl. J. Med. 327:1637-1642, 1992
PubMed
22) dawson-Hughes, B., Harris, S., Krall, E. et al.:Effect of calcium and vitamin D supplementation on bone density in men and women 65years of age or older. N. Engl. J. Med. 337:670-676, 1997
PubMed
23) Heikinheimo, R., Inkovarra, J., Harju, E. et al.:Annual injection of vitamin D and ractures of aged bones. Calcif. Tissue Int. 51:105-110, 1992
 
24) Lips, P., Graafmans, W., Ooms, M. et al.:vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled Clinical trial. Ann. Int. Med. 124:400-406, 1996
 
25) Meunier, P.:Calcium and vitamin D are effective in preventing fractures in elderly people by reversing senile secondary hyperparathyroidism. Osteoporosis Int. 8 (Suppl 2):S1-S2, 1998
 
26) Gallagher, J., Riggs, B., Eisman, J. et al:Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients. J. Clin. Invest. 64:729-736, 1979
PubMed
27) Francis, R., Boyle, L, Moniz, C. et al:Acomparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporosis In t. 6:284-290, 1996
 
28) Christiansen, C., Christensen, M., Rodbro, P. et al.:Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Ezar. J. Clin. Invest. 11:305-309, 1981
PubMed
29) Falch, J., odegaard, O., Finnanger, A. et al.:Postmenopausal osteoporosis:No effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med. Scand. 221:199-204, 1987
PubMed
30) Ott, S., Chesnut, C.:Calciteriol treatment is not effective in postmenopausal osteoporosis. Ann. Int. Med. 110:267-274, 1989
 
31) Aloia, J., Vaswani, A., Yeh, J. et al.:Calciteriol in the treatment of postmenopausal osteoporosis. Am. J. Med. 8:401-408, 1988
PubMed
32) Gallagher, J., Goldgar, d.:Treatment of postmenopausal osteoporosis with high doses of synthetic calciteriol. Ann. Int. Med. 113:649-655, 1990
PubMed
33) Tilyard, M., Spears, G., Thompson, J. et al.:Treatment of postmenopausal osteoporosis with alciteriol or calcium. N. Engl. J. Med. 326:357-362, 1992
PubMed
34) Christiansen, C., Christensen, M., Mcnair, P. et al:Prevention of early postmenopausal bone loss:controlled 2-year study in 315 normal females. Eur. J. Clin. Invest. 10:273-279, 1980
PubMed
35) 伊丹康人, 藤田拓男, 井上哲郎ほか:アルファカルシドールの骨粗鬆症に対する効果. 医学のあゆみ123:958-973, 1982
 
36) Orimo, H., Shiraki, M., Hayashi, Y. et al.:Effects of 1α-hydroxyvitamin D on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 54:370-376, 1994
 
37) Nakamura, T.:The importance of genetic and nutritional factors in response to vitamin D and its analogs in osteoporotic patients. Calcif. Tissue Int. 60:119-123, 1997
PubMed
38) Gardiner, E., Baldock, P., Thomas, G. et al.:Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J. 14:1908-1916, 2000
PubMed
39) Shiraishi, A. ;Higashi, S., Ohkawa, H. et al.:The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif. Tissue.Int. 65:311-316, 1999
PubMed
40) lchikawa, F., Sato, K., Nanjo, M. et al.:Mouse primary osteoblasts express vitamin D325-hydroxylase mRNA and convert 1α-hydroxylvitamin D3 into 1α, 25-dihydroxyvitamin D3. Bone 16:129-135, 1995
 
41) Shiraishi, A., Takeda, S., Masaki, T. et al.:Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis:distinct actions from estrogen. J. Bone Miner. Res. 15:770-779, 2000
 
42) Chen, J., Shiraki, M., Hasumi, K. et al.:1-α-hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 20:557-562, 1997
 
43) 西井易穂:活性型ビタミンD誘導体の開発, 特にカルシウム作用と分化誘導作用の分離. ビタミン72:461-467, 1998
 
44) Bouillon, R., Okamura, W., Norman, A.:Structure-function relationship in the vitamin D endocrine system. Endocr. Rev. 16:200-257, 1995
PubMed
45) Abe, E., Miyaura, C., Sakagami, H. et al.:differentiation of mouse myeloid leukemiac cells induced by 1α, 25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 78:4990-4994, 1981
 
46) Kubodera, N., Sato, K., Nishii, Y.:Characteristics of 22-Oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy) calciteriol (Ed-7d . (Feldman, D., Glorieux, F., Pike, J. eds. ) Academic Press, San diego, London, Boston, New York, Sydney, Tokyo, Toront, 1997, p. 1071-1086
 
47) Tsurukami, H., Nakamura, T., Suzuki, K. et al.:Anovel synthetic vitamin D analogue, 2β-(3-hydroxypropoxy) 1α, 25-dihydroxyvitamin D3 (Ed-7d, increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif. Tissue.Int. 54:142-149, 1994
 
48) Ikeda, K., Ogata, E.:The ecffect of vitamin D on osteoblasts and osteoclasts. Curr. Opin. Orthop. 10:339-343, 1999
 
P.480 掲載の参考文献
1) Consensus development Conference:diagnosis, prophylaxis and treatment of osteoporosis. Am. J. Med. 94:646-650, 1994
 
2) 日本骨代謝学会, 骨粗鬆症診断基準委員会:原発性骨粗鬆症の診断基準(1996年改訂版). Osteoporosis Jpn. 4:643-652, 1996
 
3) 岩永貞昭ほか 監:ビタミンK-医学生物学領域における新展開. メディカルジャーナル社, 1994
 
4) Bouckaert, J. H., Said, A. H.:Fracture Healing by vitamin K. Nature 185:849, 1960
PubMed
5) Pettifor, J. M., Benson, R.:Congenital malformations associated with the administration of oral anticoagulants during Pregnancy. J. Pediatr. 86:459-462, 1975
PubMed
6) Price, P. A., Otsuka, A. S., Poser, J. W. et al:Characterization of a γ carboxyglutamic acidcontaining protein from bone. Proc. Natl. Acad. Sci. USA 73:1447-1451, 1976
 
7) Hauschka, P. V., Reid, M. L:Vitamin K dependence of a calcium-binding protein containing γ carboxyglutamic acid in chicken bone. J. Biol. Chem. 253:9063-9068, 1978
 
8) Price, P. A., Williamson, M. K.:Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J. Biol. Chem. 260:14971-14975, 1985
 
9) Maillard, C., Berruyer, M., Serre, C. M. et al.:Protein S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology 130:1599--1604, 1992
 
10) Hart, J. P., Shearer, M. J., Klenerman, L. et al.:Electrochemical detection of depressed circulating levels of vitamin K. in osteoporosis. J. Clin. Endocrinol. Metab. 60:1268-1269, 1985
 
11) Hodges, S. J., Akesson, K., Vergnaud, P. et al.:Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J. Bone Miner. Res. 8:1241-1245, 1993
PubMed
12) Feskanich, D., Weber, P., Wilet, W. C. et al.:Vitamin K intake and hip fractures in women;a prospective study. Am. J. Clin. Nutr. 69:74-79, 1999
 
13) 金木正夫, 水野有三, 細井孝之ほか:退行期骨粗鬆症における血清ビタミンK濃度の検討. 日老医誌32:195-211, 1995
 
14) Plantalech, L, Guillaumont, M., Philippe, V. et al:Impairment of γ calboxylation of circulating osteocalcin (bone gla protein) in elderly women. J. Bone Miner. Res. 6:1211-1216, 1991
 
15) Szulc, P., Arlot, M., Chapuy, M.-C. et al.:Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J. Bone Miner. Res. 9:1591-1595, 1994
PubMed
16) Szulc, P., Chapuy, M.-C., Meunier, P. J. et al:Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J. Clin. Invest. 91:1769-1774, 1993
PubMed
17) Vergnaud, P., Garnero, P., Meunier, P. J. et al.:Undercalboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women:The EPIDOS Study. J. Clin. Endocrinol. Metab. 82:719-724, 1997
 
18) Plantalech, L., Chapuy, M. C., Guillaumont, M. et al.:Impaired calboxylation of serum osteocalcin in elderly women. Osteoporosis. Effects ot vitamin K1 treatment. (Cristiansen, C., Overgaard, K. eds. ) 1990, p. 345-347
 
19) Shiraki, M., Shiraki, Y., Aoki, C. et al.:Vitamin K2 (Menatetorenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporois. J. Bone Miner. Res. 15:515-521, 2000
 
20) Luo, G., Ducy, P., McKee, M. d. et al.:Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78-81, 1997
PubMed
21) Vermeer, C., Knapen, M. H., Schurgers, L. J.:Vitamin K and metabolic bone disease. J. Clin. Pathol. 51:424-426, 1998
PubMed
22) Knapen, M. H. J., Hamulyak, K., Vermeer, C.:The effect of vitamin K supplementation on circulating osteocalcin (bone Gla-protein) and urinary calcium excretion. Ann. Intern. Med. 111:1001-1005, 1989
 
23) Kiyama, Y., Hara, K., Ohkawa, I. et al.:Effects of menatetrenone on bone loss induced by ovariectomy in rats. Jpn. J. Pharmacol. 62:145-153, 1993
 
24) Hara, K., Akiyama, Y., Ohkawa, I. et al.:Effects of menatetrenone on predonisolone-induced bone loss in rat. Bone 14:813-818, 1993
 
25) 折茂 肇, 藤田拓男, 小野村敏信ほか:骨粗鬆症に対する Ea-0167(Menatetrenone)の臨床評価. 臨床評価 20:45-100, 1992
 
26) Koshihara, K., Hoshi, K., Ishibashi, H. et al.:Vitamin K2 promote 1,25 (OH) 2 vitamin D3-induced mineralization in human periosteal osteoblasts. Calcif. Tissue Int. 59:466-473, 1996
 
27) Koshihara, Y., Hoshi, K.:Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J. Bone Miner. Res. 12:431-438, 1997
PubMed
28) Koshihara, Y., Hoshi, K., Shiraki, M.:Vitamin K2 (menatetrenone) inhibits prostaglandin synthesis in cultured human osteoblast-like periosteal cells by inhibiting prostaglandin H synthase activity. Biochem. Pharmacol. 46:1355-1362, 1993
PubMed
29) Hara, K., Akiyama, Y., Tajima, T. et al.:Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro. J. Bone Miner. Res. 8:535-542, 1993
PubMed
30) Hara, K., Akiyama, Y., Nakamura, T. et al.:The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone 16:179-184, 1995
 
31) Kameda, T., Miyazawa, K., Mori, Y. et al:Vitamin K sub 2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem. Biophys. Res. Commun. 220:515-519, 1996
 
32) Nakamura, Y. S., Hakeda, Y., Takakura, N. et al:Tyro 3 receptor tyrosine kinase and its ligand, Gas6, stimulate the function of osteoclasts. Stem. Cells. 16:229-238, 1998
PubMed
33) Fiore, C. E., Tamburino, C., Foti, R. et al.:Reduced bone mineral content in patients taking an oral anticoagulant. South Med. J. 83:538-542, 1990
PubMed
34) Resch, H., Pietschmann, P., Krexner, E. et al.:decreased peripheral bone mineral content in patlents under anticaglant therapy with phenproumon. Ezar. Heart J. 14:439-441, 1991
 
35) Caraballo, P. J., Heit, J. A., Atkinson, E. J. et al.:Long-term use of oral anticoagulants and the risk of fracture. Arch. Intern. Med. 159:1750-1756, 1999
PubMed
P.490 掲載の参考文献
1) Suda, T., Takahashi, N., Udagawa, N. et al:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357, 1999
PubMed
2) Kanatani, M., Sugimoto, T., Takahashi, Y. et al.:Estrogen via the estrogen receptor blocks cAMP-mediated parathyroid hormone (PTH)-stimulated osteoclast formation. J. Bone Miner. Res. 13:854-862, 1998
PubMed
3) Lindsay, R., Nieves, J., Formica, C. et al.:Randomized controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 350:550-555, 1997
PubMed
4) Cosman, F., Nieves, J., Woelfert, L. et al.:Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J. Bone Miner. Res. 13:1051-1055, 1998
PubMed
5) Podbesek, R., Edourard, C.:Effect of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 112:1000-1006, 1983
 
6) Zhang, L., Takahashi, H. E., Inoue, J. et al.:Effects of intermittent administration of low dose human PTH (1-34) on cancellous and cortical bone of lumber vertebral bodies in adult beagles. Bone 21:501-506, 1997
 
7) Hock, J. M., Gera, I.:Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to PTH. J. Bone Miner. Res. 7:65-72, 1992
PubMed
8) Mitlak, B. H., Burdette-Miller, P.:Sequential effects of chronic human PTH (1-84) treatment of estrogen deficiency osteopenia in the rat. J. Bone Miner. Res. 11:430-439, 1996
 
9) Meng, X. W., Liang, X. G., Birchman, R. et al.:Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J. Bone Miner. Res. 11:421-429, 1996
PubMed
10) Okimoto, N, Tsurukami, H., Okazaki, Y. et al.:Effects of a weekly injection of human parathyroid hormone (1-34) and withdrawal on bone mass, strength, and turnover in mature ovariectomized rats. Bone 22:523-531, 1998
 
11) Hock, J. M., Hummert, J. R., Boyce, R. et al.:Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J. Bone Miner. Res. 4:449-458, 1989
 
12) delmas, P. D., Vergnaud, P., Ariot, M. E. et al.:The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610, 1995
 
13) Yamamoto, N., Takahashi, H. E., Tanizawa, T. et al.:Maintenance of bone mass by physical exercise after discontinuation of intermittent hPTH (1-34) administration. Bone-Miner. 23:333-342, 1993
PubMed
14) Zhang, L., Takahashi, H. E., Tanizawa, T. et al.:Maintenance of bone mineral density of femoral cortex in ovariectomized rats after withdrawal of concurrent administration of human parathyroid hormone (1-34) and incadronate disodium (YM175) . J. Bone Miner. Metab. 15:206-212, 1997
 
15) Isogai, Y., Akatsu, T., Ishizuya, T. et al.:Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J. Bone Miner. Res. 11:1384-1393, 1996
PubMed
16) Hollnagel, A., Ahrens, M., Gross, G.:Parathyroid hormone enhances early and suppresses late stages of osteogenic and chondrogenic development in a BMP-dependent mesenchymal differentiation system (C3H10T1/2) . J. Bone Miner. Res. 12:1993-2004, 1997
 
17) Ishizuya, T., Uzawa, T., Takao, R. et al.:Parathyroid hormone inhibits differentiation of bon marrow adipocytes. J. Bone Miner. Res. 14:S209, 1999
 
18) Nishida, S., Yamaguchi, A., Tanizawa, T. et al.:Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15:717-723, 1994
 
19) Kostenuik, P. J., Harris, J., Halloran, B. P. et al.:Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-1. J. Bone Miner. Res. 14:21-31, 1999
PubMed
20) Onishi, T., Zhang, W., Cao, X. et al.:The mitogenic effect of parathyroid hormone is associated with E2F-dependent activation of cyClin-dependent kinase (cdc2) in osteoblast precursors. J. Bone Miner. Res. 12:1596-1605, 1997
PubMed
21) Jilka, R. L., Weinstein R. S., Bellido, T. et al.:Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. .Invest. 104:439-446, 1999
PubMed
22) Ishizuya, T., Yokose, S., Hori, M. et al:Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99:2961-2970, 1997
 
23) Canalis, E., Cehtrella, M., Burch, W. et al.:Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J. Clin. Invest. 83:60-65, 1989
 
24) Hock, J. M., Fonseca, J.:Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone. Endocrinology 127:1804-1810, 1990
PubMed
25) Andress, d. L, Birnbaum, J.:Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J. Biol. Chem. 267:22467-22472, 1992
 
26) Nasu, M., Sugimoto, T., Chihara, K.:Stimulatory effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on insulin-like growth factor-binding protein-5 mRNA expression in osteoblastic cells:the difference between transient and continuous treatments .FEBS Lett. 409:63-66, 1997
PubMed
27) Linkhart, T. A., Mohan, S.:Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-1) and IGF-II from neonatal mouse calvaria in organ culture. Endocrinology 125:1484-1491, 1989
PubMed
28) Pfeilschifter, J., Mundy, G. R.:Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA 84:2024-2028, 1987
PubMed
29) Klein-Nulend J., Pilbeam, C. C., Harrison, J. R. et al.:Mechanism of regulation of prostaglandin production by parathyroid hormone, interleukin-11 and cortisol in cultured mouse parietal bones. Endocrinology 128:2503-2510, 1991
 
30) Centrella, M., McCarthy, T. L, Canalis, E.:Parathyroid hormone modulates transforming growth factor β activity and binding in osteoblast-enriched cell cultures from fetal rat parietal bone. Endocrinology 85:5889-5893, 1988
 
31) drake, M. T., Baldassare, J. J., McConkey C. L. et al.:Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-01 cells. Endocrinology 134:1733-1737, 1994
PubMed
32) Chow, J. W. M., Fox, S., Jagger, C. J. et al.:Role for parathyroid hormone in mechanica responsiveness of rat bone. Am. J. .Physiol. 274:E146-E156, 1998
 
33) Ma, Y., Jee, W. S. S., Yuan, Z. et al.:Parathyroid hormone and mechanical usage have a synergistic effect in rat tibial diaphyseal cortical bone. J. Bone Miner. Res. 14:439-448, 1999
 
34) Kano, J., Sugimoto, T., Kanatani, M. et al.:Second messenger signaling of c-fos gene induction by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells:its role in osteoblast proliferation and osteoclast-like cell formation. J. Am. Physiol. 161:358-366, 1994
 
35) Mosekilde, L., Sogaard, C. H., danielsen, C. C. et al.:The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biochemical testing:Acomparison study between hPTH-(1-34) and hPTH-(1-84) . Epidemiology 129:421-428, 1991
 
36) Nasu, M., Sugimoto, T., Kano, J. et al:Carboxyl-terminal parathyroid hormone fragments stimulate type-Iprocollagen and insulin-like growth factor-bindillg protein-5 mRNA expression in osteoblastic UMR-106 cells. Endocr. J. 45:229-234, 1998
 
37) Nakaoka, D., Sugimoto, T., Kobayashi, T. et al.:Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 85:1901-1907, 2000
PubMed
38) Reeve, J., Meunier, P. J., Parsons, J. A. et al.:Anabolic effect of human PTH on trabecular bone in involutional osteoporosis:amulticenter trial. Br. Med. J. 280:1340-1344, 1980
 
39) Sone, T., Fukunaga, M., Ono, S. et al.:A small dose of human parathyroid hormone (1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Miner. Electrolyte Metab. 21:232-235, 1995
 
40) Fujita, T., Inoue, T., Morii, H. et al:Effect of intermittent weekly dose of a human parathyroid hormone (1-34) on osteoporosis. a randomized double-masked prospective study using three dose levels. Osteoporos. Int. 9:296-306, 1999
PubMed
41) Finkelstein, J. S., Klibanski, A., Arnold, A. L. et al:Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34) . J. Am. Med. Associat. 280:1067-1073, 1998
 
42) Lane, N. E., Sanchez, S., Modin, G. W. et al.:Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis:Results of a randomized controlled Clinical trial. J. Clin. Invest. 102:1627-1633, 1998
PubMed
43) Slovik, d. M., Rosenthal, D. I., Doppelt, S. H. et al.:Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 125-dihydroxyvitamin D. J. Bone Miner. Res. 1:377-381, 1986
 
44) Hodsman, A. B., Fraher, LJ., Watson, P. H. et al.:A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequehtial calcitonin to improve bone mass in post-menopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 82:620-628, 1997
 
P.505 掲載の参考文献
1) Marcelli, C., Yates, A. J., Mundy, G. R.:In vivo effects of human recombinant transforming growth factor beta on bone turnover in normal mice. J. Bone. Miner. Res. 5:1087-1096, 1990
 
2) dunstan, C. R., Boyce, R., Boyce, B. F. et al.:Systemic administration of acidic fibroblast growth factor (FGF-d prevents bone loss and increases new born formation in ovariectomized rats. J. Bone Miner. Res. 14:953-959, 1999
 
3) Harris, S. E., Bonewald, L. F., Harris, M. A. et al.:Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, Osteocalcin, osteopontin alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J. Bone Miner. Res. 9:855-863, 1994
 
4) Chen, D., Harris, M. A., Rossini, G. et al.:Bone morphogenetic protein 2 (BMP-2) enhances BM-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif. Tissue Int. 60:283-290, 1997
 
5) Harris, S. E.:Recombinant bone morphogenetic protein 2 accelerates bone cell differentiation and stimulation BMP 2 mRNA expression and BMP 2 promoter activity in primary fetal rat calvarial osteoblast cultures. Mol. Cell. Diff. 3:137-155, 1997
 
6) Ghosh-Choudhury, N., Windle, J. J., Koop, B. A. et al.:Immortalized murine osteoblasts derived from BMP2-T-antigen expressing transgenic mice. Endocrinology 137:331-339, 1996
PubMed
7) Rossouw, J. E., Lewis, B., Rifkind, B. M.:The value of lowering cholesterol after myocardial infarction. N. Engl. J. Med. 323:1112-1119, 1990
PubMed
8) Law, M. R., Wald, N. J., Thompson, S. G.:By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Brit. Med. J. 308:367-372, 1994
PubMed
9) Mundy, G., Garrett, R., Harris, S. et al.:Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949, 1999
PubMed
10) Fisher, J. E., Rogers, M. J., Halasy, J. M. et al.:Alendronate mechanism of action:geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96:133-138, 1999
PubMed
11) Russell, R. G. G., Rogers, M. J.:Bisphosphonates:From the laboratory to the Clinic and back again. Bone 25:97-106, 1999
 
12) Garrett, I. R., Escobedo, A., Mundy, G. R.:N2-containing bisphosphonates risedronate and ibandronate stimulate bone formation in organ culture. J. Bone Miner. Res. 14 (Suppl. 1):S525, 1999
 

書評

最近チェックした商品履歴

Loading...